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Diffuse large B cell lymphomas (DLBCLs) are a heterogeneous group of 
molecularly complex malignancies. The majority of DLBCL tumors arise from 
cells that are arrested in or have passed through the germinal center (GC). 
During the GC response, B cells undergo massive clonal expansion and 
somatic hypermutation of their immunoglobulin loci to produce high-affinity 
antibodies. Therefore GC B cells need to tolerate replicative and genotoxic 
stress without inducing cell cycle arrest, suggestive of a specialized stress 
response. Consistent with this hypothesis, we have discovered that a 
dominant regulator of the conserved stress response, heat shock factor 1 
(HSF1), is important for the GC response. HSF1 regulates the stress-
dependent induction of BCL6, an essential factor for GC formation that 
represses genes involved in DNA damage sensing and checkpoint activation. 
Hsf1-/- mice have smaller GCs and defects in the production of high-affinity 
antibodies. Because coordinate expression of genes is required for the GC 
response and post-GC differentiation, deregulation of certain genes, including 
BCL6, can lead to lymphomagenesis. Therefore the same pathways 
sustaining the GC response may be involved in maintaining DLBCL survival. 
We find that HSF1 controls a transcriptional program during the GC reaction 
that is necessary to tolerate stress associated with rapid replication and 
genomic instability. HSF1 is required to maintain the malignant phenotype in 
DLBCL due the regulation of genes involved in protein homeostasis and cell 
cycle control. We demonstrate that the stress axis of HSF1 and BCL6 is an 
evolutionarily conserved feature of vertebrates and BCL6 acts as a stress 
response gene. BCL6 mediates stress tolerance through a lateral groove on 
its BTB domain that forms docking sites for NCOR, SMRT, and BCOR 
corepressors. Genetic or pharmacologic disruption of this motif abrogated the 
stress tolerance function of BCL6. Notably, a survey of human tumor cells 
revealed that HSF1-dependent expression of BCL6 enables them to tolerate 
exposure to cytotoxic agents. Taken together, the evolutionarily conserved role 
of BCL6 and its BTB domain in mediating tolerance to stress in vertebrates 
provides the basis for using BCL6 BTB domain inhibitors as a broadly relevant 
therapeutic approach for cancer.   
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CHAPTER ONE 
INTRODUCTION 
 
1. Heat shock response 
The heat shock response is a highly conserved mechanism shared by all 
organisms in response to a variety of chemical and physiological stresses. It 
was first described in 1962, when Ferrucio Ritossa noticed a distinct pattern of 
temperature- and chemical-induced puffing in polytene chromosomes of 
Drosophila larvae (Ritossa, 1962). These puffs were later shown to be 
transcriptionally active loci, encoding a set of conserved polypeptides 
collectively referred to as heat shock proteins (HSPs) (Lindquist, 1986; 
Lindquist and Craig, 1988). This effect was also observed in prokaryotes and 
in other eukaryotes implying an ancient and conserved mechanism for stress 
response (Kelley and Schlesinger, 1978; Lemaux et al., 1978; McAlister and 
Finkelstein, 1980). Most HSPs are abundant proteins expressed under normal 
conditions and function as molecular chaperones that facilitate the folding, 
translocation, and higher order assembly of client proteins. HSPs also protect 
the cell from general protein damage caused by denaturation and aggregation, 
either facilitating protein repair and refolding or inducing degradation. A family 
of transcription factors, aptly termed heat shock factors (HSFs), mediates the 
expression of HSPs and the response to stress. It was later found that HSFs 
not only have an essential role to play during stress response but they also 
have normal physiological functions and are important for development. 
 
Effects of heat shock  
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Heat stress has detrimental effects on the cell, affecting both nuclear and 
cytoplasmic processes. Nucleoli become less condensed, and large deposits 
of ribosomal RNAs and aggregating ribosomal proteins are observed (Welch 
and Suhan, 1985) (Figure 1.1A). There is a complete block of DNA replication 
and transcription (Jamrich et al., 1977; Warters and Stone, 1983, 1984; Wong 
and Dewey, 1982). Heat shock transiently inhibits pre-mRNA splicing and 
mRNA export and induces the formation of distinct subnuclear structures 
referred to as nuclear stress bodies (Biamonti and Vourc'h, 2010; Boulon et al., 
2010; Vogel et al., 1995). Nuclear stress bodies sequester pre-mRNA 
processing factors and a subset of splicing factors (Biamonti and Vourc'h, 
2010). Early characterization of nuclear stress bodies demonstrated that these 
structures were initiated through an interaction between HSF1 and large 
regions of pericentromeric heterochromatin that contained tandem repeats of 
satellite III (SatIII) sequences (GGAAT) (Denegri et al., 2002; Jolly et al., 2002; 
Jolly et al., 2004; Rizzi et al., 2004). It was demonstrated in later studies that 
these SatIII sequences are transcribed and are required for the formation of 
nuclear stress bodies (Jolly et al., 2004; Metz et al., 2004; Rizzi et al., 2004; 
Shevtsov and Dundr, 2011). However the function of these nuclear stress 
bodies has yet to be determined. 
 
Heat shock also induces cytoplasmic structures called stress granules, which 
are distinct from other cytoplasmic processing bodies (Collier and Schlesinger, 
1986; Nover et al., 1989). This distinct compartment accumulates cellular 
mRNAs, pre-initiation and translation-related factors, and other RNA-binding 
proteins that affect translational control and mRNA stability (Anderson and 
Kedersha, 2006). Organelles are also affected as mitochondria undergo 
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several structural changes (Figure 1.1B). These induce metabolic changes as 
the total numbers of mitochondria decrease and ATP levels dramatically drop 
(Findly et al., 1983; Patriarca and Maresca, 1990; Welch and Suhan, 1985). 
Cells undergo a massive restructuring of the cytoskeleton with mild heat stress 
altering actin filaments into stress fibers and more severe stress resulting the 
aggregation of vimentin and other filament-forming proteins. This can result in 
the breakdown of the intermediate filament, actin, and tubulin networks and 
organelle relocalization (Toivola et al., 2010; Welch and Suhan, 1985, 1986). 
Fragmentation of the endoplasmic reticulum and Golgi complexes are 
observed, leading to a complete breakdown of intracellular transport 
processes (Figure 1.1C) (Welch and Suhan, 1985).  
 
Collectively these effects lead to cell cycle arrest, decreased growth and 
reduced proliferation. If the duration and severity of stress is great enough, the 
cell will eventually accumulate enough defects that will result in cell death. 
However if the heat stress is not lethal, the cell will survive and become 
resistant to more severe and otherwise fatal stresses in a phenomenon known 
as thermotolerance (Gerner and Schneider, 1975). The increased levels of 
HSPs that are synthesized in response to stress conditions are thought to be 
the basis for this resistance (Lindquist, 1986). 
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A
B
C
Figure 1.1 Detrimental effects of heat shock in rat embryo fibroblasts.  
Electron micrographs of cells incubated at normal temperature (37 °C, left) 
or after heat shock (3 h at 42 °C, right). (A) White arrows point to changes 
in the nucleoli and the formation of nuclear inclusion bodies. (B) Structural 
changes in mitochondria. (C) Heat shock induces fragmentation of the Golgi 
network. Adapted from Welch and Suhan (1985).  
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Heat shock proteins (HSPs) 
Many studies have evaluated the heat shock response in several cell types 
and organisms on a genome-wide scale using differential display, gene 
expression profiling, and proteomics (Eisen et al., 1998; Gasch et al., 2000; 
GuhaThakurta et al., 2002; Larkindale and Vierling, 2008; Matsuura et al., 
2010; Richmond et al., 1999; Rohlin et al., 2005; Tabuchi et al., 2008; Trinklein 
et al., 2004). These studies have demonstrated that 25-200 genes are 
significantly induced in different model organisms. In addition to the induction 
of molecular chaperones, other proteins that fall under the categories of 
metabolic enzymes, components of the proteolytic system, regulatory proteins 
like transcription factors and kinases, DNA- and RNA-modifying enzymes, and 
transport, detoxifying, and membrane-modulating proteins are also 
significantly upregulated upon heat stress (Richter et al., 2010). While the 
increased need for chaperones and proteases is intuitive in a cellular system 
that requires its protein homeostasis network to be maintained, the induction 
of other proteins in response to stress likely occurs to repair specific damages. 
 
The predominant class of stress-inducible proteins is comprised of the 
molecular chaperones, HSPs. There are several major conserved families that 
are often classified by their molecular weight: HSP100s, HSP90s, HSP70s, 
HSP60s, HSP40s and small HSPs (or crystallins). HSPs are needed during 
both de novo protein folding and refolding of nonnative polypeptides (Lindquist 
and Craig, 1988; Richter et al., 2010; Saibil, 2013). In addition, HSPs can also 
mark misfolded proteins for degradation through coordination with ubiquitin 
ligases and the proteasome system (Arndt et al., 2007; Lanneau et al., 2010). 
While molecular chaperones are generally not thought to contribute structural 
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information for folding, they do prevent unwanted intermolecular interactions 
by binding to extended patches of hydrophic surfaces that can promote non-
specific protein aggregation, specific peptide sequences, or structural 
elements. Chaperones do this by a cycle of controlled binding and release of 
nonnative proteins, which is triggered by multiple rounds of ATP hydrolysis 
with the exception of small HSPs that bind ATP but do not hydrolyze it 
(Bakthisaran et al., 2015; Hartl and Hayer-Hartl, 2009). While some molecular 
chaperones are only expressed after exposure to proteotoxic stress, most 
chaperones are ubiquitously expressed at high levels under physiological 
conditions. Some HSPs like HSP70 have forms that are both constitutive and 
stress inducible (HSC70 vs HSP70). Other HSPs like HSP90 complexes 
encompass as much as 1-2% of total cellular protein content and is further 
upregulated after stress (Borkovich et al., 1989).  
 
HSP70 is one of the most highly conserved chaperones with more than 60% 
sequence identity with its prokaryotic version, DnaK (Richter et al., 2010). The 
HSP70 family has multiple genes, which are present in different cellular 
compartments and associated with a wide variety of physiological processes. 
The HSP70 family is involved in de novo protein folding, refolding of unfolded 
proteins, and preventing aggregation of unfolding proteins. HSP70 is 
indispensible for both normal growth and growth at higher temperatures 
(Lindquist and Craig, 1988). HSP70 functions together with cofactors like 
HSP40, which binds nonnative proteins, shuttles them to HSP70, and 
stimulates HSP70 ATPase activity (Kampinga and Craig, 2010; Richter et al., 
2010; Saibil, 2013).  
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Similar to HSP70, HSP90 is also very well conserved with 40% identity shared 
with its bacterial homolog, htpG (Lindquist and Craig, 1988). Interestingly while 
the HSP90 gene family is essential in S. cerevisiae for growth at high 
temperatures, the deletion of the HtpG gene in E. coli is not lethal (Bardwell 
and Craig, 1987; Borkovich et al., 1989; Lindquist and Craig, 1988). HSP90 is 
also found in almost every compartment of a eukaryotic cell. While it does not 
bind fully denatured polypeptides like HSP60 and HSP70, HSP90 binds 
partially folded protein intermediate conformations, suggesting it acts at the 
later stages of substrate folding (Jakob et al., 1995; Pearl and Prodromou, 
2006; Taipale et al., 2010). HSP90 has a large number of diverse clients, 
which includes protein kinases, nuclear steroid receptors, transcription factors, 
protein trafficking and secretion components, and RNA processing factors 
(Taipale et al., 2010). In addition to its wide range of substrates, HSP90 also 
has a large cohort of co-chaperones that influence the dynamics of 
conformational equilibrium, the rate of ATP hydrolysis, recruitment of clients, 
or catalyze downstream enzymatic reactions. These include ATPase I (AHAI), 
HSP70-HSP90 organizing protein (HOP/STIP1), CDC37, p23 (PTGES3), 
FKBP51, FKBP52, and CHIP (Eckl and Richter, 2013). 
 
Regulators of the heat shock response 
In prokaryotes, the expression of HSPs is under the transcriptional control of 
σ32, which directs the bacterial RNA polymerase core enzyme to the 
promoters of HSPs (Grossman et al., 1987; Straus et al., 1987). In the 
absence of stress, DnaK the prokaryotic ortholog of HSP70 is bound to σ32, 
preventing σ32 from associating with the RNA polymerase core enzyme. After 
exposure to stress, DnaK disassociates from σ32, enabling the formation of 
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the RNA polymerase holoenzyme, which in turn is recruited to the consensus 
sites TTGAAA in the -35 region and CCCCATNT in the -10 region of HSP 
promoters (Nonaka et al., 2006; Wade et al., 2006; Zhao et al., 2005).  
 
In eukaryotes, the expression of HSPs is tightly regulated by a family of 
transcription factors called heat shock factors (HSFs). HSFs bind to the 
upstream DNA regulatory regions of HSP genes as trimers, where each 
individual DNA-binding domain recognizes the pentameric sequence, nGAAn. 
Thus, a functional heat shock response element (HSE) is composed of at least 
three nGAAn repeats, and the promoters of most HSP genes contain more 
than one HSE, allowing for multiple HSF trimers to bind simultaneously. 
Thermal denaturation experiments demonstrated that orientation of the 
pentamers significantly drives stable HSF1-HSE interactions with cooperative 
binding only occurring when there are continuous inversions of the nGAAn 
sequence (Jaeger et al., 2014). While yeast and fruit flies have a single HSF, 
vertebrates express multiple HSFs (HSF1-4). In mammals, HSF1 is the 
dominant regulator of the heat shock response whereas this response is 
controlled by HSF3 in avian cells (Nakai, 1999). Orthologous HSF3 gene 
segments were found in the human and mouse genome (Fujimoto et al., 2010). 
However only the mouse HSF3 gene produced transcripts suggesting that the 
orthologous genomic region in humans is an HSF3 pseudogene (Fujimoto et 
al., 2010). Interestingly the murine HSF3 failed to activate the HSP70 gene 
during heat shock and was dispensable for thermotolerance (Fujimoto et al., 
2010).  
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A large body of evidence has demonstrated that in addition to governing the 
heat shock response, the HSFs play many roles in normal physiology and 
development (Akerfelt et al., 2010). In Drosophila, deletion experiments 
demonstrated that the Hsf gene was important for oogenesis and larvae 
development, and these effects were not related to major changes in HSP 
expression (Jedlicka et al., 1997). Mice lacking HSF1 are not embryonic lethal, 
survive to adulthood, and have normal basal expression of HSPs (McMillan et 
al., 1998; Xiao et al., 1999). However Hsf1-/- mice exhibit multiple 
developmental defects including prenatal lethality, decreased body weight, 
growth retardation, failed zygotic cell division, placental defects, and female 
infertility (Christians et al., 2000; Xiao et al., 1999). Hsf1-/- oocytes also fail to 
mature as they are completely devoid of HSP90α, suggesting that maternal 
expression of HSF1 is required for the normal progression of meiosis in 
oocytes (Metchat et al., 2009). In addition Hsf1-/- mice exhibit abnormal brain 
morphology including enlarged ventricles, astriogliosis, neurodegeneration, 
progressive myelin loss, and defective olfactory neurogenesis (Homma et al., 
2007; Santos and Saraiva, 2004; Takaki et al., 2006). In addition to 
developmental defects, Hsf1 null mice also display defects in the immune 
system including increased susceptibility to bacterial infections, impaired IgG 
production, reduced expression of cytokines and chemokines, and impaired T 
cell expansion after activation (Chen et al., 2012; Gandhapudi et al., 2013; 
Inouye et al., 2004).  
 
The developmental functions of the HSF family are not limited to HSF1 as 
HSF2 and -4 also play important roles as developmental regulators. Unlike 
HSF1 that is ubiquitously expressed, HSF2 expression predominantly occurs 
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in the brain and testes, and its role in the development of these organs was 
apparent in the knockout mouse (Alastalo et al., 1998; Fiorenza et al., 1995; 
Goodson et al., 1995). Hsf2-/- mice have normal HSP expression but exhibit 
increased prenatal lethality, reduced female fertility, reduced testis size and 
sperm count, and brain abnormalities that include enlarged ventricles, 
abnormal neuronal migration, and defects in cortical lamination (Chang et al., 
2006; Kallio et al., 2002; Wang et al., 2003). While Hsf2 inactivation resulted in 
obvious defects, spermatogenesis was not completely arrested, indicating 
compensatory mechanisms. Indeed double disruption of Hsf1 and Hsf2 lead to 
a more pronounced phenotype: a complete lack of spermatozoa and male 
sterility (Wang et al., 2004). Unlike HSF1 and HSF2, HSF4 expression is 
undetectable in most tissues except in the brain, heart, lung, muscle, lens, and 
in splenic T cell subsets (Jin et al., 2011a; Tanabe et al., 1999). HSF4 has two 
isoforms, HSF4a and HSF4b, derived from alternative splicing of the same 
transcript and is a constitutive trimer (Nakai et al., 1997; Tanabe et al., 1999). 
HSF4 mutations are associated with dominant inherited cataracts in humans, 
and Hsf4 inactivation in mice results in cataracts shortly after birth most likely 
due to decreased expression of γ-crystallins and failure to repress fibroblast 
growth factors (Bu et al., 2002; Fujimoto et al., 2004; Min et al., 2004). The 
lens phenotype was more severe in the double knockout of Hsf1 and Hsf4 
(Fujimoto et al., 2004; Min et al., 2004).  
 
Although HSFs have both distinct and overlapping functions, HSF1 is the 
master regulator of the inducible heat shock response. This was demonstrated 
by a complete abrogation of HSP induction in Hsf1-/- mice after heat shock and 
a failure to acquire thermotolerance in Hsf1-/- embryonic cells (McMillan et al., 
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1998; Xiao et al., 1999). Recent work has suggested a specific interplay 
between HSF1 and HSF2 in stress-inducible transcription. HSF2 can form 
heterotrimers with HSF1 and colocalize to stress-induced nuclear granules, 
but the stress-related functions of HSF2 are strictly dependent on HSF1 
(Alastalo, 2003; Ostling et al., 2006; Sandqvist et al., 2009). Under basal 
conditions, trimerization of HSF1 is inhibited by a repressive HSP90-based 
multi-chaperone complex (Ali et al., 1998; Zou et al., 1998). In response to 
proteotoxic stress, HSPs are recruited to damaged proteins, allowing HSF1 to 
form homotrimers and undergo extensive post-translational modifications, both 
of which are essential for high-affinity DNA binding activity and transactivation. 
 
Functional domains HSF1 
The highly conserved DNA-binding domain (DBD) lies at the N-terminal region 
of the HSF1 protein (Figure 1.2) (Wu, 1995). The crystal structure (Harrison et 
al., 1994) and the two solution structures (Damberger et al., 1994; Vuister et 
al., 1994) of the HSF DBD resembles the winged helix-turn-helix family of 
DNA-binding proteins and consists of a three helix bundle capped by four 
antiparallel β-sheets. Physical and genetic studies show that the third helix of 
the HSF DBD acts as the recognition helix (Vuister et al., 1994). The 
oligomerization domain is C-terminal of the DBD and consists of arrays of 
hydrophobic heptad repeats (HR-A and HR-B) that are thought to form an 
unusual triple-stranded coiled-coil configuration (Peteranderl and Nelson, 
1992). An additional C-terminal hydrophobic heptad repeat (HR-C) negatively 
regulates HSF1 trimerization by directly interacting with HR-A/B to form an 
intramolecular coiled-coil, maintaining the monomeric HSF1 in the absence of 
stress (Figure 1.2) (Farkas et al., 1998; Rabindran et al., 1993; Sarge et al., 
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1993; Zuo et al., 1994; Zuo et al., 1995). The human HSF4, in addition to the 
HSF of Saccharomyces cerevisiae and Kluvermonyces lactis, lacks a 
conserved HR-C, which may explain their constitutive trimerization and DNA-
binding activity (Chen et al., 1993; Nakai et al., 1997). The transactivation 
domain is located at the extreme C-terminal end of the HSF1 protein and is 
composed of two modules: AD1 and AD2, which are kept inactive by a 
regulatory domain found between HR-A/B and HR-C under basal conditions 
(Figure 1.2) (Green et al., 1995). While the isolated TAD has constitutive 
transcriptional activity, fusion with the regulatory domain restores stress-
inducible activation (Green et al., 1995; Newton et al., 1996). 
 
Activation and attenuation of HSF1  
In the absence of stress, HSF1 is kept inactive in a multi-chaperone complex 
with HSP90, co-chaperone p23 (PTGES3), immunophilin FK506 binding 
protein 5 (FKBP52), HDAC6, and chaperone-like AAA ATPase p97/VCP 
(Figure 1.3) (Bharadwaj et al., 1999; Boyault et al., 2006; Boyault et al., 2007; 
Duina et al., 1998; Guo et al., 2001; Pratt and Toft, 1997; Zou et al., 1998). It is 
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Figure 1.2 HSF1 organization. Functional domains of HSF1 include the 
DNA binding (DBD), heptad repeats (HR-A/B and HR-C), a regulatory 
domain (RD), and two activation domains (AD-1 and AD-2). HSF1 can be 
acetylated (A), phosphorylated (P), and sumoylated (S). 
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predicted that HSP90 prevents the formation of HSF1 trimers by interacting 
with portions of the hydrophobic repeat regions (HR-A/B and HR-C) and a 
linker sequence N-terminal to the HR-A/B since those regions are involved in 
the repression of HSF1 oligomerization (Liu and Thiele, 1999; Orosz et al., 
1996). Likewise treatment with HSP90 inhibitors has been demonstrated to 
activate HSF1 (Hegde et al., 1995; Zou et al., 1998). After heat shock, HSP90 
and HSF1 dissociate (Figure 1.3). The mechanism of release is thought to 
rely on the dynamic nature of associations between HSPs and their substrates. 
Proteotoxic stress induces more protein unfolding, increasing the 
concentration of nonnative proteins that serve as substrates for HSP90. Due to 
the competition of HSF1 and misfolded proteins for HSP90, the rate of 
assembly of the HSF1-HSP90 complex is reduced, and unbound HSF1 
monomers will rapidly trimerize (Voellmy, 2004). Zhou et al. (1998) 
experimentally demonstrated this when he showed that the addition of 
chemically denatured proteins to an in vitro system of Hela cells triggered 
HSF1 oligomerization. While HSF1 trimers gain DNA-binding activity, 
transactivation can only occur after the protein is extensively modified post-
translationally (Figure 1.3). 
 
Upon heat shock, HSF1 is hyperphosphorylated although the regulation of the 
effect of each phospho-residue on transcriptional competence is more 
complex. In addition to phosphorylation, HSF1 undergoes other post-
translation modifications, including sumoylation, acetylation, and 
ubiquitinylation (Figure 1.3). Mass spectrometry analysis has revealed at least 
12 serine residues that are phosphorylated within the regulatory domain of 
HSF1 (Guettouche et al., 2005). While stress-induced phosphorylation of both 
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Ser230 and Ser326 have been associated with increased transcriptional 
activity, Guettouche et al. (2005) demonstrated that Ser326 but no other 
serines residues specifically enhances HSF1 transcriptional competence 
(Holmberg et al., 2001). HSF1 is also phosphorylated under non-stress 
conditions. For instance, phosphorylation of Ser303 and Ser307 by GSK3β 
and ERK1 maintains HSF1 in a transcriptionally inactive state and may also 
mediate a protein-protein interaction with the scaffolding protein 14-3-3, which 
sequesters HSF1 in the cytoplasm (Chu et al., 1996; He et al., 1998; Kline and 
Morimoto, 1997; Knauf et al., 1996; Wang et al., 2004; Wang et al., 2003; 
Xavier et al., 2000). In addition to cytoplasmic sequestration, phosphorylation 
of Ser303/307 has been recently shown to facilitate an interaction with 
FBXW7α, a substrate-targeting unit of the Skp1-Cul1-F box ubiquitin ligase 
complex, which results in poly-ubiquitinylation, nuclear clearance, and 
degradation of HSF1 (Kourtis et al., 2015). Phosphorylation of Ser303 is also a 
prerequisite for a small ubiquitin-related modifier (SUMO) to be conjugated to 
Lys298, resulting in the repression of HSF1 transcriptional activity 
(Hietakangas et al., 2003). Unlike the rapid phosphorylation and sumoylation 
events that occur after heat shock, the acetylation of HSF1 at Lys80 by 
CBP/p300 is delayed and occurs when HSF1 activity is attenuated after 
activation (Figure 1.3) (Ghosh et al., 2011; Raychaudhuri et al., 2014; 
Westerheide et al., 2009). Lys80 is located in a short domain connecting the 
DNA recognition helix with the solvent-exposed loop and forms a hydrogen 
bond with the DNA phosphate backbone. Therefore, the neutralization of the 
positively charged Lys side chain would disrupt the DNA-HSF1 interaction. 
Deacetylation of HSF1 by SIRT1 enhances and prolongs DNA binding activity 
(Westerheide et al., 2009).  
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Figure 1.3 The HSF1 activation and attenuation cycle. Under basal 
conditions, HSF1 is a monomer and phosphorylated (P) in a complex with 
HSP90. After stress, HSF1 dissociates from the HSP90 complex, 
trimerizes, and binds to heat shock elements in its target genes. It 
undergoes other post-translational modifications that regulate its 
transactivation capacity like sumolyation (S) and phosphorylation (P). HSF1 
attains transcriptional activity and induces the expression of its targets. 
HSF1 attenuation occurs by negative feedback from other HSPs that 
inhibits transactivation and by acetylation of Lys80 in the HSF1 DBD that 
inhibits DNA binding. SIRT1 antagonizes the actions of p300 by 
deacetylating HSF1. Adapted from Akerfelt et al. (2010). 
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After a cell has overcome stress and is returning to homeostasis, the 
oligomerization and activity of HSF1 must return to basal conditions. This is 
likely mediated by chaperones, as there is a decreased pool of unfolded 
proteins, which will shift chaperone complexes to form with HSF1. HSP70 and 
its co-chaperone HSP40 have been shown to interact with HSF1 to reduce its 
transactivation capacity without altering DNA binding (Figure 1.3) (Abravaya 
et al., 1992; Baler et al., 1992; Shi et al., 1998). In addition, the HSP90-
multichaperone complex is able to associate with HSF1 trimers through its 
regulatory domain, which is distinct from the interaction HSP90 has with 
monomeric HSF1 (Guo et al., 2001).  
 
HSF1-induced transcriptional regulation 
Much of work that has provided insight into the transcriptional regulation of the 
heat shock response by HSF has been accomplished by extensive studies of 
the HSP70 promoter in Drosophila. RNA polymerase II (Pol II) is 
transcriptionally engaged but paused downstream at the transcriptional start 
site of the HSP70 promoter (Core and Lis, 2008). After heat shock, HSF binds 
HSEs within the HSP70 promoter and recruits transcriptional coactivator 
Mediator, which collaborates with positive transcription elongation factor-b (P-
TEFb) (Lis et al., 2000; Park et al., 2001). P-TEFb then phosphorylates the C-
terminal domain (CTD) of Pol II, allowing for productive elongation (Marshall et 
al., 1996). In addition to P-TEFb, HSF1 also recruits histone-modifying 
enzymes, like Trithorax and CREB-binding protein (CBP), Spt6, a nucleosome 
chaperone, and Topoisomerase (Topo) I, which removes supercoils generated 
by transcription (Boehm et al., 2003; Ni et al., 2008; Smith et al., 2004). A 
recent study has demonstrated that the recruitment of HSF after heat shock 
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occurs rapidly while the recruitment of Pol II, Spt6, and Topo I occur much 
later (Zobeck et al., 2010). In addition to these transcriptional regulators, 
decondensation and nucleosome loss at the HSP70 locus are dependent on 
poly(ADP)-ribose polymerase (PARP) (Petesch and Lis, 2008). After heat 
shock, PARP is rapidly redistributed along the HSP70 locus (Petesch and Lis, 
2012). The activation of PARP and accumulation of its catalytic product, PAR, 
at HSP70 induce the formation of a localized compartment that retains Pol II 
for sustained transcriptional activation (Zobeck et al., 2010). This process is 
dependent on HSF1, which directs the acetylation of H2AK5 by the histone 
acetyltransferase TIP60, an event that is required for PARP activation, 
nucleosome loss, and transcriptional activation of HSP70 (Petesch and Lis, 
2012).  
 
The mammalian HSP70 promoter also houses paused Pol II. In fact, HSP70 is 
bookmarked by HSF2, preventing its compaction by condensin and 
maintaining the gene in a transcriptionally competent or poised state (Xing, 
2005). This allows HSF1 to bind and activate HSP70 expression if cells in the 
early G1 phase were suddenly exposed to stress. Fujimoto et al. (2012) also 
demonstrated that low levels of HSF1 are bound to the HSP70 locus and other 
HSF1 targets under normal physiological conditions in a complex with 
Replication Protein A (RPA), a protein known to stabilize single stranded DNA 
during DNA replication (Wold, 1997). The RPA-HSF1 complex opens the 
chromatin structure of the HSP70 promoter by recruiting a histone chaperone 
FACT, which displaces histones, facilitating the preloading of Pol II (Fujimoto 
et al., 2012; VanDemark et al., 2006). This mechanism was found to be 
required for basal expression of HSF1 targets (Fujimoto et al., 2012).  During 
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heat shock, active HSF1 recruits ATF1 and mitochondrial SSBP1 to the 
HSP70 promoter (Takii et al., 2015; Tan et al., 2015). Both the HSF1-ATF1 
and HSF1-SSBPI complexes have been demonstrated to be required for 
maximal recruitment of coactivators, lysine acetyltransferase CBP/p300 (Xu et 
al., 2008) and the BRG1-containing ATP-dependent chromatin-remodelling 
complex SWI/SNF, and optimal induction of HSP70 (Corey, 2003; Sullivan et 
al., 2001; Takii et al., 2015; Tan et al., 2015; Xu et al., 2008). ATF1 also 
attenuates HSF1 activity by promoting acetylation of HSF1 via p300/CBP 
thereby decreasing its DNA binding activity (Ghosh et al., 2011; Raychaudhuri 
et al., 2014; Takii et al., 2015; Westerheide et al., 2009). Similar to the HSP70 
locus, HSF1 was shown to bind the IL-6 promoter and induce the opening of 
its chromatin structure by recruiting CBP and the SWI/SNF complex (Inouye et 
al., 2007). However unlike HSP70, HSF1 recruits a negative regulator of IL-6, 
ATF3, which inhibits IL-6 expression (Takii et al., 2010).  
 
Although heat shock increases the transcription of HSPs and other 
cytoprotective proteins, it also induces a global downregulation of many other 
housekeeping genes. This is partially mediated by the noncoding RNAs 
(ncRNAs) transcribed from mouse B2 and human Alu short interspersed 
elements (SINEs), which act as general transcriptional repressors by 
associating with Pol II complexes at promoters (Espinoza et al., 2004; Mariner 
et al., 2008). In addition to ncRNAs, HSF1 may also play a role in the 
downregulation of genes by potentially inducing changes in chromatin 
architecture or recruiting corepressors although the precise mechanisms have 
yet to be defined. However, HSF1 has been demonstrated to interact with and 
increase the activity of HDAC1 and HDAC2 after heat shock, resulting in a 
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global deacetylation of core histones (Fritah et al., 2009). An interaction 
between HSF1, HDAC1/2, and MTA1 has also been reported in breast cancer 
cells (Khaleque et al., 2008). Moreover, CoREST, an integral component of a 
histone deacetylase complex also containing HDAC1/2, interacts with HSP70 
in a negative feedback loop that regulates HSP70 gene expression (Gomez et 
al., 2008). Through this interaction, CoREST has been shown to repress 
HSF1-dependent transactivation. 
 
Heat shock response and cancer 
HSPs have been implicated in tumor initiation and survival, stabilizing many of 
the signaling pathways that are frequently hijacked to induce and maintain a 
malignant phenotype (Workman et al., 2007; Zuehlke and Johnson, 2010). In 
addition, tumor cells become addicted to HSPs because of oncoproteins that 
need a high degree of chaperoning because they are aberrantly expressed 
(HER2), mutated (B-RAF), or chimeric due to a genetic translocation (BCR-
ABL) (Trepel et al., 2010; Workman et al., 2007; Zuehlke and Johnson, 2010). 
This is further confirmed by the fact that tumor-specific HSP90 participates in 
higher-order multi-chaperone complexes and has higher affinity for HSP90 
inhibitors relative to normal tissues (Kamal et al., 2003; Moulick et al., 2011). 
This most likely represents a stress-specific form of HSP90 chaperone 
complexes in tumor cells that is necessary for executing functions required to 
maintain a malignant lifestyle. In fact many HSP90 inhibitors preferentially 
accumulate in the tumor and exhibit surprisingly low toxicity (Kamal et al., 
2003; Moulick et al., 2011; Vilenchik et al., 2004). Thus several HSP90 
inhibitors have been developed since the concept of targeting HSP90 first 
arose in the 1990s with the discovery of geldanamycin (Whitesell et al., 1994). 
	  20 
While geldanamycin proved too toxic and unstable for clinical use, 
geldanamycin analogs were promising and demonstrated proof-of-concept 
anti-tumor activity but with hepatic toxicity due to their quinone metabolism 
(Jhaveri et al., 2014; Neckers and Workman, 2012). Geldanamycin and many 
other HSP90 inhibitors all take advantage of the core network of hydrogen-
bonding interactions to anchor the drug into the N-terminal ATP-binding pocket 
of HSP90 (Prodromou et al., 1997; Roe et al., 1999; Stebbins et al., 1997). 
High throughput screening and structure-based design methods have been 
employed to find newer HSP90 inhibitors that can be administered more 
frequently, achieve higher maximal doses, and lack significant hepatotoxicity, 
which was limiting for geldanamycin chemotypes. Many of these inhibitors fall 
into the purine scaffold series, with candidates BBIIB021, BIIB028, PU-H71, 
and the resorcinols, which include NVP-AUY922 (Cheung et al., 2005; Chiosis 
et al., 2001; Eccles et al., 2008; Neckers and Workman, 2012). 
 
Due to its role in regulating the stress response, HSF1 has also been 
implicated in allowing cells to tolerate the imbalances of protein homeostasis 
that occurs during malignancy. While elevated HSP levels have been noted in 
several tumor types, increased HSF1 expression has also been found in 
human prostate carcinoma cell lines and HSF1 depletion sensitizes cells to 
proteasome and HSP90 inhibitors (Jolly and Morimoto, 2000; Tang et al., 
2005; Zaarur et al., 2006). Susan Lindquist and colleagues demonstrated that 
genetic elimination of HSF1 protects mice against tumorigenesis in cancer 
models driven by loss-of-function TP53 mutations and chemical carcinogens 
(Dai et al., 2007; Jin et al., 2011b; Min et al., 2007). While overexpression of 
HSF1 alone is unable to induce transformation in immortalized mouse 
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embryonic fibroblasts (MEFs), HSF1 enables cellular transformation initiated 
by oncogenic RAS and PDGF-B (Dai et al., 2007). These results are 
concordant with another study demonstrating a role for HSF1 in HER2-induced 
transformation of a breast epithelial cell line (Khaleque et al., 2008; Meng et al., 
2010). Furthermore knockdown of HSF1 results in decreased cell viability in a 
number of malignant cell lines including breast, cervical, prostate, and kidney 
cancer (Dai et al., 2012; Dai et al., 2007; Meng et al., 2010; Min et al., 2007; 
Santagata et al., 2012; Zhao et al., 2011). Although HSF1 acts neither as a 
classical oncogene or tumor suppressor, HSF1 seems to govern a broad 
network of signaling pathways to support the tumorigenic environment. 
 
Many studies have demonstrated that HSF1 regulates the expression of other 
genes in addition to HSPs (Dai et al., 2007; Khaleque et al., 2008; Mendillo et 
al., 2012; Trinklein et al., 2004). HSF1 modulates a number of cellular 
processes including signal transduction, proliferation, glucose metabolism, and 
protein translation (Dai et al., 2007; Lee et al., 2008; Zhao et al., 2011; Zhao et 
al., 2009). Therefore it was possible that HSF1 plays a larger role to directly 
rewire the transcriptome to maintain the malignancy of cancer cells. By using 
isogenic human breast cancer cell lines with different tumorigenic and 
metastatic potential and transforming them, Mendillo et al. (2012) 
demonstrated that the highly metastatic and tumorigenic cells have stronger 
HSF1 nuclear staining and were more dependent on HSF1. By using 
chromatin immunoprecipitation (ChIP) followed by next-generation sequencing 
(ChIP-seq) in heat shocked or transformed cell lines, Mendillo et al. (2012) 
went on to show that the HSF1 transcriptional program in malignant cells was 
distinct from cells exposed to heat shock. While many HSF1 gene targets 
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enrich in protein folding and stress response categories, other HSF1 regulated 
genes fall under categories of protein translation, RNA binding, metabolism, 
immune processes, cell cycle/proliferation, and cell adhesion (Mendillo et al., 
2012). Activation of the HSF1-cancer program is associated with disease 
progression and can predict poor prognosis in breast, colon, lung, and 
hepatocellular carcinoma patients	   (Fang et al., 2012; Mendillo et al., 2012; 
Santagata et al., 2011). 
 
While many studies have shown a clear role for HSF1 in maintaining a 
malignant phenotype in cancer cells, HSF1 also plays a part reprogramming 
tumor stroma to further enable tumor growth in a non-cell autonomous manner 
(Scherz-Shouval et al., 2014). HSF1 has been demonstrated to be active in 
cancer-associated fibroblasts (CAFs) (Scherz-Shouval et al., 2014). This 
specific subset of fibroblasts and myofibroblasts are recruited by the tumor to 
support proliferation, invasion, metastasis, angiogenesis and drug resistance 
by secreting extracellular matrix components, chemokines, cytokines, and 
growth factors.	   (Erez et al., 2010; Kalluri and Zeisberg, 2006; Lu et al., 2012; 
Olumi et al., 1999; Orimo et al., 2005; Pickup et al., 2013; Siegel and 
Massague, 2003; Straussman et al., 2012; Wilson et al., 2012). HSF1 
activation in CAFs induces the expression and secretion of TGF-β and SDF1, 
which have been previously demonstrated to enhance the protumorigenic 
phenotype	   (Kojima et al., 2010; Scherz-Shouval et al., 2014). These results 
were further confirmed by the observation that HSF1 depletion in CAFs results 
in decreased growth of the tumor in a xenograft model (Scherz-Shouval et al., 
2014). Interestingly the HSF1 transcriptional program in stromal cells was 
profoundly different from the transcriptional program it drives in cancer cells, 
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suggesting that HSF1 can drive highly divergent transcriptional responses 
depending on the cellular context (Scherz-Shouval et al., 2014). 
 
2. B cell activation and lymphomagenesis 
The immune system has two arms that protect an organism from pathogens: 
innate and adaptive immunity. The first line of defense is the innate immune 
system, which plays an essential role to mount an inflammatory response and 
activate the complement system. This controls the infection until the adaptive 
immune response can take effect. However the effectors of the innate immune 
response are limited in that they can only recognize some (not all) pathogens 
because they rely on germline-encoded receptors that identify microorganisms 
that may evolve more rapidly than the host they infect. In addition, innate 
immunity effectors lack immunological memory and are unable to provide long-
lasting immunity. The adaptive immune response on the other hand has 
lymphocytes that undergo genetic recombination of variable regions within 
their germline antigen receptor genes during development to produce a 
clonally diverse repertoire of antigen receptors. While each lymphocyte will 
carry only one antigen specificity, millions of lymphocytes are produced to 
allow for the recognition of an almost infinite number of pathogens. After 
encountering an antigen, lymphocytes adapt their receptors to bind the antigen 
with higher affinity by undergoing additional somatic mutations and clonally 
expand to allow for the differentiation of enough effector cells to clear the 
antigen. After the antigen has been removed, many of the lymphocytes 
specific to that antigen will undergo apoptosis, leaving a few antigen-specific 
cells that remain and act as memory cells. These cells provide lasting 
protective immunity by allowing for a more rapid and enhanced response to 
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later encounters with the same pathogen. The humoral immune response, an 
important feature of adaptive immunity that is mediated by immunoglobulin 
molecules (or antibodies), protects extracellular spaces and prevents the 
spreading of intracellular infections. This response requires the coordinated 
efforts of both B and T cells for the maximal production of high-affinity 
antibodies by B cells. 
 
B cell development 
B cells are derived from a common lymphoid progenitor in the bone marrow by 
the concerted action of a network of stimulator molecules and transcriptional 
regulators that induces a specific lineage-defining gene expression program. 
In mice, the transition to the first step in B cell development, the pre-pro-B 
stage, is driven by interleukin (IL)-7 produced by stromal cells and signaling 
via the IL-7 receptor (Figure 1.4) (Milne and Paige, 2006). By activating the IL-
7 receptor and STAT5, IL-7 induces the expression of early B cell factor (EBF) 
1 (DeKoter et al., 2002; Dias et al., 2005; Kikuchi et al., 2005). EBF1 together 
with E2A and FOXO1 induce the expression of the essential B lineage-
commitment factor, PAX5, which in turn participates in a positive feedback 
loop to further upregulate EBF1 (Lin et al., 2010; Milne and Paige, 2006; Nutt 
and Kee, 2007). PAX5 activates genes necessary for subsequent B cell 
development while repressing genes involved in the development of non-B 
lineage cells (Delogu et al., 2006; Fuxa and Busslinger, 2007; Medvedovic et 
al., 2011). 
 
The B cell antigen receptor (BCR) is a surface immunoglobulin (Ig) molecule 
consisting of two heavy and two light chains. Before the BCR can be 
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expressed on the surface of a B cell, the receptor must be assembled by DNA 
recombination events that join the variable (V), diversity (D), and joining (J) 
segments of the heavy (IgH) chain gene and V to J segments of the light chain 
(Igκ and Igλ) genes. This process is called V(D)J recombination, and it 
requires the endonucleases recombination activating genes (RAG) 1 and 2. 
RAGs introduce a double-strand break between a variable region segment and 
a nearby recombination signal sequence. This is followed by repair by 
nonhomologous end-joining (NHEJ) proteins, which generates a newly joined 
gene arrangement. To prevent aberrant recombination events, V(D)J 
recombination is tightly and temporally controlled during B cell development by 
(i) limiting the expression of RAG1/2 to certain stages of B cell maturation and 
(ii) limiting RAG1/2 access to the different Ig gene segments by epigenetic 
mechanisms (Jhunjhunwala et al., 2009; Perlot and Alt, 2008).  
 
DH-JH rearrangement of the IgH loci precedes VH-DJH recombination and 
occurs in lymphoid progenitors in a mechanism dependent on E2A and EBF1 
activating the expression of RAG genes (Figure 1.4) (Goebel et al., 2001; 
Perlot and Alt, 2008; Romanow et al., 2000). In committed pro-B cells, PAX5 
mediates the contraction of the IgH locus, which is necessary for the 
juxtaposition of distal VH genes to proximal DJH segments (Fuxa et al., 2004). 
Other studies have demonstrated that additional transcriptional regulators that 
include YY1, CCCTC-binding factor (CTCF), and members of the cohesin 
family also coordinate this event (Degner et al., 2009; Ebert et al., 2011; Liu et 
al., 2007). Upon productive rearrangement of one IgH allele, intact µ 
transcripts are expressed, which assemble with a surrogate light chain and 
accessory chains Igα and Igβ to form the pre-BCR (Figure 1.4) (Nishimoto et 
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al., 1991). Pre-BCR signaling acts to transiently downregulate the expression 
of RAGs, and attenuation of IL-7 receptor signaling also decreases the 
accessibility of the IgH locus to the RAGs (Chowdhury and Sen, 2003; Jung et 
al., 2006). If the first VH-DJH rearrangement was nonproductive, VH-DJH 
rearrangement occurs on the other chromosome. After successful IgH 
rearrangement and formation of the pre-BCR, B cells progress to the pre-B 
cell stage where they enlarge and receive signals to proliferate (Figure 1.4) 
(Melchers, 2005). Pro-B cells that have nonproductive rearrangements at both 
IgH alleles are unable to form the pre-BCR, making them incapable of 
receiving this proliferative signal, and undergo apoptosis. 
 
The proliferating large pre-B cells eventually transition to small resting pre-B 
cells (Figure 1.4). This proliferative burst likely occurs to produce enough 
progeny so that each can produce a different light chain gene with differing 
antigen specificity thereby increasing BCR diversity. However pre-B cells must 
exit the cell cycle to allow for the reactivation of RAG expression and induction 
of light chain rearrangement (Lin and Desiderio, 1994). This occurs when the 
pre-B cells migrate away from IL-7-rich niches of the bone marrow (Tokoyoda 
et al., 2004). Light chain recombination tends to occur first on the Igκ locus 
and is driven by pre-BCR-dependent and -independent mechanisms and 
requires some of the same transcription factors involved in IgH rearrangement 
like PAX5 and E2A (Hamel et al., 2014; Lazorchak et al., 2006; Sato et al., 
2004). Activated ERK induces E2A, which binds the Igκ enhancers to change 
the epigenetic landscape into a more open chromatin structure (Mandal et al., 
2009). In addition, the loss of IL-7 receptor signaling leads to activation of PI3 
kinase (PI3K)/Akt, resulting in increased FOXO expression (Amin and 
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Schlissel, 2008). FOXO1 directly induces the expression of the RAGs and 
kinases, SYK and BLNK (Amin and Schlissel, 2008; Ochiai et al., 2012). The 
SYK/BLNK module induces IRF4 and IRF8 expression, which also bind the 
Igκ enhancers and further increase Igκ accessibility (Johnson et al., 2008; Lu 
et al., 2003; Ma et al., 2008). Collectively, these events make the Igκ locus 
more accessible to transcription and recombination (Hamel et al., 2014). Once 
Ig light chains have been productively rearranged, they replace the surrogate 
light chain and combine with the rearranged heavy chain to form intact IgM 
molecules (Figure 1.4). IgM together with signaling accessory chains, Igα and 
Igβ, form the mature and fully functional BCR complex.  
 
The now immature B cells undergo a negative selection process that will allow 
the cell to emigrate out of the bone marrow if it does not encounter a strong 
cross-linking antigen (i.e. self). Self-reactive B cells can undergo receptor 
editing, which requires additional rearrangement of their light chains to change 
their self-reactive receptors into non-self-reactive receptors (Gay et al., 1993; 
Tiegs et al., 1993). If they fail to edit their receptors appropriately, the cells will 
be deleted or silenced in a process referred to as anergy (Goodnow et al., 
1988; Lederberg, 1959; Nemazee and Burki, 1989; Nossal and Pike, 1980). 
Immature B cells migrate out of the bone marrow and into secondary lymphoid 
organs like the spleen and lymph nodes. Secondary lymphoid organs have 
distinct compartments for B, T, and leukocyte and non-leukocyte stromal cells 
based on the expression patterns of chemoattractant receptors. Here the 
immature B cells compete for access to follicles formed by other B cells and 
attain signals for survival and maturation (Dal Porto et al., 2002). Once mature, 
resting B cells express both surface IgM and IgD (Figure 1.4). If they have not 
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encountered antigen, naïve B cells will leave the lymphoid organs via the 
efferent lymph (as in lymph nodes) or the marginal sinus (as in the spleen) to 
recirculate throughout the body or to another tissue in search for its antigen. 
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Figure 1.4 B cell development is marked by the rearrangement and 
expression of Ig genes. Pre-pro B cell differentiation from a stem cell is 
driven by IL-7 signaling through its receptor (IL-7R), which induces heavy 
chain rearrangement first. DH-JH rearrangement occurs in the pre-pro B cell 
followed by VH-DJH rearrangement in the late pro-B cell stage. Once 
productive VDJH rearrangement has occurred, µ chain transcripts are 
expressed forming the pre-BCR with Igα/β and surrogate light chain (SLC). 
Pre-BCR signaling stimulates cells to grow and proliferate and also 
dampens IL-7R signaling. Large pre-B cells stop proliferating and become 
resting small pre-B cells to undergo light chain rearrangement. After 
productive light chain rearrangement, the fully functional BCR is formed 
from IgM, resulting in immature B cells. Immature B cells leave the bone 
marrow and migrate to peripheral secondary lymphoid organs to mature. At 
this stage, mature naïve B cells express both surface IgD and IgM from an 
alternative mRNA splicing mechanism. Adapted from Janeway et al. 
Immunobiology (2001). 
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B cell activation and the germinal center 
Once a mature B cell encounters antigen in the lymphoid follicles either 
directly or through other antigen-presenting cells like macrophages, follicular 
or other local dendritic cells, its surface BCRs begin to cluster and crosslink 
with each other to induce a signaling cascade that results in the first stages of 
B cell activation (Figure 1.5). Then the B cell internalizes and processes the 
antigen for presentation by its major histocompatibility complex (MHC) class II 
proteins to T cells. Maximal B cell activation can only occur after additional 
signals from a specific subset of cognate T cells referred to as T follicular 
helper (TFH) cells. Dendritic cells prime CD4+ T cells to the TFH cell fate through 
inducible costimulator (ICOS), various interleukins, and T cell receptor (TCR) 
signaling, which together upregulate the expression of B cell lymphoma 6 
(BCL6) and other TFH markers like CXC-chemokine receptor 5 (CXCR5) and 
programmed cell death protein 1 (PD1) (Choi et al., 2013; Choi et al., 2011; 
Crotty, 2014). Activated B cells and TFH cells migrate to the borders of the 
follicle and T zone (i.e. the interfollicular zone) where they have long-lived 
interactions via MHC-TCR and CD40-CD40L interactions (Figure 1.5) (De 
Silva and Klein, 2015; Okada et al., 2005; Qi et al., 2008). Here activated B 
cells can undergo one of several fates. If the activated B cell has a BCR with 
high-affinity for the antigen, it will move to the extra-follicular regions and 
differentiate into short-lived plasma cells that secrete antibody (Jacob and 
Kelsoe, 1992; O'Connor et al., 2006; Paus et al., 2006). Alternatively, they can 
differentiate unto unswitched, recirculating memory B cells (Taylor et al., 2012). 
Finally a subset of B cells will be stimulated by TFH cells to proliferate and 
migrate to the center of the B cell follicle where they will form distinct 
structures called secondary follicles or germinal centers (GCs) (Figure 1.5) 
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(Baumjohann et al., 2011; Choi et al., 2011; Kerfoot et al., 2011; Kitano et al., 
2011; Pereira et al., 2009). GCs are the sites of affinity maturation where B 
cells clonally expand and are selected for producing high-affinity antibodies 
against antigen, and this process is highly dependent on BCL6, the master 
regulator of both the TFH and GC B cell program (Basso and Dalla-Favera, 
2010; Johnston et al., 2009; Nurieva et al., 2009). 
 
Once B cells migrate into the center of the follicle, they grow and differentiate 
into blast-like cells (or centroblasts) that proliferate rapidly. The proliferation of 
centroblasts pushes naive B cells outward, forming the mantle zone that 
surrounds the GC (Figure 1.5) (De Silva and Klein, 2015; Victora and 
Nussenzweig, 2012). The GC becomes polarized into two discrete 
compartments referred to as the dark and light zone based on their histological 
appearance. The dark zone consists of densely packed centroblasts whereas 
the light zone has B cells interspersed in a network of follicular dendritic cells 
(FDCs), TFH, and macrophages (De Silva and Klein, 2015; Victora and 
Nussenzweig, 2012). Apart from anatomical differences, chemokine gradients 
and the expression of their receptors also segregate GC cells into dark and 
light zone compartments. Dark zone B cells express high levels of CXCR4 and 
lower levels of CD83 and CD86 whereas light zone B cells express low levels 
of CXCR4 and high levels of CD83 and CD86 (Allen et al., 2004; Allen et al., 
2007; Caron et al., 2009; Victora et al., 2010).  
 
In the dark zone, centroblasts undergo somatic hypermutation (SHM) of their 
IgV regions by activation-induced cytidine deaminase (AID). AID deaminates 
deoxycytosines into deoxyuracils on single-stranded DNA producing 
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mismatches that are removed by base excision repair or mismatch repair 
mechanisms ultimately producing an Ig receptor with a spectrum of affinities 
for the antigen (Dominguez and Shaknovich, 2014; Zan and Casali, 2013). GC 
B cells then migrate to the light zone where they are positively selected if they 
express high-affinity antigen receptors and are signaled to re-enter the dark 
zone for further cell division and mutations. Many rounds of mutation and 
selection allow for the production of the highest-affinity antibodies (De Silva 
and Klein, 2015; Victora and Nussenzweig, 2012). Selection of GC B cells is 
dominated by TFH cells, which have also homed to the light zone of the GC 
(Figure 1.5) (Victora et al., 2010). Many studies have demonstrated that TFH 
cells provide survival and proliferative signals via its TCR to GC B cells 
through peptide-MHC complexes (De Silva and Klein, 2015; Victora and 
Nussenzweig, 2012). In fact GC B cells that present a higher density of 
antigen on MHC complexes have the largest and longest contacts with TFH 
cells, and this is directly correlated to the number of times the cell divides after 
re-entering the dark zone and the accumulation of SHM (Gitlin et al., 2014; 
Shulman et al., 2014; Victora et al., 2010). While BCR affinity is directly 
associated to the amount of antigen captured and presented on MHC 
complexes, BCR signaling does not influence GC B cell selection by either TFH 
cells or FDCs. In fact BCR signaling is quiescent due to increased 
phosphatase activity of SHP1 (Khalil et al., 2012; Victora et al., 2010). In 
addition to receiving proliferative signals from TFH cells, GC B cells also 
provide signals to TFH cells. Shulman et al. (2014) demonstrated that contact 
between TFH and GC B cells results in increased calcium signaling and IL-4 
and IL-21 production in TFH cells, which enhances GC TFH function (Shulman 
et al., 2014). In addition, GC B cells express ICOSL that enhances interactions 
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with ICOS-expressing TFH cells (Liu et al., 2015). This in turn increases the 
surface display of CD40L on TFH cells, which provides GC B cells with CD40 
stimulation that induces more ICOSL on GC B cells (Liu et al., 2015). Once 
selected in the light zone, GC B cells can undergo class-switch recombination 
(CSR) of their Ig loci, which like SHM is also mediated by AID, to produce a 
different isotype of antibody for different effector function (De Silva and Klein, 
2015; Victora and Nussenzweig, 2012). After CSR, GC B cells can re-circulate 
back to the dark zone or directly differentiate further. This process is regulated 
by TFH-mediated production of IL-4 and IL-21 (Zotos and Tarlinton, 2012).  
 
The end product of the GC response is the differentiation of B cells to two 
post-GC compartments: memory B cells or plasmablasts (Figure 1.5). 
Memory B cells recirculate in the periphery and will rapidly differentiate into 
plasma cells if they re-encounter the same antigen (Gray, 1993). Plasmablasts 
will differentiate further into long-lived plasma cells and home to the bone 
marrow (Shapiro-Shelef and Calame, 2005). The mechanisms governing the 
fate of GC B cells to the either cell compartments are not fully understood. 
Entry into the memory compartment is hypothesized to be a stochastic event 
in that if the GC B cell is selected and survives apoptosis, this might be 
sufficient for progression towards the memory cell fate (Victora and 
Nussenzweig, 2012; Zotos and Tarlinton, 2012). Commitment to the plasma 
cell fate has been demonstrated to occur through CD40 activation of the NF-
κB pathway and induction of IRF4. IRF4 suppresses BCL6 and induces the 
expression of BLIMP1, which is the master regulator of plasma cell 
differentiation (Oracki et al., 2010; Victora and Nussenzweig, 2012).  
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Figure 1.5 Germinal center formation. To generate high-affinity 
antibodies, antigen-activated B cells migrate to the interfollicular zone 
where TFH cells stimulate them to move to the center of the follicle, 
proliferate, and differentiate into centroblasts, resulting in the formation of 
GCs. Centroblasts undergo clonal expansion and somatic hypermutation of 
the IgV loci to produce Ig of heterogeneous affinities to antigen. GC B cells 
with high-affinity antigen-specific Ig are selected by TFH cells that provide 
them with proliferative and survival signals whereas those cells with 
mutations that encode low-affinity Ig are not selected and undergo 
apoptosis. After selection, GC B cells can differentiate further into either 
antibody-secreting plasma cells or memory B cells. BCL6 is the master 
regulator of the GC response in GC B cells and TFH cells. However BCL6 
expression must be downregulated to ensure post-GC exit and terminal 
differentiation, and constitutive expression of BCL6 can transform GC B 
cells into malignant lymphomas. GCs are detectable by 
immunohistochemistry using peanut agglutinin (PNA) to stain splenic 
tissues obtained from immunized mice (top right inset). Adapted from 
Bunting and Melnick (2013) and Beguelin et al. (2013). 
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GCs and B cell lymphomas 
While GCs are necessary for the immune response, they need to be tightly 
regulated to prevent transformation into lymphomas. GC B cells undergo 
genotoxic and replicative stress due to SHM and CSR of their Ig loci and 
clonal expansion. Both processes are essential for the production high-affinity 
antibodies. However aberrant SHM and/or CSR can make the GC B cell 
susceptible to chromosomal translocations and deregulation of proto-
oncogenes resulting in malignancy (Klein and Dalla-Favera, 2008; Lenz and 
Staudt, 2010). In fact the majority of human B cell lymphomas have somatic 
mutations in the IgV loci suggesting that they are either blocked in or have 
passed through the GC (Klein and Dalla-Favera, 2008; Seifert et al., 2013). 
GC B cells can give rise to a number of lymphomas, including follicular, Burkitt, 
and diffuse large B cell lymphomas.  
 
Diffuse large B cell lymphoma (DLBCL) is the most common form of 
lymphoma, accounting for 30-40% of newly diagnosed lymphomas (Lenz and 
Staudt, 2010; Rodriguez-Abreu et al., 2007; Roschewski et al., 2014). They 
are aggressive but have a greater than 50% response rate to the current 
standard therapeutic regimen of cyclophosphamide, doxorubicin, vincristine, 
prednisone, and rituximab (R-CHOP) (Roschewski et al., 2014). DLBCL is a 
heterogeneous group of malignancies that can be subdivided into three 
molecular subtypes based on gene expression profiling studies: GC B cell-like 
(GCB), activated B cell-like (ABC), and primary mediastinal B cell lymphoma 
(PMBL) (Lenz and Staudt, 2010; Roschewski et al., 2014). Furthermore whole-
genome and exome sequencing of DLBCL primary tumor samples have 
revealed a gamut of mutations that add an additional level of complexity to the 
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disease (Lohr et al., 2012; Morin et al., 2011; Pasqualucci et al., 2011b; Zhang 
et al., 2013). The three DLBCL subtypes have differing clinical presentations, 
cure rates, and therapeutic responsiveness (Lenz and Staudt, 2010; 
Roschewski et al., 2014). For example GCB DLBCL has a better prognosis 
than ABC DLBCL with R-CHOP treatment or a modified treatment regimen 
that adds dose-adjusted etoposide to R-CHOP (DA-EPOCH-R) (Roschewski 
et al., 2014). Patients with PMBL have an extremely high cure rate after 
treatment with DA-EPOCH-R relative to both GCB and ABC DLBCL patients 
(Dunleavy et al., 2013). In addition to clinical differences, these DLBCL 
subtypes also differ widely in mechanisms of oncogenic activation (Lenz and 
Staudt, 2010; Roschewski et al., 2014). 
 
GCB DLBCLs have a genetic signature similar to normal GC B cells (Lenz and 
Staudt, 2010; Roschewski et al., 2014). GCB DLBCLs have highly mutated 
and switched Ig loci, and SHM is ongoing on malignant cells (Klein and Dalla-
Favera, 2008; Lenz and Staudt, 2010; Roschewski et al., 2014). GCB-specific 
genetic lesions include the t(14;18) translocation, which results in ectopic 
expression of anti-apoptotic BCL2; the loss of PTEN and amplification of the 
microRNA miR-17-92 cluster, which activate the PI3K/AKT pathways to 
promote growth and proliferation; and TP53 mutations that result in increased 
genomic instability (Lohr et al., 2012; Morin et al., 2011; Pasqualucci et al., 
2011b; Zhang et al., 2013). Somatic mutations that are GC-specific occur in 
EZH2, resulting in a proliferative effect and differentiation blockade by aberrant 
H3K27 trimethylation; MEF2B, which enhances the GC-phenotype by inducing 
BCL6; BCL2, resulting in the activation of anti-apoptotic pathways; and GNA13, 
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which results in the activation of AKT signaling (Beguelin et al., 2013; 
Caganova et al., 2013; Muppidi et al., 2014; Ying et al., 2013).  
 
Unlike GCB DLBCLs, ABC DLBCLs have gene expression patterns that are 
more similar to B cells undergoing plasmacytic differentiation, and therefore 
the hallmark signature of ABC DLBCL is the constitutive activation of NFκB 
signaling (Lenz and Staudt, 2010; Roschewski et al., 2014). Persistent NFκB 
signaling leads to a host of downstream cellular processes involved in tumor 
development and progression (Lenz and Staudt, 2010; Roschewski et al., 
2014; Staudt, 2010). ABC-specific somatic mutations frequently occur in 
MYD88, an adaptor protein that interacts with toll-like receptors (TLRs) (Morin 
and Gascoyne, 2013; Roschewski et al., 2014). This mutation induces rapid 
proliferation in the absence of TLR ligands by activating the NF-κB and 
JAK/STAT3 pathways (Ngo et al., 2011). Activating mutations can also occur 
in the Igα/Igβ co-stimulatory molecules of the BCR (CD79A/CD79B, 
respectively), inducing chronic BCR activation, and CARD11, a member of the 
CARD11/BCL10/MALT1 (CBM) complex that activates the IkB kinase (IKK) 
complex resulting in nuclear translocation of NF-κB dimers (Morin and 
Gascoyne, 2013; Roschewski et al., 2014). ABC DLBCLs also have genetic 
lesions that inactivate negative regulators of the NF-κB pathway. ABC 
DLBCLs have frequent nonsense mutations or genetic deletions of TNFAIP3, 
which encodes A20 a deubiquitinating enzyme that inactivates IKK 
(Roschewski et al., 2014; Staudt, 2010).  
 
PMBL DLBCL genetic signatures are similar to Hodgkin lymphomas in that 
both rely heavily on NF-κB and JAK-STAT6 signaling. The characteristic 
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genetic lesion of PMBL DLBCL is the amplification of chromosome 9p24 (Lenz 
and Staudt, 2010; Roschewski et al., 2014; Shaffer et al., 2012). This results in 
amplification of JAK2. PMBL DLBCLs also frequently have deletions of 
SOCS1, a negative regulator of JAK2, and mutations in STAT6, collectively 
increasing the activity of the JAK-STAT pathway. PMBL DLBCL patients also 
have translocations of a transactivator of MHC class II genes (CIITA) that 
produce fusion proteins. These fusions result in the inactivation of CIITA and 
loss of MHC class II proteins thereby allowing tumor cells to evade immune 
surveillance (Jardin, 2014; Morin and Gascoyne, 2013; Roschewski et al., 
2014; Shaffer et al., 2012). 
 
While DLBCL sub-types differ cytogenetically and by mutational status, they all 
deregulate transcriptional mechanisms intended to control the GC response. 
Many of these mechanisms involve chromatin remodeling factors and 
epigenetic regulators and are also targets for aberrant regulation due to 
mutations. These mutations are not sub-type specific but do occur at different 
frequencies. Mutations in the methyltransferase MLL2 are equally distributed 
between GCB and ABC DLBCL and result in a truncated form of the protein 
(Jardin, 2014; Morin and Gascoyne, 2013). The acetyltransferase genes, 
CREBBP and EP300, also have loss-of-function mutations, which are found in 
both GCB and ABC DLBCL and follicular lymphoma (Jardin, 2014; Morin and 
Gascoyne, 2013). As alluded to earlier, BCL6 is the master regulator of the GC 
program. Therefore it is one of the most commonly deregulated genes in 
DLBCLs (Ci et al., 2008). Chromosomal translocations involving BCL6 at 
chromosome 3q27 are found in 30-40% of DLBCLs and interestingly occur 
more frequently in ABC versus GCB DLBCL (Ci et al., 2008). Moreover 70% of 
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DLBCLs display somatic mutations in the 5’ regulatory regions of BCL6 
(Pasqualucci et al., 2001). Either of these genetic aberrations leads to 
constitutive BCL6 expression and the maintenance of the proliferative and 
genetically unstable GC phenotype (Hatzi and Melnick, 2014). 
  
3. The BCL6 transcriptional repressor 
BCL6 is a transcriptional regulator that plays an important role in B cell 
development and the formation of GCs. Pre-B cells induce BCL6 during light 
chain rearrangement for its pro-survival functions (Duy et al., 2010). This is 
required for pre-B cells to generate an extensive repertoire of polyclonal B 
cells (Duy et al., 2010). BCL6 null mice fail to develop GCs and cannot 
generate affinity-matured antibodies (Dent et al., 1997; Ye et al., 1997). BCL6 
allows GC B cells to sustain SHM and CSR of their Ig loci without inducing cell 
arrest or apoptosis by repressing genes involved in DNA damage sensing and 
response, apoptosis, and checkpoint activation (Phan and Dalla-Favera, 2004; 
Phan et al., 2005; Ranuncolo et al., 2007; Ranuncolo et al., 2008a). It also 
maintains the centroblast phenotype by repressing genes involved in 
premature B cell activation and plasma cell differentiation (Li et al., 2005; 
Shaffer et al., 2000; Tunyaplin et al., 2004). However BCL6 expression must 
be downregulated to enable post-GC differentiation and normal growth, and as 
discussed earlier, its deregulation is often associated with lymphomagenesis 
(Hatzi and Melnick, 2014). In addition to being essential for the survival of GC 
B cells, BCL6 is also critical for TFH cell differentiation to repress genes that 
drive differentiation towards alternate T helper cell lineages (Crotty, 2014; 
Johnston et al., 2009; Nurieva et al., 2009). 
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BCL6 structure and function 
BCL6 is a member of the bric-a-brac, tramtrack, broad complex/pox virus zinc 
finger (BTB/POZ) family of proteins. The human BCL6 protein is 706 amino 
acids and consists of an N-terminal BTB/POZ domain (residues 5-129) and six 
C-terminal Krüppel C2H2-type zinc finger (ZF) domains (residues 518-681) 
(Figure 1.6). The N-terminal and C-terminal domains are connected by a large, 
unstructured linker that contains another regulatory domain referred to as RD2 
(residues 350-395) (Figure 1.6). Through its various protein domains, BCL6 is 
able to recruit a diverse set of chromatin-modifying complexes and therefore 
has multi-faceted biochemical mechanisms of gene repression (Figure 1.6). 
 
The BCL6 BTB domain is an obligate homodimer and has autonomous 
repressor activity (Ahmad et al., 2003; Chang et al., 1996; Deweindt et al., 
1995). The interface between monomers create two extended lateral grooves 
that serve as docking sites to corepressors NCOR1 (NCOR), NCOR2 (also 
known as SMRT), and BCOR (Ahmad et al., 2003; Dhordain et al., 1997; 
Ghetu et al., 2008; Huynh and Bardwell, 1998; Huynh et al., 2000). NCOR and 
SMRT have 45% sequence identity yet bind the BCL6 BTB domain with a 
highly similar sequence (Ahmad et al., 2003). In comparison, the BCOR BTB 
binding domain (BBD) is different in sequence and structure to NCOR and 
SMRT but binds to the same lateral groove on the BCL6 BTB domain (Ghetu 
et al., 2008). The BBD residues of NCOR, SMRT, and BCOR are specific for 
the BCL6 BTB domain, and conversely, the BCL6 BTB domain surface 
residues that interact with these corepressors are also unique to BCL6 
(Stogios et al., 2010). It was thought that corepressor binding to the BCL6 BTB 
domain was mutually exclusive (Huynh et al., 2000). However Hatzi et al. 
	  40 
(2013) demonstrated that a ternary complex consisting of both BCOR and 
SMRT is able to bind simultaneously to symmetrical sites on the BCL6 domain. 
BCL6 BTB corepressors act as adaptor proteins for other chromatin modifying 
proteins. NCOR and SMRT form complexes with histone deacetylase 3 
(HDAC3) whereas BCOR forms a Polycomb repressive complex 1 (PRC1)-like 
complex (Farcas et al., 2012; Gao et al., 2012; Gearhart et al., 2006; 
Karagianni and Wong, 2007; Sanchez et al., 2007). Mutating the residues 
(N21K and H116A) within the BCL6 BTB domain that make contact with the 
corepressors abrogates binding to NCOR and SMRT and diminishes BTB 
repressor activity in reporter assays (Ahmad et al., 2003).  
 
BCL6 is a sequence-specific transcriptional repressor and binds DNA via its 
ZF domain (Baron et al., 1995; Chang et al., 1996; Deweindt et al., 1995; 
Kawamata et al., 1994). The BCL6 consensus core sequence is 
TTCCT(A/C)GAA but more degenerate sequences have been found by 
mapping BCL6 binding sites using chromatin immunoprecipitation (ChIP) 
(Baron et al., 1995; Chang et al., 1996; Ci et al., 2009; Kawamata et al., 1994). 
Mutational studies demonstrated that the first two ZFs are dispensable for 
DNA binding activity while mutations in the other four ZFs resulted in a 
complete inability of BCL6 to bind to its consensus motif (Mascle et al., 2003). 
In addition to being required for DNA binding, the BCL6 ZF domain can 
mediate transcriptional repression (Albagli et al., 1996; Lemercier et al., 2002). 
The BCL6 ZFs have been shown to interact with class II HDACs and the 
corepressor ETO to enhance its own repressor activity (Chevallier et al., 2004; 
Lemercier et al., 2002). It has also been demonstrated to bind AP-1 proteins 
and repress their transcriptional activity (Vasanwala et al., 2002). 
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The RD2 domain of BCL6 is found between the BTB domain and ZF domains 
and, like them, has autonomous repressor activity (Figure 1.6) (Chang et al., 
1996; Lemercier et al., 2002). The minimal residues of this linker region 
required for repressor activity were mapped to amino acids 350-395 (Huang et 
al., 2014). The RD2 domain has been shown to mediate transcriptional 
repression by interacting with MTA3, which recruits the Mi-2/NuRD complex to 
BCL6 targets and facilitates HDAC-dependent repression (Fujita et al., 2004; 
Huang et al., 2014). This interaction was dependent on the acetylation status 
of KKYK residues that map to amino acids 387-379 on the RD2 domain (Fujita 
et al., 2004). The acetyltransferase p300 binds to BCL6 and acetylates these 
residues, inactivating BCL6 (Bereshchenko et al., 2002). Therefore HDAC 
Figure 1.6 BCL6 organization. Functional domains of BCL6 include the 
BTB domain, the middle repressor domain (RD2), and six zinc finger (ZF) 
domains. BCL6 stability and repressor activity is regulated by post-
translational modifications including acetylation (A) and phosphorylation (P) 
and three PEST sequences found in the middle linker region. Each BCL6 
domain can mediate interactions with other proteins including corepressors 
and other chromatin-modifying proteins. 
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complexes are important for BCL6-mediated transcriptional repression by 
maintaining its inhibitory capacity and by modifying chromatin to a more 
repressive state (Bereshchenko et al., 2002). Phosphorylation of the RD2 
domain is another means to modulate BCL6 stability. MAP kinase can 
phosphorylate residues within proline-, glutamate-, serine-, and threonine-rich 
PEST sequences in the RD2 domain and mark it for degradation by the 
ubiquitin-proteasome pathway (Niu et al., 1998). 
 
BCL6 repressive mechanisms in GC B cells and lymphoma 
The formation of GCs is a sequential and coordinated process that relies 
heavily on BCL6 induction in both GC B cells and TFH cells (Crotty, 2014; Hatzi 
and Melnick, 2014). BCL6 is critical for GC B cells to sustain DNA damage 
associated with SHM and CSR while proliferating rapidly because it silences 
DNA damage sensing and response, apoptosis, and cell cycle checkpoints 
genes like ATR, ATM, TP53, CHECK1, and CDKN1A (Phan and Dalla-Favera, 
2004; Phan et al., 2005; Ranuncolo et al., 2007; Ranuncolo et al., 2008a). By 
generating mutant knock-in mice that have disrupted BTB or RD2 function, our 
lab was able to demonstrate that the BCL6 repressor domains mediate distinct 
steps in GC development (Huang et al., 2014; Huang et al., 2013). Mice with 
mutations in the BCL6 BTB domain (N21K and H116A) that abrogate the 
recruitment of NCOR, SMRT, and BCOR were able to form early GC clusters 
but unable to sustain the rapid proliferative and DNA damage-tolerant 
phenotype of GC B cells (Huang et al., 2013). These results were confirmed 
by ChIP-seq studies in human GC B cells that showed BCL6 recruited SMRT 
or BCOR to key cell cycle genes like ATR, TP53, and CDKN1A (Hatzi et al., 
2013). The GC defects from BCL6 BTB mutant mice were B cell autonomous 
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and did not affect TFH function (Huang et al., 2013). Interestingly, mutations in 
the RD2 domain (KKYK to QQYQ) that prevent the recruitment of MTA3/Mi-
2/NuRD and HDAC2 complexes resulted in a failure to form nascent GCs due 
to impaired B cell trafficking to the GC (Huang et al., 2014). TFH cells were 
partially impaired in RD mutant mice most likely due to decreased IL-21 
expression and derepression of Blimp1 (Huang et al., 2014). These studies 
were the first to demonstrate that BCL6 can mediate distinct biological 
functions through its repressor domains. 
 
The repression of BCL6 targets that enables a proliferative and pro-survival 
phenotype in GC B cells can also make them vulnerable to malignant 
transformation (Hatzi and Melnick, 2014). Transgenic mice that have 
constitutive expression of BCL6 in GC B cells develop GC hyperplasia and 
tumors similar to human DLBCL (Baron et al., 2004; Cattoretti et al., 2005). 
BCL6 expression is tightly regulated at the transcriptional and post-
transcriptional level in GC B cells. The induction of BCL6 is a complex process 
and several reports have identified multiple transcription factors involved 
including IRF8, STATs, and AP-1 (Arguni et al., 2006; Lee et al., 2006; 
Scheeren et al., 2005). However it has yet to be determined which factor plays 
the leading role in driving BCL6 expression. Many proteins including HSP90, 
FBXO11, and p300 regulate BCL6 protein stability (Bereshchenko et al., 2002; 
Cerchietti et al., 2009a; Duan et al., 2012). Nuclear HSP90 is found in the 
majority of primary DLBCL patient samples and forms a complex with BCL6 at 
its target genes. FBXO11 controls the ubiquitinylation and degradation of 
BCL6, but it is mutated or deleted in many DLBCL cell lines, leading to 
increased levels and stability of BCL6 (Duan et al., 2012). Finally as discussed 
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earlier, p300 acetylates BCL6, inactivating its repressor function. However 
somatic, inactivating mutations in EP300 and its closely related protein 
CREBBP occur frequently in lymphoma and might augment BCL6 activity 
(Pasqualucci et al., 2011a). 
 
The transcriptional program mediated by the BCL6 BTB domain induces a 
stress-tolerant phenotype in GC B cells. DLBCL cells share this same program 
with GC B cells as 85% of BCL6-corepressor targets in DLBCL were also 
found in GC B cells (Hatzi et al., 2013). BCL6 mediates transcriptional 
repression in two ways: (i) by forming a potently, repressive ternary complex at 
promoters and (ii) by toggling enhancers from an active to a poised state by 
recruiting SMRT and HDAC3. BCL6 represses a subset of its bound promoters 
by forming a complex with both SMRT and BCOR (Hatzi et al., 2013). This 
subset of promoters have a repressive chromatin state associated with them: 
depletion of activating histone marks (H3K4me3, H3K9Ac, H3K79me2, and 
H3K27me3) and enrichment of repressive marks (H3K27me3 and DNA 
methylation) (Hatzi et al., 2013). In addition, these repressed genes had lower 
levels of elongated Pol II (Hatzi et al., 2013). 85% of BCL6-SMRT complexes 
occurred outside of promoters, and the majority were associated with 
transcriptional enhancers as defined by an enrichment of H3K4me1 and lack 
of H3K4me3 (Hatzi et al., 2013). BCL6-SMRT complexes at enhancers were 
found to regulate the most proximal gene by recruiting HDAC3 that 
deacetylated H3K27Ac, decommissioning the enhancer from an active to a 
poised state and antagonizing the H3K27-acetylating activity of p300 (Hatzi et 
al., 2013). Enhancer toggling is likely required to mediate rapid transcriptional 
changes in response to external stimuli as in the course of GC development. 
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However somatic mutations in EP300 and CREBBP could lock the BCL6 
transcriptional program by failing to activate genes necessary for post-GC exit 
and normal terminal differentiation (Pasqualucci et al., 2011a). 
 
Inhibiting the BCL6 BTB domain 
BCL6 is constitutively expressed in the majority of DLBCL and follicular 
lymphoma and it is required for lymphoma survival, making it a very attractive 
therapeutic target (Hatzi and Melnick, 2014). Structural studies of the BCL6 
BTB domain and its corepressor BBDs demonstrated that the interface 
between the BBD and the BTB domain are specific to BCL6 and its 
corepressors (Stogios et al., 2010). Therefore the docking site on the lateral 
groove of the BCL6 BTB domain provided a unique chance for the rational 
design of both biological and chemical inhibitors specific for the BCL6 BTB 
domain without affecting other BTB proteins. Early studies demonstrated an 
effectiveness of cell-penetrating peptides that mimicked the SMRT BBD for 
BCL6 BTB inhibition (Figure 1.7) (Polo et al., 2004). The BCL6 peptide 
inhibitor (BPI) blocked the recruitment of BCL6 corepressors resulting in the 
loss of repressive chromatin modifications and reactivation of BCL6 targets 
(Polo et al., 2004). BPI treatment in vivo resulted in the loss of GCs and potent 
anti-lymphoma activity in DLBCL (Cerchietti et al., 2008; Cerchietti et al., 
2009b; Parekh et al., 2007; Ranuncolo et al., 2008a; Ranuncolo et al., 2008b). 
This peptide was further improved to make it more stable and potent, resulting 
in a retro-inverso BCL6 peptide inhibitor (RI-BPI) (Cerchietti et al., 2009b). In 
addition to peptide inhibitors, computer-aided drug design allowed for the 
identification of small molecules that could specifically bind and inhibit BCL6 
BTB domain repressor activity (Figure 1.7) (Cerchietti et al., 2010a). One 
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compound, 79-6, was found to dock in the lateral groove of the BCL6 BTB 
domain (Figure 1.7) (Cerchietti et al., 2010a). 79-6 treatment induces the de-
repression of BCL6 targets and selective killing of BCL6-depedent DLBCL cell 
lines in vitro and in vivo in a xenograft model (Cerchietti et al., 2010a). 
  
  
A B
C D
Figure 1.7 Targeting the BCL6 BTB domain with small molecule 
inhibitors. (A) Structure of the BCL6 BTB dimer with each monomer 
colored coded in red and blue with two SMRT peptides. The lateral groove 
of the BTB binding pocket is circled. (B) View of selected compounds in the 
same binding pocket shared with SMRT. (C) Compound 79-6 in the lateral 
groove of the BTB dimer. (D) A magnified view showing the molecular 
interactions between 79-6 and the BTB dimer. Residues on each BTB chain 
are distinguished with no primes or primes (‘). Adapted from Cerchietti et al. 
(2010). 
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A role for BCL6 outside of the GC 
Although its role in GC B and TFH cells is well characterized, BCL6 also 
mediates differentiation of other immune cells like T cell subtypes and 
macrophages (Bunting and Melnick, 2013). BCL6 null mice have a lethal 
inflammatory phenotype due to suppression of TH2 and TH17 differentiation 
(Dent et al., 1997; Mondal et al., 2010; Ye et al., 1997). In macrophages, 
BCL6 occupied genomic sites overlap with the NF-κB cistrome, suggesting 
that BCL6 has a role limiting the extent of NF-κB-directed inflammation (Barish 
et al., 2010; Barish et al., 2012). However both the BCL6 BTB or RD2 mutant 
mice had normal T helper responses, suggesting these domains are 
dispensable for suppressing inflammatory responses and likely rely on other 
functions of BCL6 (Huang et al., 2014; Huang et al., 2013).  
 
BCL6 is also expressed in a number of cell-types with no immune-related 
function and in many cases acts as a cell survival factor (Bajalica-Lagercrantz 
et al., 1998; LaPensee et al., 2014; Meyer et al., 2009; Otaki et al., 2010; 
Tiberi et al., 2014; Tiberi et al., 2012; Zhang et al., 2007). A role for BCL6 in 
neurogenesis is emerging with recent studies (Otaki et al., 2010; Tiberi et al., 
2014; Tiberi et al., 2012; Zhang et al., 2007). Tiberi et al. (2012, 2014) 
demonstrated that BCL6 is expressed in neuronal precursors and mediates 
neuronal differentiation in the cerebral cortex by altering the composition of 
transcriptional complexes to silence Notch targets despite active Notch 
signaling. BCL6 also promotes the survival of sensory neurons to allow them 
enough time for efficient differentiation into mature olfactory sensory neurons 
(Otaki et al., 2010). How BCL6 is induced and whether there is a common 
biological function shared by all cell types remain unanswered questions.  
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4. Hypothesis 
In order to generate high-affinity antibodies, antigen-activated B cells are 
stimulated to proliferate and differentiate into centroblasts, resulting in the 
formation of GCs (Klein and Dalla-Favera, 2008). GC B cells are unique in that 
they have gained the ability to sustain genotoxic, replicative, metabolic, and 
oxidative stress associated with massive clonal expansion and SHM of their Ig 
loci that would otherwise be lethal (Doughty et al., 2006; Klein and Dalla-
Favera, 2008). BCL6 maintains the survival and proliferate state of GC B cells 
by repressing genes involved in DNA damage sensing and checkpoint 
activation (Hatzi and Melnick, 2014). Because GC B cells undergo rapid cell 
division and tolerate genomic instability, the constitutive expression of factors 
required to maintain the GC phenotype can lead to lymphomagenesis (Hatzi 
and Melnick, 2014). Along these lines, GC-derived DLBCLs are heavily 
dependent on BCL6, and inhibition or knockdown of BCL6 kills DLBCLs. The 
distinctive characteristics of GC B cells suggest that they require a specialized 
stress response for the production affinity-matured Ig and this reliance may 
also be inherited in DLBCL.  
 
In the context of the GC, the biological function of BCL6 is to mediate survival 
despite undergoing severe stress. To carry out its function, BCL6 requires a 
highly specialized form of HSP90 that is stress-specific and found to be 
enriched in tumor cells (teHSP90) (Cerchietti et al., 2009a; Moulick et al., 
2011). TeHSP90 binds with BCL6 to its targets and is required for BCL6 
transcriptional repression (Cerchietti et al., 2009a). HSP90 stabilizes both 
BCL6 mRNA and protein in DLBCL cells, suggesting that HSP90 may also be 
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required in GC B cells to facilitate BCL6 function (Cerchietti et al., 2009a). 
HSP expression is governed by HSF1, the dominant regulator of the stress 
response (Akerfelt et al., 2010). Because HSF1 contributes to maintaining 
homeostasis after exposure to various proteotoxic stress, it has been 
implicated in tumorigenesis and maintaining malignancy (Dai et al., 2007; Jin 
et al., 2011b; Min et al., 2007). Since GC B cells display a unique ability to 
withstand stress, it is hypothesized that HSF1 mediates a specialized stress 
response that is required for the survival of GC B cells. HSF1 likely drives a 
transcriptional program complementary to BCL6 that allows GC B cells to 
tolerate stress associated with rapid proliferation and genomic instability. 
These two items will be explored in chapter two and three. HSF1 dependency 
may also be required by GC-derived lymphomas to maintain the malignant 
phenotype, which will be investigated in chapter three. Because BCL6 is 
intimately linked to the stress response via HSP90 and it rescues cells from 
high-stress environments, it is postulated that BCL6 may have evolved as a 
stress response factor. This may point to a broader conserved role of BCL6 in 
inducing stress tolerance in a diverse set of cell types than previously confined 
to the GC. This idea will be examined in chapter four. 
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CHAPTER TWO 
ROLE OF HSF1 IN GERMINAL CENTERS 
 
1. Introduction 
In order to produce high-affinity antibodies, antigen-stimulated B cells are 
activated to proliferate and differentiate, resulting in the formation of district 
structures in secondary lymphoid organs termed germinal centers (GCs) (Klein 
and Dalla-Favera, 2008). GC B cells clonally expand while simultaneously 
undergoing somatic hypermutation (SHM) of their immunoglobulin variable 
regions and later class-switch recombination (CSR), a non-homologous end-
joining process that allows the expression of different classes of antibody. 
During this stage, GC B cells require the expression of BCL6 to tolerate the 
genotoxic stress associated with rapid proliferation and DNA damage events 
(SHM and CSR) without inducing cell cycle arrest or apoptosis (Klein and 
Dalla-Favera, 2008). BCL6 is a transcriptional repressor that maintains the GC 
phenotype by repressing several genes involved in DNA damage sensing, 
DNA damage response, apoptosis, checkpoint activation, premature activation 
of B cells, and plasma cell differentiation (Klein and Dalla-Favera, 2008). 
However, BCL6 expression is turned off to enable post-GC differentiation and 
normal cell growth, and its deregulation is often associated with 
lymphomagenesis (Hatzi and Melnick, 2014). Due to BCL6 control of 
transcriptional programs related to stress tolerance, GCs seemed to have 
acquired a specialized stress response. 
 
Heat shock proteins (HSPs) are molecular chaperones that elicit several 
adaptive responses to help organisms survive a milieu of environmental 
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stressors, including heat, hypoxia, oxidative stress, ATP depletion, and pH 
changes (Richter et al., 2010). However, a large body of evidence also 
implicates HSPs in tumor initiation and survival, stabilizing many of the 
signaling pathways that are frequently hijacked to induce and maintain a 
malignant phenotype (Workman et al., 2007; Zuehlke and Johnson, 2010). In 
fact, our laboratory has recently shown that a specialized form of HSP90 that 
is enriched in tumors (teHSP90) stabilizes BCL6 at the mRNA and protein 
level in B cell lymphoma (Cerchietti et al., 2009a). TeHSP90 forms a complex 
with BCL6 at its target genes and is required for transcriptional repression of 
BCL6 targets (Cerchietti et al., 2009a). If BCL6 requires HSP90 for its 
biological function in DLBCL cells, it is likely that the same mechanism is used 
by BCL6 in GC B cells that are also highly stressed, suggesting that the entire 
heat shock response may also be active during the GC reaction. 
 
HSP expression is transcriptionally regulated by a small family of proteins 
referred to as heat shock factors (HSFs) (Akerfelt et al., 2010). Within this 
family, HSF1 is the master regulator of the stress response. HSF1 is reported 
to be involved in affinity maturation as HSF1 knockout mice have decreased 
serum levels of class-switched Ig, especially IgG2a (Inouye et al., 2004). 
However a specific role for HSF1 in GC was not demonstrated. Due to the 
stress tolerant phenotype of GC B cells, we wondered if HSF1 and the heat 
shock response are important for the survival of GC B cells and required for 
the production of affinity-matured antibodies.  
 
2. Results 
2.1 BCL6 is transcriptionally regulated by HSF1 in B cells   
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BCL6 is the master regulator of the GC response and BCL6 mRNA is strongly 
upregulated in GC B cells (Klein and Dalla-Favera, 2008). HSF1 is the 
dominant regulator of stress response and induces expression of HSPs after 
exposure to stress. These considerations led us to ask whether BCL6 is an 
HSF1 target gene. To address this question we first examined the BCL6 
promoter for HSF1 binding sites, known as heat shock elements (HSEs). We 
identified two highly conserved HSEs consisting of three tandem inverted 
repeats of 5’-nGAAn-3’ within the BCL6 promoter. We also identified a third 
HSE that was less conserved (Figure 2.1A). To identify if these were bona 
fide HSEs, we designed an AlphaLisa assay to quantify HSF1 DNA binding 
with biotinylated oligonucleotides encoding both wild type and mutant versions 
of each of the three BCL6 HSEs in the presence of a recombinant form of 
HSF1, which can spontaneously trimerize in the absence of HSP90 (Figure 
2.1B) (Goodson and Sarge, 1995; Zhong et al., 1996). HSF1 exhibited 
concentration dependent specific binding to the wild type but not mutant 
probes corresponding to all three BCL6 promoter HSEs (Figure 2.1C). A 
consensus HSPA1A HSE was used as a positive control.  
 
We next performed quantitative ChIP analysis to determine if HSF1 binds to 
the BCL6 promoter after heat shock in human tonsillar naïve B (NB) cells. 
Heat shock markedly increased HSF1 enrichment by 6-fold at the BCL6 
promoter (Figure 2.1D). Because BCL6 expression is naturally induced in GC 
B cells undergoing massive stress, we also tested whether HSF1 binding is 
increased in primary human GC B cells under basal conditions (no exogenous 
stress). We found that HSF1 binding is more than 3-fold enriched at the BCL6 
promoter in GC B cells relative to NB cells (Figure 2.1D). Furthermore HSF1 
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binding was also increased at the HSP90AA1 promoter in GC B cells relative 
to NB cells (Figure 2.1D), suggesting that the HSF1 becomes active and 
induces BCL6 and HSP90 expression during the GC response.  
 
Because HSF1 becomes transcriptionally active and is present at the BCL6 
promoter in GC B cells, we wondered whether HSF1 is required for stress-
dependent induction of BCL6 transcripts. However, because teHSP90 can 
post-transcriptionally stabilize BCL6 mRNA (Cerchietti et al., 2009a), it was 
necessary to specifically determine whether heat shock and HSF1 could 
induce the formation of newly transcribed BCL6 mRNA. To this end, splenic 
B220+ cells purified from Hsf1+/+, Hsf1+/-, and Hsf1-/- mice were heat shocked 
while simultaneously being pulsed with an alkyne-modified nucleotide analog 
(5’ethynyl uridine, EU), which would allow for the capture for newly transcribed 
EU-labeled transcripts by biotin-azide treatment and streptavidin pull-down. 
After heat shock, there was a 5-fold induction of nascent Bcl6 transcripts in 
Hsf1+/+ cells and an HSF1 dose-dependent decrease in Hsf1+/- cells with a 
complete lack of Bcl6 induction in Hsf1-/- cells (Figure 2.1E). There was also a 
dose-dependent reduction of Hspa1a nascent transcripts, measured as 
positive controls. Because there are three HSF transcription factors (HSF1, -2, 
and -4), it is likely that one of the other HSFs could partially compensate for 
lack of HSF1 in inducing Hspa1a after heat shock explaining the residual 
induction of these transcripts.  
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Figure 2.1 HSF1 transcriptionally regulates BCL6 expression. (A) 
UCSC genome browser plot of vertebrate conservation of the BCL6 
promoter. Red boxes highlight potential heat shock elements (HSEs). (B) 
Schematic of alphaLISA detection of HSF1 binding activity. A biotinylated 
HSE is used to capture transcriptionally active HSF1 present in nuclear 
extracts on the streptavidin donor. After laser excitation at 680 nm, short-
lived oxygen molecules produced by the donor bead can reach the anti-
HSF1 coated alphaLISA acceptor bead and generate a chemiluminescent 
signal at 615 nm. (C) AlphaLISA activity of the consensus HSPA1A HSE 
and the three BCL6 HSEs described in (A) with increasing concentrations of 
recombinant HSF1. (D) Quantitative ChIP of HSF1 in resting IgD+ naïve B 
cells (NB), heat shocked NBs, and resting GC B cells at the BCL6 promoter, 
HSP90AA1 promoter, and a negative control gene HBB. (E) qRT-PCR of 
nascent Bcl6 and Hspa1a mRNA in heat shocked murine B220+ 
splenocytes of Hsf1+/+, Hsf1+/-, and Hsf1-/- mice. Data was normalized to 
murine Hprt1. Values in (C-E) are the mean of triplicates ± SEM. Values in 
(E) represent a mean of triplicates ± SEM (n = 2-3 mice per group). A t-test 
was used to assess significance. 
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2.2 HSF1 is activated in GC B cells  
The fact that BCL6 is an HSF1 target gene led us to question whether HSF1 is 
active and important during the development of GC B cells, which is a 
canonical BCL6-dependent process. HSF1 gains transactivation capability 
after becoming hyperphosphorylated. Phosphorylation at Ser326 is the best 
indicator of HSF1 transcriptional activation (Guettouche et al., 2005). To 
determine whether HSF1 is activated in GC B cells, we performed 
immunofluorescence studies on tissue sections of human tonsils using 
antibodies to BCL6 and HSF1-pSer326. Examination of GCs revealed 
colocalization of these two proteins in the majority of GC cells (Figure 2.2A). 
As a second line of evidence for HSF1 activation, we compared DNA binding 
activity of HSF1 in nuclear lysates of NB vs. GC B cells using the AlphaLisa 
quantitative DNA binding assay and probes corresponding to wild-type or 
mutant HSE. These experiments showed significant increase in HSF1 DNA 
binding in GC B cells vs. NB cells (p<0.01, Figure 2.2B). Note that this is not 
due to differential expression of HSF1 since the protein levels were identical in 
NB and GC B cells (Figure 2.2C). Having established that HSF1 is active in 
GC B cells, we wondered whether this was purely due to stress or whether 
immune signaling linked to initiation of the GC reaction might also be involved. 
We therefore treated primary human NB cells with CD40L, IL-4, or IL-21 
(signals linked to GC initiation) and compared HSF1 binding activity to that 
induced by the canonical heat shock response. All three of these signaling 
ligands induced a significant and similar degree of HSF1 activation as heat 
shock (p<0.01, Figure 2.2D).  
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Figure 2.2 HSF1 is activated in GC B cells. (A) Immunofluorescence of 
paraffin-embedded serial human tonsillar sections. (B) AlphaLISA activity of 
the consensus HSPA1A HSE with nuclear extracts of naïve B cells (NB) 
and germinal center B cells (GCB) isolated from human tonsils. (C) 
Immunoblot of HSF1 protein levels in NB and GCB cells isolated from three 
independent human tonsils. (D) AlphaLISA activity of the consensus 
HSPA1A HSE with nuclear extracts from human splenic NB cells that were 
resting at 37 ºC (CON), heat shocked for 15 min at 43 ºC (HS), and treated 
for 1 h with 500 ng/mL CD40 ligand (CD40L), 100 ng/mL IL-4, or 100 ng/mL 
IL-21. Values in (B and D) are the mean of triplicates ± SEM. A t-test was 
used to assess significance, ** p<0.01. 
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2.3 Heat shock response is required for GC formation  
To identify if the stress response becomes active during GC formation, we 
immunized mice with T cell-dependent antigen, sheep red blood cells (SRBC), 
and randomized pairs of mice to receive either 75 mg/kg body weight per day 
of an HSP90-specific inhibitor, PU-H71, that targets teHSP90 (Moulick et al., 
2011) or vehicle. Mice were sacrificed at various time points after SRBC 
immunization, as early as 3 h later and up to 10 days later when the GC 
reaction is at its peak, and spleens were harvested for examination with a 
tissue microarray (TMA) (Figure 2.3A). Immunohistochemical analysis of the 
TMA revealed very few small peanut agglutinin (PNA) + and BCL6+ clusters 
(both of which specifically stain GC B cells) present as early as 6 h post-SRBC, 
suggesting basal levels of spontaneously formed GCs. Moderately sized 
clusters appear at day 5 post-SRBC and the largest clusters appear at 8-10 
days post-SRBC (Figure 2.3B). Quantification of the PNA+ clusters of PU-
H71-treated mice revealed a complete abrogation of GCs at early time points 
and very few, smaller GCs at day 10 post-SRBC (Figure 2.3C). The histologic 
appearance of the spleen was otherwise normal. These results demonstrate 
that the stress-specific form of HSP90 is required for the survival of GC B cells. 
In DLBCL cells, HSP90 binds with BCL6 at its target, and HSP90 is required 
for BCL6-mediated transcriptional repression (Cerchietti et al., 2009a). 
Therefore we wondered if HSP90 is also important for BCL6 function in normal 
GC B cells. Quantitative ChIP assays performed in human tonsillar CD77+ GC 
B cells revealed the presence of HSP90 at the promoters of BCL6 targets, 
ATR, CCN1, TP53, and ZFP443 but not at a negative control region within the 
human HBB locus (Figure 2.3D). These results suggest that HSP90 is also 
required for BCL6 to repress its target genes in non-malignant GC B cells. 
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Figure 2.3 Heat shock response is required for GC formation. (A) 
Schematic representation of the PU-H71 treatment course after SRBC 
immunization of C57BL/6 mice. (B) Immunohistochemistry of paraffin-
embeded spleen sections of C57BL/6 mice 8 d after SRBC immunization 
with vehicle or PU-H71. (C) Quantification of immunopositive area of PNA 
(top) and BCL6 (bottom) from a tissue microarray of splenic sections 
harvested from mice several time points after SRBC immunization. Values 
in (C) are the mean of 4-6 mice per group ± SEM. Values in (D) are the 
mean ± SEM of three independent experiments. 
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2.4 HSF1 is required for development of GC B cells  
Hsf1-/- mice were shown to have decreased levels of class-switched antibodies 
(Inouye et al., 2004), suggesting a key role for HSF1 in humoral immunity. 
However it was not known whether HSF1 is required for the development of 
GC B cells or whether the affinity maturation defect was due to other effects in 
the immune system. Phenotypic analysis of Hsf1-/- mice showed normal early 
development of pro-B (B220+, CD43+, IgM-), pre-B (B220+, CD43-, IgM-), and 
immature B cells (B220+, CD43-, IgM+) in the bone marrow and normal T 
(CD3+) and B (B220+) lymphocyte populations in spleens (Figure 2.4A-B). In 
addition, Hsf1-/- mice formed normal splenic lymphoid follicles (Figure 2.4C).  
 
The fact that HSF1 is active in GC B cells indicates that it is functional. But to 
determine whether this activity translates into phenotypic effects, we first 
immunized Hsf1-/- or Hsf1+/+ mice with a T cell dependent antigen (SRBC) and 
then examined spleens for GC formation 10 days later. Immunohistochemistry 
staining with PNA revealed that GCs were significantly reduced in numbers 
(p<0.05) and smaller in area relative to spleen size (p<0.001, Figure 2.5A). As 
additional confirmation of this finding, we performed flow cytometry to 
determine the percentage GC B cells (B220+, FAS+, GL7+) among total splenic 
B220+ B cells. Hsf1-/- exhibited an approximately 50% reduction in the number 
of GC B cells compared to wild type (p<0.05, Figure 2.5B). Because the 
formation of GCs requires T follicular (TFH) cells to stimulate and drive GC B 
cells (Victora and Nussenzweig, 2012), we next examined the development of 
total TFH cells (CD4+, CXCR5lo-hi, PD1lo-hi) and GC-specific TFH cells (CD4+, 
CXCR5hi, PD1hi). The frequency of TFH cells in either compartment did not 
differ in Hsf1-/- mice relative to Hsf1+/+ mice (Figure 2.5C). Because there was 
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no difference in overall numbers of B220+ B cells in Hsf1-/- mice (Figure 2.4B-
C), the defect observed is specific to GC but not total B cells.  
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Figure 2.4 Hsf1-/- mice have normal development of B and T cells in 
bone marrow and splenic follicles. (A) Expression of B220, CD43, and 
IgM in bone marrow cells from Hsf1+/+ and Hsf1-/- mice. Top panel 
distinguishes pro-B (B220+ CD43+) and pre-B cells (B220+ CD43-), and 
bottom panel distinguishes pre-B (B220+ CD43- IgM-) and immature B cells 
(B220+ CD43- IgM+). (B) Flow cytometry of CD3+ T cell and B220+ B cell 
populations in spleen. Quantification of the total number of B220+ cells 
(right). (C) Immunohistochemistry of paraffin-embdedded splenic sections 
from Hsf1+/+ and Hsf1-/- mice stained for H&E and B220. Data in (A-C) are 
representative of at least two independent experiments (n=3-5 per group). 
Values in (B) the mean ± SEM of 4 mice per group. 
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Figure 2.5 HSF1 is required for development of GCs. (A) 
Immunohistochemistry of paraffin-embeded spleen sections of Hsf1+/+ and 
Hsf1-/- mice 10 d after SRBC immunization. Quantification of the number 
and size of GCs (right). (B) Flow cytometry (left) and quantification (right) of 
splenic GC B cells (FAS+ GL7+) among live B220+ cells obtained from 
Hsf1+/+ and Hsf1-/- mice 10 d after SRBC immunization. (C) Flow cytometry 
(left) and quantification (right) of splenic total TFH cells (CXCR5lo-hi PD1lo-hi) 
and GC-specific TFH cells (CXCR5hi PD1hi) among live CD4+ B220- cells 
obtained from Hsf1+/+ and Hsf1-/- mice 10 d after SRBC immunization. 
Values in (A-C) are representative of at least two independent experiments 
(n=3-7 mice per group). Each symbol represents an individual mouse; error 
bars indicate the mean ± SEM. A t-test was used to assess significance. 
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To determine whether there is indeed a defect in affinity maturation linked to 
this GC phenotype (Inouye et al., 2004), we immunized Hsf1-/- and Hsf1+/+ 
mice with the specific T cell dependent antigen, 4-hydroxy-3-nitrophenylacetyl 
chicken gamma globulin (NP-CGG), and measured the levels of antigen-
specific GC B cells (NP+, GL7+). NP-specific GC B cells were severely reduced 
in Hsf1-/- compared to Hsf1+/+ mice (Figure 2.6A). GC formation results in the 
production of plasma cells that secrete high-affinity Ig. Therefore we then 
investigated whether HSF1 was required for the formation of plasma cells. 
Hsf1-/- mice had lower total plasma cells (B220-, CD138+) and lower NP-
specific plasma cells (B220-, CD138+, NP+) vs wild-type mice (Figure 2.6B). 
Finally the titer of high-affinity antibodies was measured by NP4 ELISA with 
serum collected 14 d after immunization. Hsf1-/- mice generated significantly 
lower titers of high-affinity NP4 IgG2a compared to wild type (p<0.05) and 
lower titers of NP4 IgG1 although not significant (p=0.06, Figure 2.6C). These 
results demonstrate definitively that Hsf1-/- mice have defects in affinity 
maturation. 
 
It is important to note that GC formation requires the intimate cooperation 
between GC B cells and GC TFH cells (Victora and Nussenzweig, 2012). Loss 
of function of either one will result in reduced GC formation and affinity 
maturation. Hence the experiments above are not sufficient to prove that GC B 
cells are HSF1-dependent. TFH cells do not undergo massive proliferation or 
SHM and do not undergo the level of stress that must be endured by GC B 
cells. Hence we predicted that the GC impairment phenotype was B cell 
autonomous. To determine if this is the case, we performed mixed chimera 
bone marrow transplantations using irradiated Rag1-/- mice (deficient in T and 
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B cells) as recipients. Rag1-/- recipients were transplanted with CD45.1+ bone 
marrow from Hsf1+/+ mice mixed with either CD45.2+ Hsf1-/- or CD45.2+ Hsf1+/+ 
cells, at 50% ratio (Figure 2.7A). After engraftment, GC formation was 
Figure 2.6 Hsf1-/- mice have defects in affinity maturation. (A) Flow 
cytometry analysis of NP-specific GC B cells (NP+ GL7+) among live B220+ 
cells from mice left unimmunized (UI) or 10 d after immunization with NP-
CGG. (B) Flow cytometry of total plasma cells (CD138+ B220dim) among 
DAPI- spleen cells with further gating of the NP+ compartment of total 
plasma cells (bottom) from mice left unimmunized (UI) or 10 d after 
immunization with NP-CGG. (C) Titers of NP-specific immunoglobulins, 
measured with NP4-BSA in serum from mice 35 d after primary 
immunization with NP-CGG and presented as relative units (RU) as serial 
dilution of serum relative to antibody end-point titers. Values in (A-C) are 
representative of at least two independent experiments (n=3-7 mice per 
group). Each symbol represents an individual mouse; error bars indicate the 
mean ± SEM. A t-test was used to assess significance. 
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induced by immunization with SRBC and spleens examined 10 days later. 
While we detected no difference in CD45.1+ GC B cells or GC TFH cells 
between each chimera (Figure 2.7B-C, top), we again observed a significant, 
50% reduction in the formation of GC B cells (B220+, FAS+, GL7+) from 
CD45.2+ Hsf1-/- as compared to CD45.2+ Hsf1+/+ cells (p<0.01, Figure 2.7B, 
bottom). In marked contrast there was no defect in GC TFH cells (CD4+, PD1+, 
CXCR5+, B220-) (Figure 2.7C, bottom). Hence HSF1 effects in GC B cells are 
B cell autonomous. 
 
2.5 HSF1 induces BCL6 expression in GC B cells 
We demonstrated earlier that HSF1 induces BCL6 expression after heat stress 
in B cells. BCL6 allows GC B cells to sustain replicative and genotoxic stress 
from clonal expansion and SHM. Because Hsf1-/- mice have defects in GC 
number and size and is this accompanied with defects in the production of 
high-affinity antibodies, we wondered if BCL6 induction is impaired in Hsf1-/- 
GC B cells. By using flow cytometry, we observed high levels of BCL6 staining 
intensity in Hsf1+/+ GC B cells (B220+, FAS+, GL7+) (Figure 2.8A). In stark 
contrast, Hsf1-/- GC B cells exhibited a higher percentage of cells with BCL6 
intensity overlapping with the isotype controls, suggesting a population of cells 
with almost no BCL6 induction (Figure 2.8A). Notably there were populations 
of Hsf1-/- GC B cells that had similar levels of BCL6 staining to wild-type 
(Figure 2.8A). This might explain why a complete abrogation of GC formation 
is not observed in Hsf1-/- mice. Some cells must be able to overcome the 
HSF1 defect and perhaps rely on other transcription factors that respond to 
immune signaling like IRF8 to compensate and induce BCL6 (Bunting and 
Melnick, 2013).  
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Figure 2.7 GC defect in Hsf1-/- are B cell autonomous. (A) Strategy for 
generating chimeras by transplantation of mixed bone marrow (BM). (B) 
Ratio of the frequency of GC B cells (FAS+ GL7+) among live B220+ cells 
from CD45.1+ and CD45.2+ donors, quantified by flow cytometry 10 d after 
SRBC immunization. (C) Ratio of the frequency of GC TFH cells (CXCR5hi 
PD1hi) among live B220- CD4+ T cells from CD45.1+ and CD45.2+ donors, 
quantified by flow cytometry as in (B). Values in (B-C) are representative of 
two independent experiments (n = 3-5 mice per group). Error bars indicate 
the mean ± SEM. A t-test was used to assess significance, ** p<0.01. 
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Figure 2.8 HSF1 is required for BCL6 induction in GC B cells. (A) Flow 
cytometry of intracellular levels of BCL6 in GC B cells (B220+ FAS+ GL7+) 
from Hsf1+/+ (red filled) and Hsf1-/- (blue filled) mice at 10 d after 
immunization with SRBC. IgG1 κ is used as an isotype control (red/blue 
outline). (B) Flow cytometry (left) and quantification (right) of BrdU 
incorporation in GC B cells (B220+ FAS+ GL7+) from mice immunized with 
SRBC. (C) Immunhistochemistry of TUNEL staining in representative 
germinal centers (left) of paraffin-embedded splenic sections of Hsf1+/+ and 
Hsf1-/- mice 10 d after SRBC immunization. Quantification of TUNEL+ cells 
per 40X field. TUNEL+ cells were counted in 5 fields per mouse with 5 mice 
per group. Values in (B-C) are representative of two independent 
experiments (n = 3-5 mice per group). Error bars indicate the mean ± SEM. 
A t-test was used to assess significance, * p<0.05. 
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Along the lines that BCL6 mediates the survival and proliferative state of GC B 
cells, we investigated whether Hsf1-/- GC B cells are unable to maintain GCs 
and instead undergo less cell division and more apoptosis. To determine 
effects on proliferation rates, we analyzed BrdU incorporation of GC B cells 
isolated from spleens of SRBC-immunized Hsf1+/+ and Hsf1-/- mice. We 
observed a significant decrease in the number of Hsf1-/- GC B cells cycling in 
the S phase compared to wild-type controls (p<0.05, Figure 2.8B). We also 
noted an increased percentage of cells in sub-G1 (lower DNA content) 
although it was not significant (Figure 2.8B). To more precisely determine if 
GC B cells in Hsf1-/- mice have increased levels of apoptosis, DNA 
fragmentation was measured using Terminal deoxynucleotidyl transferase 
dUTP nick-end labeling (TUNEL) immunohistochemistry, which specifically 
labels blunt ends of double-stranded DNA breaks and marks cells that are 
undergoing the last phase of apoptosis. TUNEL staining was performed on 
splenic sections from SRBC-immunized Hsf1+/+ and Hsf1-/- mice, and the 
percentage of TUNEL-positive cells in the GCs were quantified in 5 high-
powered fields per mouse (n=5). Hsf1-/- mice had a significantly higher number 
of TUNEL+ GC cells compared to Hsf1+/+ mice (p<0.0001, Figure 2.8C). 
Taken together with the induction of HSF1 downstream of GC activation 
signals, our data suggest that the described HSF1-BCL6 stress response axis 
plays a cooperating and necessary role in formation of GCs integrated with 
canonical immune signaling events.  
 
3. Discussion 
Herein we demonstrate that HSF1 induces nascent transcription of BCL6 in B 
cells exposed to thermal stress. The GC is a high-stress environment where B 
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cells proliferate rapidly while undergoing DNA damage events to mutate their 
Ig genes. GC B cells are therefore exposed to a variety of stressors 
associated with increased cell division, genomic instability, nutrient starvation, 
and hypoxia. We have shown that the conserved stress response is active in 
GC B cells and is necessary for their survival. It is interesting to note that while 
HSF1 null mice were only found to have a partial defect in GC formation, 
pharmacological inhibition of the stress-activated form of HSP90 (teHSP90) 
resulted in almost a complete lack of GCs. This discrepancy could be a 
measure of how each protein regulates BCL6. While HSF1 transcriptionally 
induces nascent BCL6 transcripts, a number of other mechanisms exist in 
between the stages of mRNA and protein production that could compensate 
for decreased levels of nascent gene expression. HSP90 has a more of a 
direct role in regulating BCL6 because it is critical for maintaining BCL6 protein 
stability (Cerchietti et al., 2009a). Therefore inhibiting HSP90, an effector 
protein of the heat shock response, more effectively impedes BCL6 function 
whereas Hsf1-/- GC B cells likely rely on other mechanisms to induce BCL6 or 
HSP90.  
 
It is interesting to speculate that the role of HSP90 in BCL6 transcriptional 
repression may be more complex than just effects on protein stability. While 
HSP90 forms a complex with BCL6 at its targets and is required for its 
repressor activity, HSP90 has been demonstrated to interact with and be 
essential for the function of other transcription factors and chromatin-modifying 
protein like the trithorax group proteins (Taipale et al., 2010). This presents an 
interesting scenario where BCL6 competes with these transcriptional 
regulators for a limited pool of HSP90. In this situation, an increase in BCL6 at 
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the transcriptional level (via HSF1) may tip the balance in favor of BCL6 
repression programs. An alternative mechanism of HSP90 enhancing BCL6 
function is linked to pausing RNA polymerase II (Pol II). HSP90 preferentially 
occupies the transcriptional start site (TSS) of genes with paused Pol II and 
stabilizes the negative elongation factor (NELF) (Sawarkar et al., 2012). 
Paused Pol II is found in genes that have to be rapidly induced in response to 
external stimuli (like in the GC where B cell must get cues from other cell types 
to proliferate or differentiate). HSP90 inhibition releases paused Pol II, allowing 
it to transcribe the entire gene (Sawarkar et al., 2012). Notably BCL6 ternary 
corepressor complexes that form in gene promoters suppress Pol II elongation, 
resulting in increased levels of paused Pol II (Hatzi et al., 2013). It is 
interesting to speculate that HSP90 may act as bridge between BCL6 and Pol 
II to tether Pol II at the TSS and increase pausing. This could result in 
enhanced suppression of Pol II elongation thereby increasing the repression of 
BCL6 targets.  
 
The moderate defects in affinity maturation in immunized HSF1 null mice is in 
part explained due to the presence of Hsf1-/- GC B cells that efficiently 
upregulate BCL6 levels similar to wild-type cells. While we have demonstrated 
that BCL6 induction after heat stress is HSF1-dependent and others have 
already established this for HSP90, their expression in the GC could be 
compensated by additional factors that also respond to immune stimuli. In fact 
BCL6 regulation in the GC is complex and can be attributed to several factors 
that work in concerted fashion or independently at various stages of GC 
development (Bunting and Melnick, 2013). During the GC response, B cells 
encounter stimulation signals from many different cytokines including IL-4, IL-
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21, and CD40. While we have shown that HSF1 undergoes transactivation 
after these stimuli, they can also activate a plethora of other transcription 
factors, some of which have been reported to regulate BCL6 in B cells or other 
cell types (Bunting and Melnick, 2013). IL-21R signaling is required for GC B 
cells to induce and maintain the expression of BCL6 (Bunting and Melnick, 
2013). IL-21R signaling stimulates the phosphorylation and activation of 
STAT3, which induces its binding to the BCL6 promoter (Arguni et al., 2006).  
Notably STAT binding sites closely resemble HSEs and therefore are the 
same sites found on the BCL6 promoter (Arguni et al., 2006). STAT3 has also 
been observed to transcriptionally regulate the expression of HSP90 in 
response to IL-6 (Stephanou and Latchman, 2011). Therefore STAT3 is a 
likely suspect for a compensatory factor that relieves defective BCL6 and 
HSP90 induction in HSF1 null mice. In addition to STATs, BCL6 expression is 
also transcriptionally regulated by IRF8. IRF8 knockout mice have decreased 
GC formation and lower levels of BCL6 although not completely absent, 
suggesting that other factors in these mice contribute to BCL6 induction (like 
HSF1 and STAT3) (Lee et al., 2006). 
 
It is important to note that while BCL6 is crucial for both GC B cell and TFH cell 
lineage commitment, the GC defect in HSF1 null mice was B cell autonomous 
and TFH cell defects were not observed. These results further corroborate our 
hypothesis that HSF1 is required for stress-mediated induction of BCL6 in GC 
B cells, which are highly stressed due to clonal expansion and DNA damage 
events due to SHM. The circumstances that mediate BCL6 induction appear to 
be quite in different in TFH cells compared to GC B cells. GC TFH cells 
upregulate BCL6 expression in a mechanism independent of IL-21 and IL-6 
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(Bunting and Melnick, 2013). ICOS signaling has been implicated in the 
induction of BCL6 in the early steps of TFH differentiation. In vitro studies have 
also demonstrated a potential role for STAT and FOXO proteins in regulating 
BCL6 to direct TH1 differentiation to the TFH lineage (Oestreich et al., 2012). 
These results suggest an HSF1-independent mechanism for BCL6 induction in 
TFH cells. 
 
Collectively we have demonstrated that HSF1 mediates stress-induced levels 
of BCL6. BCL6 is the master regulator of the GC response and is aberrantly 
expressed in DLBCL. For these reasons, HSF1 may also be important to 
maintain BCL6 expression in DLBCL and other cell types that express BCL6 in 
response to stress. 
 
4. Materials and Methods 
AlphaLISA 
Biotinylated and standard oligonucleotides (Vuori et al., 2009) were purchased 
from Integrated DNA Technologies, diluted in Tris⁄EDTA buffer (pH 8.0) and 
annealed. Cells were treated and nuclear extracts were prepared using the 
Nuclear Extraction kit (Active Motif). For the entire assay, solutions were 
diluted to their working concentrations in Alphalisa Immunoassay buffer 
solution 5X (AL001F). Protein A acceptor beads (6760137, PerkinElmer) were 
incubated with polyclonal rabbit HSF1 antibody (ADI-SPA-901, Enzo Life 
Sciences) for 1 h at room temperature with agitation. Streptavidin donor beads 
(6760002, PerkinElmer) were added and the mixture was kept in the dark with 
agitation. Meanwhile, 2 µg of nuclear extract were incubated with annealed 
biotinylated HSPA1A HSE or mutated HSE for 30 min in white 384-well 
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Optiplates (6005620, PerkinElmer). The acceptor and donor beads mixture 
was added to each well and incubated for an additional 1 h. Luminescence 
was measured in an EnVision Multilabel Plate Reader (PerkinElmer) and then 
analyzed. 	  
Primary cell isolation 
Human tissues were obtained with approval of the Institutional Review Board 
(IRB), Office of Research Integrity of the Weill Cornell Medical College and in 
accordance with the Declaration of Helsinki. Human IgD+ naïve B cells and 
CD77+ GC B cells were isolated from de-identified human tonsillectomy 
specimens or spleens. After centrifugation in Fico/Lite-LymphoH density 
gradient media (Atlanta Biologicals), mononuclear cells were collected and 
affinity-purified using microbead cell separation via the autoMACS system 
(Miltenyi Biotec). Naïve and GC B cell purity was determined by flow 
cytometric analysis to be >90% IgD+/CD38low and >90% CD77+/CD38high. 
Single-cell suspensions of mononuclear cells were generated from murine 
spleens using red blood cell lysis (Qiagen) or Fico/Lite-LM density gradient 
media (Atlanta Biologicals). For B220 purification, cells were affinity-purified 
using positive selection with anti-B220 microbeads or negative selection with 
anti-CD43 microbeads and the autoMACS (Miltenyi Biotec). Splenocytes were 
determined to be >95% B220+ by flow cytometric analysis. 
 
Nascent RNA capture 
Murine B220+ splenocytes or human cells transfected with HSF1-targeting 
siRNA for 48 h were heat shocked at 43 ºC for 2 h followed by recovery at 37 
ºC for 2 h or treated with 100 nM doxorubicin for 4 h while simultaneously 
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pulsed with 0.2 mM ethnyl uridine (EU). EU-labeled RNA was captured with 
the Click-It Nascent RNA capture kit (Molecular Probes). Briefly, RNA was 
extracted using Trizol reagent (Invitrogen), resuspended with RNase-free H2O, 
and quantified with the Nanodrop (Thermo Scientific). 1 µg total RNA was 
biotinylated by a click reaction with 0.5 µM biotin azide and re-precipitated with 
Glyco-blue (Ambion), ammonium acetate, and ice cold 100% ethanol. RNA 
was spun at 13,000xg for 15 min at 4 ºC, washed with 75% ethanol, dried for 5 
min at room temperature, and resuspended in RNase-free H2O. RNA 
concentration was re-measured by the Nanodrop (Thermo Scientific) and 
equal amounts of RNA (0.75-1 µg) were allowed to bind to 25 µL Dynabeads 
MyOne Streptavidin T1 beads (Invitrogen) in the presence of RNaseOUT 
recombinant ribonuclease inhibitor (Invitrogen) for 30 min at room temperature 
with gentle agitation. The bound RNA was washed with the provided Click-it 
wash buffers and resuspended in 12 µL RNase-free H2O. The RNA bound to 
the beads was taken directly into a cDNA synthesis reaction using the 
SuperScript III first-strand synthesis system (Invitrogen). A fraction of the 
undiluted cDNA was used in real-time quantitative PCR and detected by fast 
SYBR Green (Quanta Biosciences) on the 7900HT Fast Real-Time PCR 
System (Applied Biosystems). 	  
Immunofluorescence 
De-identified human tonsillar specimens were fixed in 4% formaldehyde and 
embedded in paraffin. Sections were prepared, cleared in xylene, and 
hydrated through a descending alcohol series. Antigens were unmasked in 
rehydrated slides by boiling in 1 mM EDTA buffer pH 8.0 and incubating for 15 
min at sub-boiling temperature. After cooling, slides were blocked with 
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blocking buffer (PBS, 5% normal goat serum, 0.3% Triton X-10). Primary 
antibodies (anti-BCL6 D8, Santa Cruz; anti-HSF1-pSer326 EP1713Y, 
Epitomics) were diluted in blocking buffer and applied overnight at 4 ºC. Slides 
were rinsed in PBS and fluorochrome-conjugated secondary antibodies (Alexa 
Fluor 488 goat anti-mouse IgG, Alexa Fluor 647 goat anti-rabbit IgG, Molecular 
Probes) were diluted in blocking buffer and applied for 1 h at room 
temperature. Slides were rinsed and mounted in Prolong Gold Antifade 
Reagent with DAPI (Molecular Probes) and imaged with an Axiovert 200M 
fluorscent microscope (Zeiss Inc). 	  
Immunoblot 
Whole cell lysate was prepared using lysis buffer (20mM Tris pH 8.0, 150 mM 
NaCl, 5 mM EDTA, 1% Triton X-100) supplemented with protease inhibitors 
and resolved by SDS-PAGE, transferred to PVDF membranes, probed with 
primary antibodies (anti-HSF1 E-4, Santa Cruz; anti-β-ACTIN AC-15, Sigma) 
followed by HRP-conjugated secondary antibodies (Santa Cruz) and detected 
with enhanced chemiluminescence (Pierce). 	  
Animals 
C57BL/6, Hsf1+/+, Hsf1-/-, CBy.SJL(B6)-Ptprca/J (CD45.1), and BALB/c Rag1-/- 
were obtained from Jackson Laboratories. The maintenance and procedures 
of all animals were in accordance with and approved by the Research Animal 
Resource Center of the Weill Cornell Medical College. 	  
Germinal center formation 
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Age- and sex-matched mice were immunized intraperitoneally at 8 to 12 
weeks of age with 0.5 mL 2% v/v sheep red blood cells (SRBC, Cocalico 
Biologicals) or a 1:1 mixture of 100 µg of NP-CGG (ratio 20-29, Biosearch 
Technologies) and Imject alum (Pierce). For PU-H71 experiments, C57BL/6 
mice were randomized into two groups immediately after SRBC immunization 
and after 3 days, sterile PBS or 75 mg/kg PU-H71 (generously provided by 
Gabriela Chiosis) was administered via daily intraperitoneal injections for up to 
7 days. Age- and sex-matched Hsf1+/+ and Hsf1-/- mice were immunized with 
SRBC or NP-CGG and sacrificed at day 10.  	  
Immunohistology 
Mouse spleens were fixed in 4% formaldehyde and embedded in paraffin. 
Sections were prepared, cleared in xylene, and hydrated through a 
descending alcohol series. Slides were boiled with antigen retrieval buffer (10 
mM sodium citrate buffer pH 6.4 or 1 mM EDTA buffer pH 8.0) and cooled. 
Endogenous peroxidase activity was quenched by treatment with 3% 
hydrogen peroxide in methanol and permeabilized (0.5% Triton X-100, 20mM 
HEPES pH 7.4, 50 mM NaCl, 3 mM MgCl2, 30 mM Sucrose). Slides were 
blocked with 5% non-fat milk powder in PBS-Tween and then incubated with 
biotin-conjugated PNA (Vector Laboratories) or biotin-conjugated anti-B220 
(Invitrogen RM2615). Avidin-horseradish peroxidase (HRP) was applied, and 
peroxidase activity was detected with DAB color substrates (Vector 
Laboratories) and counterstained with hematoxylin. Images were obtained 
using an Axioskop imaging microscope (Zeiss Inc) and ImageJ software (NIH) 
was used to quantify germinal centers. 
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Chromatin Immunoprecipitation (ChIP) 
ChIP was performed as previously described (Hatzi et al., 2013). Briefly, naïve 
B cells that were heat shocked at 43 ºC for 30 min or GC B cells were fixed 
with 1% formaldehyde for 10 min at room temperature, quenched with 125 mM 
glycine, and lysed in modified RIPA buffer (150 mM NaCl, 1% v/v Nonidet P-
40, 0.5% w/v deoxycholate, 0.1% w/v SDS, 50 mM Tris pH 8, 5 mM EDTA) 
supplemented with protease inhibitors. Cell lysates were sonicated using a tip 
sonicator (Branson) to generate fragments less than 400 bp. Precleared 
lysates were incubated overnight with 5 µg anti-HSF1 (ADI-SPA-901, Enzo 
Life Sciences), 5 µg anti- anti-BCL6 (N3, Santa Cruz), 100 uL of anti-HSP90β 
supernatant (H9010, Invitrogen) or control IgG antibody. Immunocomplexes 
were recovered, sequentially washed with increasing stringency of wash 
buffers (150 mM NaCl, 250 mM NaCl, 250 mM LiCl), and eluted with 1% SDS 
and 100 mM NaHCO3. Crosslinks were reversed, and DNA was purified using 
a Qiaquick PCR purification kit (Qiagen). ChIP DNA was amplified with real-
time quantitative PCR using SYBR Green (Quanta Biosciences) and 7900HT 
Fast Real-Time PCR System (Applied Biosystems). Input standard curves 
were used for estimation of relative enrichment. 
 
Flow cytometric analysis 
Single-cell suspensions of mononuclear cells were generated from bone 
marrow and murine spleens using red blood cell lysis (Qiagen) and Fico/Lite-
LM density gradient media (Atlanta Biologicals), respectively. Mononuclear 
cells were washed with PBS with 1mM EDTA, filtered, and resuspended in 
staining buffer (PBS, 1% FBS, 0.09% sodium azide). Fluorescent-labeled 
antibodies (Table 2.1) were diluted in staining buffer and applied to cells for 20 
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min at 4 ºC. If primary antibodies were not conjugated to fluorochromes, cells 
were washed, and incubated with fluorochrome-conjugated secondary 
antibodies for 20 min at 4 ºC. Cells were washed and resuspended in stain 
buffer. Flow cytometry data was acquired with the Macsquant (Miltenyi Biotec) 
or FACS Canto II (BD Biosciences) flow cytometer and analyzed with FlowJo 
software package (TreeStar). 
 
Table 2.1 Summary of antibodies used for flow cytometry. 
   
Antigen Host Fluorophore Clone Manufacturer 
Anti-mouse B220 Rat  PE/FITC/APC RA3-6B2 BD Pharmingen 
Anti-mouse B220 Rat  PE-Cy7 RA3-6B2 eBioscience 
Anti-mouse CD43 Rat FITC eBioR2/6
0 
eBioscience 
Anti-mouse IgM Rat APC II/41 eBioscience 
Anti-mouse IgD Rat PE 11-
26.ca2 
BD Pharmingen 
Anti-mouse CD3 Rat APC 17A2 BioLegend 
Anti-mouse FAS Hamster PE Jo2 BD Pharmingen 
Anti-mouse GL7 Rat FITC GL7 BD Pharmingen 
Anti-mouse CD4 Rat APC GK1.5 eBioscience 
Anti-mouse CXCR5 Rat PE-Cy7 2G8 BD  
Anti-mouse PD1 Hamster PE/FITC J43 eBioscience 
NP  PE  Biosearch 
Technologies 
Anti-mouse CD138 Rat BV421 281-2 BioLegend 
Anti-mouse CD45.1 Mouse PerCP-Cy5.5 A20 eBioscience 
Anti-mouse CD45.2 Mouse PerCP-Cy5.5 104 eBioscience 
Anti-human IgD Mouse FITC IA6-2 BD Pharmingen 
Anti-human CD77 Rat Purified 38-13 AbD Serotec 
Anti-rat IgM Goat PerCP Poly Jackson 
Anti-human CD38 Mouse APC HB7 BD Biosciences 
	  78 
Enzyme-linked immunosorbent assay (ELISA) 
Mice were immunized twice with NP-CGG, with the second NP-CGG 
immunization occurring at day 20-post the initial NP-CGG immunization. 
Serum samples were collected 15 days after the secondary NP-CGG 
immunization (which coincides with day 35-post primary immunization), and 
titers of isotype-specific high-affinity antibodies to NP were measured in plates 
coated with NP4-BSA with the SBA Clonotyping System (Southern Biotech) in 
serial dilutions followed by incubation with HRP-labeled detection antibodies 
and ABTS substrate solution. Titers are presented as the greatest serum 
dilution that provided an average absorbance exceeding 2-fold above the 
average background absorbance at 405 nm. 
 
Mixed-bone marrow chimera studies 
For the generation of mixed bone marrow chimera, 4 x 106 cells from a 1:1 
mixture of CBy.SJL(B6)-Ptprca/J bone marrow cells (CD45.1+) and CD45.2+ 
Hsf1+/+ or Hsf1-/- bone marrow cells were injected into the tail veins of sub-
lethally irradiated (400 cGy at 2 doses, 4 h apart) BALB/c Rag1-/- mice in 
collaboration with the MSKCC Antitumor Assessment Core Facility. Recipient 
mice were immunized with SRBC 7 weeks later and GC formation was 
assessed 10 days post-SRBC with flow cytometric analysis. 
 
Intracellular staining for BCL6 
For flow cytometric analysis of BCL6 levels, single-cell suspensions of 
mononuclear cells were generated from murine spleens using Fico/Lite-LM 
density gradient media (Atlanta Biologicals). Mononuclear cells were washed 
with PBS with 1mM EDTA, filtered, and fixed with CytoFix/CytoPerm 
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Fixation/Permeabilization buffer (BD Biosciences) for 10 min at 37 ºC. Cells 
were washed with stain buffer (PBS, 1% FBS, 0.09% sodium azide) and 
pelleted. Cells were permeabilized by vortexing gently while simultaneously 
adding drop wise cold BD Phosflow Perm Buffer III (BD Biosciences) and 
incubating on ice for 30 min. Cells were washed twice with stain buffer and 
stained with fluorescent-conjugated anti-BCL6 (K112-91, BD Pharmingen) or 
the same amount of isotype control (mouse IgG1 κ, BD Pharmingen) for 1 h at 
room temperature. Cells were washed and stained with other fluorescent-
labeled cell surface antibodies in stain buffer for 20 min at 4 ºC. Cells were 
washed and resuspended in stain buffer. Flow cytometry data was acquired 
with the Macsquant (Miltenyi Biotec) or FACS Canto II (BD Biosciences) flow 
cytometer and analyzed with FlowJo software package (TreeStar). 
 
BrdU detection 
For BrdU labeling, mice were injected intraperitoneally with 1-2 mg BrdU 
(Sigma-Aldrich) 2 h before sacrificing. Mononuclear cells were prepared using 
Fico/Lite-LM density gradient media (Atlanta Biologicals). Cells were stained 
with the appropriate cell surface markers. Then BrdU-positive cells were 
detected by BrdU Flow kits (BD Pharmingen) according to the manufacturer's 
protocol.  
 
TUNEL assay 
Apoptotoic cells were detected in situ by labeling and detecting DNA strand 
breaks by the terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) method using the ApopTag Peroxidase In Situ Apoptosis Detection 
Kit (Millipore). Briefly, formalin-fixed paraffin-embedded spleens were 
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deparaffinized and pre-treated with trypsin (Zymed) to expose DNA. 
Endogenous peroxidase was quenched using 3% hydrogen peroxide (Sigma) 
followed by incubation with TdT enzyme for 1 h. Then, anti-digoxigenin-
peroxidase was applied to the slides. Color was developed with 
diaminobenzoate chromogen peroxidase substrate (Vector Laboratories) and 
counterstained with methyl green (Fisher Scientific). Images were obtained 
using an Axioskop imaging microscope (Zeiss Inc) and TUNEL-positive cells 
were counted in 40X high-powered fields of 5 germinal centers per mouse 
(n=5). 
 
Statistical analysis 
Student’s t-test was used for statistical analysis unless otherwise stated. All 
statistical analyses were done using GraphPad Prism 5.  
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CHAPTER THREE 
ROLE OF HSF1 IN DLBCL 
 
1. Introduction 
DLBCL is the most common form of aggressive lymphoid malignancy, 
accounting for nearly 40% of all non-Hodgkin lymphomas (Lenz and Staudt, 
2010). Current therapy includes R-CHOP, the combination of a monoclonal 
antibody (rituximab), three chemotherapeutics (doxorubicin, vincristin, 
cyclophosphamide), and one steroid (prednisone). While more than 50% of 
DLBCL patients respond to this drug cocktail, up to one-third of patients 
remain incurable, and the chemotherapy drug regimen is not without its 
toxicities, highlighting a need for more targeted treatments (Roschewski et al., 
2014). Understanding the etiology of DLBCL will provide additional avenues to 
improve existing therapies and facilitate the discovery of novel therapeutic 
targets. Somatically mutated Ig loci and gene expression profiles of DLBCL 
tumors suggest that the majority of them arise from B cells transiting or exiting 
the germinal center (GC) reaction (Klein and Dalla-Favera, 2008; Lenz and 
Staudt, 2010; Seifert et al., 2013). Dissecting the molecular mechanisms 
underlying the biology of GC B cells will help to further elucidate how GC B 
cells transform into DLBCL tumors. 
 
The formation of GCs is essential for the generation of high-affinity antibodies. 
GC B cells undergo clonal expansion and SHM of their Ig variable regions 
without undergoing cell cycle arrest or apoptosis because of the induction of a 
B cell-specific stress response program (Klein and Dalla-Favera, 2008). BCL6 
is the master regulator of this program and maintains the GC phenotype by 
	  82 
repressing several genes involved in DNA damage sensing, apoptosis, 
checkpoint activation, and plasma cell differentiation (e.g. ATR, CHEK1, TP53, 
CDKN1A, and PRDM1) (Hatzi and Melnick, 2014). BCL6 expression must 
eventually be turned off to enable post-GC differentiation and normal cell 
growth, and its deregulation is often associated with lymphomagenesis (Hatzi 
and Melnick, 2014).  
 
HSP90 was found to stabilize BCL6 mRNA and protein levels in DLBCL. 
Treatment of DLBCL cell lines with HSP90 inhibitors including the purine-
scaffold molecule, PU-H71, results in the degradation of BCL6 and apoptosis 
of BCL6-dependent DLBCL cells (Cerchietti et al., 2009a). Furthermore PU-
H71 treatment abrogates the GC response in mice, demonstrating that HSP90 
may also function to stabilize BCL6 in the normal physiological setting. The 
master regulator of the conserved heat shock response is HSF1, which 
transcriptionally regulates the expression of HSPs and other stress proteins 
(Akerfelt et al., 2010). In fact HSF1 is active in GC B cells and regulates 
stress-dependent induction of BCL6. Moreover HSF1 null mice have smaller 
GCs and defects in affinity maturation demonstrating that HSF1 plays an 
important role in maintaining the GC program in normal B cells. 
 
Because HSF1 contributes to maintaining homeostasis after exposure to 
various stressors, it has been implicated in cellular adaptation to the malignant 
phenotype (Whitesell and Lindquist, 2009). Increased HSF1 expression has 
been found in several tumor types, and HSF1 depletion results in decreased 
cell viability and chemosensitization (Dai et al., 2012; Dai et al., 2007; Jolly 
and Morimoto, 2000; Tang et al., 2005; Zaarur et al., 2006; Zhao et al., 2011). 
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Furthermore HSF1 is required for tumorigenesis and transformation by a 
number of oncogenes including RAS, PDGF-B, and HER2 (Dai et al., 2007; 
Jin et al., 2011b; Khaleque et al., 2008; Meng et al., 2010; Min et al., 2007). 
Although HSF1 is not a classical oncogene, HSF1 seems to govern a broad 
network of signaling pathways to support the tumorigenic environment, and 
the activation of its cancer program is associated with disease progression 
and predicts poor prognosis in cancer patients (Fang et al., 2012; Mendillo et 
al., 2012; Santagata et al., 2011).  
 
In the context of DLBCL, BCL6 is the most frequently deregulated oncogene 
with 30-40% of patients bearing chromosomal translocations of the 3q27 
region and 70% patients displaying somatic mutations in the 5’ regulatory 
regions of BCL6 (Ci et al., 2008; Pasqualucci et al., 2001). Because HSF1 
regulates BCL6 expression in GCs and is required for efficient affinity 
maturation, we therefore wondered if HSF1 is necessary for the maintenance 
of malignant phenotype and survival of DLBCL cells. 
 
2. Results 
2.1 HSF1 regulates BCL6 in DLBCL 
During the GC response, HSF1 inducibly binds HSEs in the BCL6 gene after 
immune stimuli and mediates the production of nascent transcripts from the 
BCL6 locus. Because BCL6 is highly expressed in DLBCL, we investigated if 
BCL6 expression in DLBCLs is also mediated by HSF1. We first identified if 
HSF1 binds to BCL6 by performing chromatin immunoprecipitation (ChIP) with 
an HSF1-specific antibody. We found HSF1 bound to the BCL6 promoter 
basally in DLBCL cell lines, OCI-LY1 and OCI-LY7 (Figure 3.1A). To 
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determine if HSF1 transcriptionally regulates BCL6 expression, we knocked 
down HSF1 by lentivirally transducing DLBCL cells with a puromycin-
selectable HSF1-targeting shRNA (pLKO.1). After selecting cells for 48 h, we 
observed a decrease in BCL6 mRNA and protein levels in DLBCL cells 
(Figure 3.1B-C). In addition BCL6, HSP90 levels also dropped after HSF1 
depletion, as expected since it is well-known target gene of HSF1 (Figure 
Figure 3.1 HSF1 regulates BCL6 expression in DLBCL cells. (A) 
Percent input of HSF1 ChIP at the BCL6 gene and a negative control region 
in OCI-LY1 and OCI-LY7. (B) BCL6 expression in OCI-LY1 and OCI-LY7 
cells transduced with HSF1 shRNA and a scrambled control (shScr) and 
selected for 2 d with puromycin. (C) Immunoblot of OCI-LY1 and OCI-LY7 
cells transduced as described in (B). Values in (A-C) are representative of 
three independent experiments. Error bars indicate the mean ± SEM.  
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3.1C). However HSP90 stabilizes BCL6 post-transcriptionally, therefore the 
effect seen here may reflect an indirect mechanism of HSF1-mediated 
regulation of BCL6 (Cerchietti et al., 2009a). 
 
2.2 HSF1 maintains DLBCL survival 
DLBCL cells are highly dependent on BCL6 for their pathogenesis and survival 
(Hatzi and Melnick, 2014). In addition, pharmacological inhibition of HSP90 
results in strong anti-lymphoma activity in in vitro and ex vivo models of 
DLBCL. Because HSF1 knockdown results in a decrease in both BCL6 and 
HSP90 levels, we next examined whether HSF1 knockdown affects DLBCL 
survival. We first transduced two DLBCL cell lines (OCI-LY1 and SU-DHL4) 
with 5 HSF1-targeting shRNAs in a tetracycline-inducible backbone and an 
empty vector control (pLVUTH-KRAB) (Szulc et al., 2006). After doxycycline (a 
more stable tetracycline derivative), shRNA expression is induced along with a 
GFP transgene. By measuring GFP-positive cells, cell viability and growth was 
assessed. In cells infected with the empty vector, GFP-positive cells continued 
to increase until d 3 where they plateaued to 25-30% even with continuous 
replenishment of doxycycline to the media (Figure 3.2). The percentages of 
GFP-positive cells transduced with HSF1 shRNAs were significantly lower 
compared to the empty vector in all five shRNAs in both OCI-LY1 and SU-
DHL4 (Figure 3.2). These preliminary results suggest that DLBCL cells 
require HSF1 for their normal proliferation and survival. However infection 
efficiency after transduction with this inducible shRNA system was poor and 
difficult for downstream assays to more precisely answer these questions. 
Therefore the puromycin-selectable pLKO.1 shRNA backbone was used for all 
further experiments. 
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While preliminary experiments demonstrated a potential dependency for HSF1, 
HSF1 knockdown was performed in a larger panel of DLBCL cell lines to better 
address this query. This panel included both GC B cell-like (GCB) and 
activated B cell-like (ABC) DLBCL cell lines. While they both arise from the GC, 
GCB and ABC DLBCL cells are thought to come from different cells of origin 
within GC development. GCB DLBCLs are highly dependent on BCL6 as they 
reflect more of a centroblast-phenotype whereas ABC DLBCLs have gene 
expression patterns that are more similar to B cells undergoing plasmacytic 
differentiation and are therefore in a later GC stage (Lenz and Staudt, 2010; 
Roschewski et al., 2014). Two HSF1-targeting shRNAs (shHSF1-1 and -2) and 
a scrambled control (shScr) were used to transduce 9 DLBCL cell lines. This 
panel included four GCB (OCI-LY1, OCI-LY7, SU-DHL4, SU-DHL6), two ABC 
(HBL1 and TMD), and three BCL6-independent (K422, PFEIFFER, TOLEDO) 
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Figure 3.2 DLBCL cells require HSF1 for normal growth and 
proliferation. The % GFP+ DAPI- cells after doxycycline induction in OCI-
LY1 and SU-DHL4 cells transduced with a tetracycline-inducible backbone 
with 5 HSF1-targeting shRNAs and an empty vector control. Values are 
representative of three independent experiments. Error bars indicate the 
mean ± SEM. A t-test was used to assess significance, * p<0.05 and ** 
p<0.01 at d 5, d 7, and d9. 
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cell lines. DLBCL cell lines were transduced and selected 48 h later with 1 
µg/mL puromycin. Live cells were monitored by flow cytometry using Annexin 
V- and DAPI- criteria. The percentage of live cells decreased as early as d 2 
after puromycin with the most sensitive cell lines almost completely killed by d 
4 and d 8 in shHSF1-1 and shHSF1-2, reflecting differences in HSF1 
knockdown efficiency between the hairpins (Figure 3.3A-B). The most 
sensitive cell lines (SU-DHL6, TMD8, and PFEIFFER) had efficient HSF1 
knockdown with both shRNAs and spanned all three categories of GCB, ABC, 
and BCL6-independent. The percentage of live cells also decreased in the 
other DLBCL cell lines with the greatest decrease occurring in cells transduced 
with shHSF1-1, the hairpin that was most effective at depleting HSF1 (Figure 
3.3A-B). Decreases in cell viability were accompanied by an induction of 
apoptotic markers like cleaved PARP1 (cPARP1). All the cell lines transduced 
with shHSF1-1 had higher cPARP1 levels compared to shScr (Figure 3.3B). 
These results demonstrate HSF1 is required to maintain DLBCL survival.  
 
Some DLBCL cell lines had minimal effects on cell viability, therefore we 
wondered if HSF1 knockdown may at least cause defects in the proliferation of 
cells. To test this, we examined BrdU incorporation 4 d after shRNA 
transduction. We found that shHSF1-1 expressing cells had decreased 
number of cells entering S phase and a subsequent increase of cells in G2/M-
phase (Figure 3.4A). This experiment was complemented with additional 
studies using a proliferation dye, eFluor670. Three DLBCL cell lines (OCI-LY1, 
OCI-LY7, and the BCL6-independent TOLEDO) were transduced with 
shHSF1-2, the HSF1-targeting hairpin with moderate effects on viability to 
measure changes in proliferation rate. Cells were stained with eFluor670, 
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transduced, and selected with puromycin. The proliferation index was 
calculated based on the rate of eFluor670 dilution using flow cytometry. All 
three DLBCL cell lines irrespective of BCL6 dependence had significant 
decreases in proliferation index with shHSF1-2 relative to the control shScr, 
indicating a role for HSF1 in upholding the rapid proliferate state of DLBCL 
cells (Figure 3.4B). Collectively both BCL6-dependent and -independent cell 
lines were sensitive to HSF1 knockdown, suggesting that HSF1 has 
independent functions related to cell viability and cell cycle control distinct from 
BCL6. 
Figure 3.3 HSF1 is necessary for DLBCL survival. (A) % Live cells as 
measured by Annexin V- and DAPI- in a panel of DLBCL cell lines 
transduced with two HSF1-targeting shRNAs and control shScr and 
selected with puromycin. (B) Immunoblot was performed in (A) at d2 post-
puromycin. Values in (A) are representative of three independent 
experiments. Error bars indicate the mean ± SEM.  
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Figure 3.4 DLBCL cells require HSF1 for rapid proliferation. (A) BrdU 
incorporation in OCI-LY1 cells transduced with 2 HSF1-targeting shRNAs 
and shScr vector control 4 d after puromycin selection. Quantification of cell 
populations is shown on the right. (B) Rate of proliferation in OCI-LY1, OCI-
LY7, and TOLEDO cells stained with eFluor670 and transduced with 
shHSF1-2 and selected with puromycin. Values are representative of three 
independent experiments. Error bars indicate the mean ± SEM. A t-test was 
used to assess significance, ** p<0.01. 
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2.3 Genome-wide patterns of HSF1 occupancy in DLBCL 
HSF1 facilitates the survival and proliferation of DLBCL. However how it 
coordinates these effects is still unclear. HSF1 is a transcription factor that 
mediates its function by modulating gene expression of its targets. We have 
demonstrated that HSF1 regulates BCL6 expression in GC B cells and DLBCL, 
and HSF1 knockdown is followed with decreases in BCL6 levels. Interestingly 
many DLBCL cell lines that are not dependent on BCL6 also rely on HSF1, 
implying that HSF1 regulates additional genes important for DLBCL 
pathogenesis. To determine the genome-wide transcriptional program in 
DLBCL, we performed HSF1 ChIP followed by next-generation sequencing in 
two DLBCL cell lines, OCI-LY1 and OCI-LY7. HSF1 ChIP-seq was done in 
replicates, which were highly correlated in both cell lines (Pearson r 0.87 and 
0.93 for OCI-LY1 and OCI-LY7 respectively) (Figure 3.5A-B). We identified 
HSF1 occupied sites with the ChIPseeqer peak detection tool (Giannopoulou 
and Elemento, 2011). We overlapped the replicates of each cell line and 
identified 147 and 675 reproducible peaks in both OCI-LY1 and OCI-LY7 
respectively, which amounted to 167 and 664 genes, respectively (Table 3.1). 
In OCI-LY1, more than 40% of HSF1 peaks fell within promoter regions, 20% 
within gene bodies (mainly introns), and more than 30% fell within distal and 
intergenic regions (Figure 3.5C). In OCI-LY7, equal percentages of HSF1 
peaks occupied both promoters and introns (30%), and almost 35% of peaks 
were found in distal and intergenic peaks (Figure 3.5D). The low number of 
peaks in OCI-LY1 is likely due to poor immunoprecipitation efficiency with this 
particular HSF1 antibody (Enzo). However this antibody outperformed others 
(Cell Signaling and Santa Cruz) for ChIP and these peak numbers are 
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consistent with other HSF1 genome-wide studies in cancer cell lines (Mendillo 
et al., 2012; Vihervaara et al., 2013). 
 
Table 3.1 Summary of mapped reads and detected peaks in ChIP-seq 
experiments. 
 
HSF1 binds to its target through specific regulatory elements, termed heat 
shock response elements or HSEs. We next sought to determine if many of 
the HSF1 occupied genomic sites have HSEs using the de novo motif 
discovery tool FIRE (Elemento et al., 2007). In OCI-LY1, the HSE motif was 
the only motif identified to be over-represented by FIRE, localized close to the 
center of the HSF1 peak summit, and was present in almost 60% of HSF1 
peaks (Figure 3.6A). In OCI-LY7, FIRE identified 3 motifs that were over-
represented (Figure 3.6B). The motif with the highest z-score was the 
canonical HSE, which similarly to OCI-LY1 was found close to the peak 
summit and present in 55% of all HSF1 peaks (Figure 3.6B). The other two 
motifs over-represented appear to be degenerate HSEs. Interestingly one 
motif rich in A’s was found to be under-represented in HSF1 peaks (Figure 
3.6B). The presence of an HSE in the majority of HSF1 occupied genomic 
sites suggests that HSF1 directly binds its target loci to regulate their 
expression. Those HSF1-bound sites without canonical HSEs may have 
 CHIP INPUT 
CLONAL 
READS 
PEAKS 
(T5F2) 
OVERLAPPED 
PEAKS GENES 
OCI-
LY1 
R1 12,773,795 17,794,651 <10% 651 147 167 
R2 10,768,344 21,468,559 <10% 589   
OCI-
LY7 
R1 9,561,890 16,593,942 <10% 1609 675 664 
R2 10,741,011 13,678,363 <10% 1664   
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degenerate HSEs, as found in OCI-LY7, or HSF1 may be recruited to those 
targets by another transcription factor. 
 
2.4 HSF1 regulates the expression of its target loci 
To determine the consequences of HSF1 occupancy on gene expression, we 
profiled OCI-LY1 and OCI-LY7 for global mRNA changes after HSF1 
knockdown using next-gen sequencing. We transduced DLBCL cells with two 
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HSF1-targeting (shHSF1-1 and -2) and a scrambled control shRNA (shScr) 
and analyzed mRNA expression 48 h post-puromycin selection when cell 
viability was not impaired. Differentially expressed genes were identified with 
the EdgeR package using FDR<0.05 (Robinson et al., 2010). The gene 
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expression changes resulting from both HSF1 shRNAs were well correlated in 
OCI-LY1 and OCI-LY7 (Pearson r values 0.69 and 0.66 respectively) (Figure 
3.7A-B). As observed earlier with effects on cell viability, shHSF1-1 has more 
gene expression changes (4,646 and 6,721 differentially expressed genes in 
OCI-LY1 and OCI-LY7, respectively) than shHSF1-2 (2,118 and 2,561 
differentially expressed genes in OCI-LY1 in OCI-LY7, respectively) again due 
to the differences in HSF1 knockdown efficiency, as shHSF1-1 is able to 
deplete HSF1 levels better than shHSF1-2 (Figure 3.7C). Moreover OCI-LY7 
had more genes bound by HSF1, and this was reflected with more genes 
being mobilized after HSF1 depletion. HSF1 knockdown resulted in a large 
number of downregulated genes (2,890 in OCI-LY1 and 3,442 in OCI-LY7 with 
shHSF1-1), indicating that many were transcriptionally activated by HSF1. 
However many genes also increased (1,756 in OCI-LY1 and 3,279 in OCI-LY7 
with shHSF1-1), suggesting that HSF1 can form repressive transcriptional 
complexes. Alternatively the de-repression of genes might be a secondary 
effect because of HSF1-mediated modulation of other genes that function as 
repressors like BCL6, which we demonstrated earlier is an HSF1 target. 
Genes downregulated in OCI-LY7 after shHSF1-1 were enriched in genesets 
associated with proliferation and B cell differentiation including genes 
repressed by BLIMP1, the master regulator of plasma cell differentiation 
(Figure 3.7D). These results are consistent with proliferation defects seen 
after HSF1 knockdown (Figure 3.3-3.4) but they also imply that HSF1 
knockdown releases DLBCL cells from the centroblast-phenotype and allows 
them to differentiate to plasmacytic B cells. 
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Figure 3.7 Gene expression profiling after HSF1 knockdown in DLBCL 
cells. OCI-LY1 and OCI-LY7 mRNA-seq after cells were transduced with 
two HSF1-targeting shRNAs and a control shScr and selected for 2 d with 
puromycin. Correlation of log2 fold-changes of each HSF1 shRNA to shScr. 
in (A) OCI-LY1 and (B) OCI-LY7 cells. (C) Immunoblot of cells described 
earlier. (D) Summary of Staudt gene signatures that significantly enrich with 
genes downregulated after shHSF1-1 in OCI-LY7 cells using GSEA. 
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To evaluate the effect of HSF1 binding on the expression of its target genes, 
we performed gene set enrichment analysis (GSEA) with a ranked list of all 
gene expression changes after HSF1 knockdown and HSF1 promoter targets. 
A significant enrichment was seen with HSF1-bound promoters and genes 
downregulated after HSF1 depletion with shHSF1-1 (the stronger shRNA) in 
both OCI-LY1 (NES=-1.83, FDR q-value=0.0002) and OCI-LY7 (NES=-1.42, 
FDR q-value=0.003) (Figure 3.8A-B). Enrichment was also seen between 
HSF1-bound promoters and genes downregulated after shHSF1-2 although 
with higher FDR q-values, most likely due to inefficient HSF1 knockdown 
(Figure 3.8A-B). Many of the genes bound and regulated by HSF1 were 
associated with gene ontology categories of molecular chaperones, chromatin 
binding, protein translation, and lymphocyte activation, suggesting that HSF1 
controls a unique program that includes both canonical expression of HSPs 
but also other genes involved in DLBCL malignancy and survival (Figure 
3.8C). 
 
2.5 HSF1 transcriptional programs in normal GC B cells and DLBCLs are 
distinct  
Considering that many of the molecular mechanisms governing the GC 
response are hijacked by DLBCL cells to maintain their highly proliferative and 
pro-survival phenotype, we wondered if the HSF1 transcriptional program is 
shared between DLBCL cells and GC B cells. To answer this question, we 
performed HSF1 ChIP-seq in human CD77+ GC B cells affinity-purified from 
de-identified tonsillectomy specimens. HSF1 ChIP-seq replicates correlated 
with Pearson r values of 0.80, and the overlap of ChIP-seq replicates yielded 
433 regions occupied by HSF1 with 454 unique genes potentially regulated.  
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Figure 3.8 HSF1 regulates the expression of genes that it binds. GSEA 
with HSF1 promoter targets in (A) OCI-LY1 and (B) OCI-LY7 and a ranked 
list of all gene expression changes after shHSF1-1 (top) or shHSF1-2 
(bottom). (C) Heatmap of HSF1-bound promoters and their gene expression 
changes with enriched gene ontology categories on the right. 
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GC HSF1 ChIP-seq demonstrated similar genome occupancy as DLBCL cell 
lines with more than 40% of HSF1-bound peaks falling within promoters 
(Figure 3.9A-B). Like in DLBCL cells, the canonical HSE was over-
represented (found in 57% of total peaks) and localized to the center of the 
peak summit (Figure 3.9C). HSF1 promoter targets in GC B cells were also 
strongly enriched (NES=-1.29, FDR q-value=0.00 2) in genes downregulated 
after shHSF1-1 transduction in DLBCL cells, demonstrating that HSF1 in fact 
positively regulates many of its targets in GC B and DLBCL cells (Figure 
3.9D). 
 
To understand the differences in transcriptional programs between GC B cells 
and DLBCL cells, we overlapped the HSF1-bound targets in GC B cells and 
union of genes bound in DLBCL cells. We found 130 genes that were 
occupied by HSF1 in both GC B cells and DLBCL cells, but we also found 
genes that were specific to GC B cells or DLBCL cells (Figure 3.10). As 
expected, the shared HSF1 targets reflect the canonical functions of HSF1 in 
maintaining proteostasis and include genes involved protein folding, 
translation, and the ubiquitin-proteasome system. The shared HSF1 targets 
are also involved in gene expression, as many of them are transcription 
factors, chromatin-binding proteins, and long noncoding RNAs. HSF1 targets 
that are unique to GC B cells reflect tissue-specific targets as many genes are 
involved immune signaling and protein transport. DLBCL-specific targets 
reflect the pro-survival and proliferative function of HSF1 that are required by 
DLBCL for pathogenesis. Many of these targets are involved in cell cycle 
control for uncontrolled proliferation and modulation of chromatin that is   
  
	  99 
   Figure 3.9 Genome-wide occupancy and de novo motif discovery of 
HSF1 binding sites in GC B cells.  (A) Correlation of HSF1 ChIP-seq 
replicates in human tonsillar GC B cells. Each point represents the 
maximum peak height of each peak location in replicate (R1) and R2. (B) 
Distribution of HSF1 ChIP-seq occupied regions in the genome. (C) The 
location of the top motif identified by FIRE (resembling the canonical HSE) 
in relation to the HSF1 peak summit, left. Motifs identified by FIRE that are 
over- or underrepresented in HSF1 binding sites, right. 
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required for activation of additional transcriptional programs that maintain 
genomic instability and DLBCL malignancy. 
 
3. Discussion 
In an earlier chapter, we have shown that HSF1 mediates the stress-
dependent induction of BCL6. This occurs after heat shock and also in GC B 
cells that are highly stressed due to replicative, genotoxic, and metabolic 
stress. We demonstrate here that BCL6 induction in DLBCL is also stress-
dependent as HSF1 depletion results in decreased levels of BCL6. BCL6 is 
the most frequently deregulated oncogene in DLBCL, and its constitutive 
expression in GC B cells can induce lymphomagenensis (Ci et al., 2008). Due 
to the regulation of BCL6, it was not surprising that our data indicate that 
DLBCL cells also require HSF1 to sustain their survival and rapid proliferation. 
Figure 3.10 HSF1 transcriptional program in GC B cells and DLBCL 
cells. The overlap of HSF1-bound promoters in GC B cells and DLBCL 
cells, OCI-LY1 and OCI-LY7. Gene ontology categories that enrich in the 
GC B cell-specific, left; shared between GC B cells and DLBCLs, center; 
and DLBCL-specific, right are noted. 
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Our initial hypothesis was that this was facilitated by maintenance of BCL6 
expression, and GCB DLBCL cells would therefore be more dependent on 
HSF1. However BCL6-independent and ABC DLBCL cell lines that express 
lower levels of BCL6 were also sensitive to HSF1 knockdown. These data 
suggest that HSF1 can complement other drivers of DLBCL malignancy by 
maintaining an oncogenic environment that allows cells to tolerate aberrant 
mutations, genomic instability, and a high replicative index. 
 
To identify how HSF1 maintains an oncogenic environment, we sought to 
determine the HSF1-driven transcriptional program in DLBCL. We found that 
HSF1 is directly recruited to the majority of its targets by the presence of HSEs. 
HSF1 binds to the promoters, gene bodies, and intergenic regions of genes. 
We have determined that promoter binding greatly influences whether a gene 
will be regulated by HSF1 as the majority of promoter-bound genes are 
positively regulated by HSF1. However the significance of HSF1 binding to 
other genomic regions like introns and intergenic sites is still unclear. Many of 
these regions have HSEs suggesting that they are indeed bona fide targets 
and not artifacts. Intergenic regions are frequently associated with regulatory 
elements or enhancers. HSF1 binding at these regions could indicate potential 
enhancer regions that fine-tune gene expression.  
 
Mendillo et al. (2012) found that genes that were negatively regulated by HSF1 
were more frequently bound by HSF1 at intergenic than promoter regions, 
suggesting that intergenically-bound HSF1 participates in the repression of 
proximal genes. However GSEA with our datasets did not demonstrate an 
enrichment with intronic- or intergenic-bound regions with increased or 
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decreased gene expression changes after HSF1 knockdown (not shown). If 
intergenic HSF1 binding does truly participate in regressive complexes, the 
presence of a distinguishing factor that separates out the repressor functions 
of HSF1 has not yet been elucidated. Notably the HSF1 binding site is similar 
to the BCL6 motif ([AT]TC[CT][AT][AC]GA) (Ci et al., 2009; Hatzi et al., 2013). 
BCL6 is transcriptional repressor that mediates its functions at enhancer 
regions by recruiting the corepressors SMRT and HDAC3 to toggle enhancers 
from an active to a poised state (Hatzi et al., 2013). In fact the HSF1 binding 
site was overrepresented in genomic regions bound by both BCL6 and SMRT 
(Hatzi et al., 2013). These results suggest that HSF1 could act with BCL6 to 
toggle enhancer activity, revealing a novel role for HSF1 in modulating 
enhancer activity. 
 
 A large percentage of HSF1-occupied sites also fall within introns. Instead of 
regulating the expression of genes transcriptionally, HSF1 could potentially 
regulate genes post-transcriptionally by affecting differential splicing. A 
functional screen identified several HSF1 binding proteins that are involved in 
RNA splicing, including PRPF8, SNRNP200, and EFTUD2, which together 
form the U5 snRNP components of the spliceosome (Fujimoto et al., 2012). 
EFTUD2 is an RNA helicase that unwinds U4/U6 RNA and is required for 
spliceosome activation (Bartels et al., 2002). HSF1 could directly modulate 
alternative splicing events by targeting the U5 snRNP components for 
preferential intron retention or exon skipping. Alternatively HSF1 could 
facilitate exon usage indirectly by modulating chromatin at its binding sites. It 
was recently demonstrated that trimethylation of H3K36 on a histone variant 
(H3.3) associated with actively transcribed genes can recruit BS69, a 
	  103 
chromatin reader, which mediates intron retention by directly binding to 
EFTUD2 (Guo et al., 2014). By activating trimethylation of H3K36, HSF1 could 
recruit BS69 to induce intron retention at its targets. 
 
While the exact biochemical mechanisms of HSF1 at its occupied genomic 
regions remain unclear, the transcriptional program driven by HSF1 in GC B 
cells and DLBCL has now been revealed. While many of the genes regulated 
by HSF1 are common to both GC B cells and DLBCL, there are specific 
subsets of genes uniquely found in one or the other. The gene expression 
program shared by GC B cells and DLBCL largely represents the canonical 
functions of HSF1 in maintaining protein homeostasis as many of these genes 
are molecular chaperones, components of the ubiquitin-proteasome system, 
and translational machinery. This is expected since both GC B and DLBCL 
cells are highly stressed, undergoing SHM, and therefore producing proteins 
with aberrant mutations that must be effectively chaperoned. This explains 
why DLBCL cells, independent of the oncogenic driver whether it is BCL6 or 
constitutive NF-κB signaling, are sensitive to HSF1 depletion. The HSF1-
specific program in GC B cells seems to reflect normal GC biology as many of 
these genes are involved in immune signaling and protein transport, which is 
likely required by GC B cells to constantly shuttle their Ig receptors to the 
surface for antigen presentation. The DLBCL-specific HSF1 targets include 
genes involved in cell cycle control and proliferation. This is consistent with our 
results demonstrating cell cycle arrest and decreased cell proliferation after 
HSF1 knockdown. In addition to these expected targets, HSF1 also seems to 
regulate a number of transcription factors and chromatin-modifiers. While the 
exact reasons why they might be regulated by HSF1 is still unclear and likely 
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very complex, these data implicate them in the pathogenesis of DLBCL and 
suggest that they could be important for DLBCL survival. 
 
We have found that HSF1 is critical for DLBCL survival and explored the 
transcriptional mechanisms mediating HSF1-induced malignancy. These 
studies elucidated HSF1 as a novel therapeutic target in lymphoma and also 
provided mechanistic insight into the transcriptional regulation of genes 
important for lymphoma development and survival. DLBCL is the most 
common lymphoid malignancy, accounting for almost 40% of all non-Hodgkin 
lymphomas (Lenz and Staudt, 2010). While more than 50% of DLBCL patients 
respond to current anti-lymphoma therapy, a third of patients remain incurable, 
demonstrating a need for better targeted treatments (Roschewski et al., 2014). 
A great deal of time and money has been spent to understand the molecular 
mechanisms underlying DLBCL in the hope of discovering novel therapeutic 
targets. One outcome of these efforts is the growing emergence of HSP-based 
therapies, which have proven extremely promising in animal studies and are 
currently in cancer clinical trials (Neckers and Workman, 2012). However 
targeting the upstream transcription factor that governs the expression of 
HSPs as well as multiple other pathways important for DLBCL survival may be 
a more effective way to reprogram the fundamental cellular processes that 
drive and maintain B cell malignancy. The identification of HSF1-mediated 
pathways involved in B cell transformation we present here will hopefully 
provide additional avenues to improve and specify both heat shock-targeted 
therapies and chemotherapeutic combinations for treatment of DLBCL.  
 
4. Materials and Methods 
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Mammalian Cell Lines 
The DLBCL cell lines OCI-LY1 and OCI-LY7 were grown in Isocove’s medium 
supplemented with 10% FBS and penicillin G/streptomycin. SU-DHL4, SU-
DHL6, K422, PFEIFFER, TOLEDO, HBL-1, and TMD8 were grown in RPMI 
1640 supplemented with 10% FBS, penicillin G/streptomycin, L-glutamine, and 
HEPES. Cell lines were obtained from ATCC, DMSZ or the Ontario Cancer 
Institute and grown in 37 ºC with 5% CO2. 
 
Primary cell isolation 
Human tissues were obtained with approval of the Institutional Review Board 
(IRB), Office of Research Integrity of the Weill Cornell Medical College and in 
accordance with the Declaration of Helsinki. CD77+ GC B cells were isolated 
from de-identified human tonsillectomy specimens or spleens. After 
centrifugation in Fico/Lite-dLymphoH density gradient media (Atlanta 
Biologicals), mononuclear cells were collected and affinity-purified using 
microbead cell separation via the autoMACS system (Miltenyi Biotec). GC B 
cell purity was determined by flow cytometric analysis to be >90% 
CD77+/CD38high.  
 
Chromatin Immunoprecipitation (ChIP) 
ChIP was performed as previously described (Hatzi et al., 2013). Briefly, OCI-
LY1, OCI-LY7, or GC B cells were fixed with 1% formaldehyde for 10 min at 
room temperature, quenched with 125 mM glycine, and lysed in modified RIPA 
buffer (150 mM NaCl, 1% v/v Nonidet P-40, 0.5% w/v deoxycholate, 0.1% w/v 
SDS, 50 mM Tris pH 8, 5 mM EDTA) supplemented with protease inhibitors. 
Cell lysates were sonicated using a tip sonicator (Branson) to generate 
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fragments less than 400 bp. Precleared lysates were incubated overnight with 
5 µg anti-HSF1 (ADI-SPA-901, Enzo Life Sciences) or control IgG antibody. 
Immunocomplexes were recovered, sequentially washed with increasing 
stringency of wash buffers (150 mM NaCl, 250 mM NaCl, 250 mM LiCl), and 
eluted with 1% SDS and 100 mM NaHCO3. Crosslinks were reversed, and 
DNA was purified using a Qiaquick PCR purification kit (Qiagen). ChIP DNA 
was amplified with real-time quantitative PCR using SYBR Green (Quanta 
Biosciences) and 7900HT Fast Real-Time PCR System (Applied Biosystems). 
Input standard curves were used for estimation of relative enrichment. 
 
Lentiviral transduction 
Lentivirus was produced in 293T by calcium phosphate transfection of 
pLKO.1-puromycin vectors (The RNAi Consortium) or tetracycline-inducible 
pLVUTH-KRAB vectors (Szulc et al., 2006) with the envelope and packaging 
vectors, VSV.G and Δ8.91. Lentivirus was collected 48 h after transfection and 
concentrated with PEG-it (Systems Biosciences). Cells were transduced and 
selected with 1 µg/mL puromycin or induced with 0.5 µg/mL doxycycline 48 h 
after infection.  
Control shRNA sequences: 
shSCR: 5’- CCTAAGGTTAAGTCGCCCTCG -3’ 
Human shRNA sequences: 
sh157 (also shHSF1-1): 5’- GCAGGTTGTTCATAGTCAGAA -3’ 
sh158: 5’- GCACATTCCATGCCCAAGTAT -3’ 
sh159: 5’- CCAGCAACAGAAAGTCGTCAA -3’ 
sh160: 5’- GCCCAAGTACTTCAAGCACAA -3’ 
sh161 (also shHSF1-2) : 5’- CAGTGACCACTTGGATGCTAT -3’ 
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mRNA isolation and real-time RT-qPCR 
DLBCL cells were transduced with shRNAs and then selected 48 h later with 1 
µg/mL puromycin. At d2 post-puromycin, cells were collected and 
resuspended in Trizol reagent (Invitrogen) and stored at -80 ºC until RNA 
extraction. After thawing, 1/5 volume of chloroform was added, and the 
samples were shaken vigorously for 15 sec. After 2 min incubation at room 
temperature, the samples were spun at 12,000xg for 15 min at 4 ºC. The 
aqueous phase was aspirated into a new tube, and 1 volume of isopropanol 
was added. Samples were mixed and incubated for 10 min at room 
temperature or overnight at -80 ºC. Tubes were spun again at 12,000xg for 10 
min, and then washed with 75% ethanol. Tubes were spun at 7,500xg for 5 
min, aspirated, and allowed to dry at room temperature for 5-10 min. RNA was 
resuspended in RNase-free H2O and quantified with the Nanodrop (Thermo 
Scientific). cDNA was prepared using the Verso cDNA synthesis kit (Thermo 
Scientific) and detected by fast SYBR Green (Quanta Biosciences) on the 
7900HT Fast Real-Time PCR System (Applied Biosystems). Gene expression 
was normalized to a housekeeping gene RPL13A and expressed as values 
relative to control using the ddCt method. Results were represented as fold 
change in expression with the standard error for 3 series of triplicates. 
 
Immunoblot 
Whole cell lysate was prepared from DLBCL cells with lysis buffer (20mM Tris 
pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100) supplemented with 
protease inhibitors. Protein was cleared, quantified by Bradford reagent 
(Pierce) and resolved by SDS-PAGE, transferred to PVDF membranes, 
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probed with primary antibodies (anti-HSF1 E-4, Santa Cruz; anti-β-ACTIN AC-
15, Sigma, anti-BCL6 D8, Santa Cruz; anti-cleaved PARP-1 5A5, Santa Cruz) 
followed by HRP-conjugated secondary antibodies (Santa Cruz) and detected 
with enhanced chemiluminescence (Pierce). 
 
BrdU detection 
For BrdU labeling, cells were plated several hours before being pulsed with 10 
µM BrdU (Sigma-Aldrich) for 10 min without disturbing cells. BrdU-positive 
cells were detected by BrdU Flow kits (BD Pharmingen) according to the 
manufacturer's protocol.  
 
Measuring the change in proliferation rate 
DLBCL cells were stained with 0.1 µM eFluor670 (eBioscience) according to 
the manufacturer’s instructions and then split for transduction with shRNAs. 
Cells were selected 48 h later with puromycin and monitored by flow cytometry 
for the rate of dye dilution every other day. The change in proliferation index at 
day x was measured by using the eFluor670 MFI in the formula below. 
Change in proliferation index that is less than 0 indicates decreased 
proliferation rate of shHSF relative to shScr. 
Change in proliferation index = shHSF(MFId0/MFIdx)- shScr(MFId0/MFIdx) 
 
Preparation of ChIP-seq libraries 
ChIP-seq libraries were prepared using the Illumina TruSeq DNA library prep 
kit (Illumina) with minor modifications. Briefly 5-10 ng of purified ChIP DNA 
was end-repaired using the kit’s enzymes and protocol and purified with 
minielute columns (Qiagen). A-tailing was performed to add A bases to the 3’ 
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ends of the DNA fragments using the kit’s enzymes and protocol and purified 
with minielute columns (Qiagen). Adapters were ligated using the Quick 
Ligation kit (New England Biolabs). Stop ligation solution was added and DNA 
was cleaned up using Ampure XP beads (Agencourt) at a 1:1 ratio of 
beads:DNA solution. Adaptor-modified ChIP DNA was size-selected using 
SPRIselect beads (Beckman Coulter) by adding a 0.5X volume of beads to 
allow fragments greater than 400 bp to bind the beads. The supernatant was 
collected and 1X volume of beads was added. The supernatant was aspirated, 
and the beads were washed 2X with 80% ethanol, dried, and eluted with 
resuspension buffer. Adaptor-modified ChIP DNA was amplified using 12 PCR 
cycles. Libraries were quantified using the Qubit (Life Technologies) and size 
was verified using the Bioanalyzer (Agilent). The library was cluster amplified 
and sequenced on the Illumina HiSeq2500 (Illumina). Reads were processed 
using CASAVA 1.8 and mapped to hg19. 
 
ChIP-seq peak detection 
Peak calling and all downstream analysis including annotation and FIRE was 
performed with the ChIPseeqer detection algorithm (Giannopoulou and 
Elemento, 2011). Each ChIP-seq dataset was normalized to its corresponding 
input lane. Peaks were annotated using the RefSeq database (hg19). 
 
Preparation of mRNA-seq libraries 
DLBCL cells were transduced with HSF1 shRNAs and shScr and selected for 
48 h with puromycin. RNA was purified using Trizol extraction (Invitrogen) and 
treated with Dnase (Qiagen). RNA quality was verified using the Agilent 2100 
Bioanalyzer (Agilent Technologies) and the RNA integrity number values were 
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greater than 8 for all samples. Sequencing libraries were generated with 
polyA+ RNA using the TruSeq RNA sample prep kit (Illumina). Libraries were 
cluster amplified and sequenced for 50 cycles using the Illumina HiSeq2000. 
Reads were aligned to hg19 using TopHat (Trapnell et al., 2009), and gene 
expression values were calculated by counting how many reads map uniquely 
to the union of all gene exons using HTseq-count. Samples were normalized 
for sequencing depth, and differentially expressed genes were identified with 
the edgeR package(Robinson et al., 2010). Genes with counts per million > -3 
and an FDR value < 0.05 were considered differentially expressed.  
 
Statistical analysis 
Student’s t-test was used for statistical analysis unless otherwise stated. All 
statistical analyses were done using GraphPad Prism 5.  
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CHAPTER FOUR 
BCL6 IS AN EVOLUTIONARILY CONSERVED STRESS RESPONSE GENE 
 
1. Introduction 
BCL6 was initially identified because it was frequently translocated to 
heterologous promoters leading to its constitutive expression and linking it to 
the pathogenesis of diffuse large B cell lymphomas (DLBCL) (Ci et al., 2008). 
DLBCLs arise from GC B cells, which form transient structures in secondary 
lymphoid organs after exposure to T-cell dependent antigens (Klein and Dalla-
Favera, 2008). The transition from resting to GC B cells requires a major 
phenotypic shift. GC B cells attain the unique ability to tolerate rapid cell 
proliferation while simultaneously undergoing DNA damage events in their Ig 
genes with the goal of producing high-affinity antigen-specific antibodies (Klein 
and Dalla-Favera, 2008). BCL6 is the master regulator of the GC 
transcriptional program that drives GC development and is essential for GC B 
cells to endure replicative and genotoxic stress (Basso and Dalla-Favera, 
2010). BCL6 maintains the survival of these cells by directly repressing genes 
involved in DNA damage sensing and response and cell cycle checkpoint 
activation (Hatzi and Melnick, 2014). Therefore it is not surprising that DLBCL 
cells inherit the biological dependency on BCL6, which reflects the biology of 
GC B cells (Hatzi and Melnick, 2014). Consequently, BCL6 inhibition or 
knockdown rapidly kills DLBCL cells, underscoring the significance of BCL6 as 
a therapeutic target in the disease(Cerchietti et al., 2010b; Cerchietti et al., 
2008; Cerchietti et al., 2009b; Parekh et al., 2007; Ranuncolo et al., 2008a; 
Ranuncolo et al., 2008b). 
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Although BCL6 is often thought of in the highly specialized context of the 
humoral immune response, its role in GC B cells is consistent with functionality 
linked to surviving severe stress. Along these lines, BCL6 is highly dependent 
on a fraction of HSP90 that is activated upon stress and enriched in GC B 
cells and DLBCL (teHSP90) (Cerchietti et al., 2009a). TeHSP90 is required for 
BCL6 stability and its transcriptional repressor function (Cerchietti et al., 
2009a). In fact, it was demonstrated in an earlier chapter that HSF1, the 
dominant regulator of the stress response, is required for stress-mediated 
induction of BCL6 in B cells. Collectively these mechanistic associations are 
suggestive of an intimate role of BCL6 in the stress response. Along these 
lines, BCL6 has been shown to be induced in various cell types when they are 
submitted to stressful conditions such as the withdrawal of growth factors, 
exposure to drugs that target key survival factors, or oxidative stress (Duy et 
al., 2011; LaPensee et al., 2014; Meyer et al., 2009; Toney et al., 2000). 
Moreover BCL6 is often expressed in cell types that tolerate a great deal of 
stress under basal conditions such as cardiac and skeletal myocytes, dermal 
epithelial cells, and melanocytes (Kageshita et al., 2006; Miki et al., 1994; 
Yoshida et al., 1999; Yoshida et al., 1996). 
 
These considerations prompted us to wonder about the forces of natural 
selection that resulted in the phylogenetic development of BCL6.  Because of 
the connection between HSF1 and HSP90-mediated regulation of BCL6, its 
prominent role in the high-stress environment of the GC, and its function in 
rescuing several cell types from stress-induced growth arrest and death, it was 
postulated that BCL6 may have evolved as a stress response factor that might 
reprogram cells to operate under stress conditions. Such functionality might be 
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helpful in tissues that must maintain their integrity in spite of sustained stress 
and for complex organisms with relatively longer life spans and more limited 
reproductive capacity.         
 
2. Results 
2.1 The HSF1-BCL6 stress response axis is an evolutionarily conserved 
feature of vertebrate organisms  
HSF1 is the master regulator of stress response and its binding sites at the 
BCL6 promoter are evolutionarily conserved. This notion led us to consider 
whether HSF1-mediated induction of BCL6 might be a general feature of 
stress response beyond GC B cells. We therefore subjected a variety of 
tissues to proteotoxic stress (in the form of heat shock) and measured relative 
BCL6 transcript abundance by qRT-PCR. We observed significant 
upregulation of BCL6 mRNA in mouse brain, kidney, and liver (p<0.05, Figure 
4.1A). To determine if BCL6 induction was dependent on HSF1, we next 
examined whether heat shock induced BCL6 in brain, kidney and liver of 
Hsf1+/-. In all cases there was profound impairment of BCL6 upregulation after 
heat shock in Hsf1+/- vs. Hsf1+/+ mice (Figure 4.1A). As a complementary 
approach, we used siRNA transfection to knock down HSF1 in human 
fibroblasts and then used heat shock to induce stress response and measured 
BCL6 nascent transcripts compared to a control non-targeted siRNA. HSF1 
knockdown significantly impaired heat shock-induced BCL6 nascent 
transcripts (p<0.01, Figure 4.1B). 
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Given the conservation of HSEs in the BCL6 promoter and its general role as 
an HSF1 target gene in various distinct tissue types, we postulated that BCL6 
evolved as a component of the HSF1 stress response pathway. HSF1 is 
conserved throughout eukaryotic evolution while BCL6 orthologs first 
appeared in chordates. BCL6 is a member of the BTB-ZF family, which are 
found throughout the metazoans. However clear BCL6 orthologs are restricted 
to the vertebrates. Notably jawless fish (agnathosomes) such as lampreys, the 
first vertebrates to evolve approximately 500 million years ago, contain a gene 
that encodes a protein with more than 40% sequence identity to human BCL6 
(Figure 4.2A). Importantly lamprey BCL6 identifies with human BCL6 as the 
Figure 4.1 HSF1 mediates BCL6 induction in response to stress in 
mammalian cells. (A) qRT-PCR of total Bcl6 mRNA in heat shocked 
murine brain, kidney, and liver tissues of Hsf1+/+ and Hsf1+/- mice 
normalized to GAPDH. (B) qRT-PCR of nascent BCL6 mRNA in heat 
shocked human fibroblasts transfected with nontargeting (siNT) or HSF1 
siRNA (siHSF1) for 48 h. Data was normalized to human HPRT1 (left). 
Representative immunoblot of HSF1 knockdown in human fibroblasts 48 h 
after transfection with siNT and siHSF1 (right). Values in (A) represent a 
mean of triplicates ± SEM (n = 2 mice per group). Values in (B) are the 
mean of triplicates ± SEM. A t-test was used to assess significance, ** 
p<0.01, *** p<0.001. 
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top hit in a reciprocal blast search (G. Privé, unpublished results). BCL6 is also 
present in all jawed vertebrates (gnathosomes), which branched off from the 
agnathosomes in the Ordivician period (Figure 4.2A). Hence HSF1 preceded 
BCL6, which seems to have evolved through natural selection accompanying 
the appearance of vertebrate animals. As with other BTB-ZF proteins, BCL6 
can be divided into three discrete regions: an N-terminal BTB domain that 
forms an obligate homodimer and mediates transcriptional repression; a 
middle region that is dynamically disordered but contains a 40 amino-acid 
autonomous repression domain (RD2); and a C-terminal cluster of C2H2-type 
zinc finger domains that binds to DNA. Examination of BCL6 sequence 
conservation by Shannon entropy analysis reveals high conservation of the 
BTB and zinc-finger domains whereas the RD2 domain is less conserved 
(Figure 4.2B) (provided by G. Privé). 
 
To determine if BCL6 functions as a stress inducible gene in animal species 
representing the spectrum of vertebrate evolution, we induced heat shock in 
cells from mammals (humans, mice, dogs), birds (chicken), reptiles (iguana), 
ray-finned fish (zebrafish), and agnathosomes (lamprey). BCL6 transcripts 
were detected by qRT-PCR and were significantly upregulated after 
proteotoxic stress in every species (p<0.05, Figure 4.3A). Given the amino 
acid conservation of the N-terminus, we used an N-terminal polyclonal 
antibody to perform western blots with lysate from cells exposed to stress from 
each species to detect BCL6 protein. In all cases we observed an increase in 
BCL6 protein abundance (Figure 4.3B). Collectively these data are consistent 
with the notion that BCL6 is a central component of vertebrate-specific stress 
response downstream of HSF1. 
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Figure 4.2 BCL6 protein is evolutionarily conserved in vertebrate 
organisms. (A) Heatmap representating percent identity of predicted BCL6 
protein orthologs as defined by the orthologous matrix (OMA) group 26555 
and the predicted sequence from Lethenteron japonicum. (B) Shannon 
protein variability per amino acid in multiple sequence alignments of BCL6. 
Average protein variability of the BTB, minimal RD2, and zinc finger (ZF) 
domains are reported above the plot. Provided by G. Privé. 
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Figure 4.3 BCL6 induction after stress is an evolutionarily conserved 
feature of vertebrate organisms. (A) qRT-PCR of BCL6 in heat shocked 
human adult fibroblasts, murine BCL1 B cells, dog Cf2Th thymocytes, 
iguana IgH-2 epithelial cells, chicken DT-40 B cells, zebra fish embryos, 
and sea lamprey typhlosole tissue and normalized to HPRT1, ACTB or 
GAPDH. (B) Representative immunoblots of BCL6 from whole cell extracts 
isolated from cells heat shocked as above and returned to resting 
temperature for 6 hrs. The average densitometry of immunoblots is below. 
Samples are separated by the phylogenetic relationship (Miller et al., 2007). 
Values in (A and B) represent the mean of triplicate experiments ± SEM and 
t-test was used to assess significance, * p<0.05. 
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2.2 BCL6 is required for stress tolerance 
To further understand the significance of BCL6 in vertebrate stress response, 
we next performed functional assays to assess for a putative contribution to 
survival under stress conditions. To determine whether induction of BCL6 was 
required for cells to survive exposure to proteotoxic stress, we isolated purified 
naïve B cells from wild type and Bcl6-/- mice, exposed them to heat shock, and 
measured viability relative to control cells by trypan blue exclusion. Both 
Bcl6+/+ and Bcl6-/- exhibited approximately 25% loss of viability (Figure 4.4A). 
Hence loss of BCL6 did not affect survival after acute stress exposure.  
 
During the GC reaction, B cells are repeatedly exposed to stress as they 
undergo rapid sequential replication cycles and somatic hypermutation. 
Moreover, unlike HSF1, which is present under basal conditions and is rapidly 
activated by stress conditions, BCL6 must first be transcribed and translated in 
order to carry out any biological function. Hence we wondered whether BCL6 
stress function might engage at a later stage, for example in enabling cells to 
adapt to recurrent or ongoing stress. Therefore we exposed primary murine 
resting B cells to sequential proteotoxic stress and then measured cell viability 
after the second stress exposure. In this case, we observed a significant, 5-
fold reduction in the percentage of dead cells after repeated heat shocks in 
Bcl6+/+ B cells (p<0.001) relative to Bcl6-/- B cells (Figure 4.4B), suggesting 
that BCL6 is indeed required for stress tolerance. To determine whether this 
function is evolutionarily conserved, we performed similar experiments with 
zebrafish embryos depleted of BCL6. The zebrafish embryos injected with 
BCL6 or control morpholinos were exposed to either single or repeated 
proteotoxic stress and then examined for viability. In this case, depletion of 
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BCL6 was associated with a trend towards increased embryo death after the 
first heat shock (p=0.06, Figure 4.4C). However the difference was much 
more dramatic and significant after the second heat shock, where we again 
observed a five fold increase in cell death in BCL6 depleted vs. control 
embryos (p=0.01, Figure 4.4D). Hence BCL6 mediates adaptation of 
Figure 4.4 BCL6 is required for stress tolerance. (A-B) Murine B220+ 
splenocytes from Bcl6+/+ and Bcl6-/- and (C-D) zebrafish embryos injected 
with control or bcl6 mo were heat shocked either (A, C) once (Post 1HS, 
orange) or (B, D) serially heat shocked (Post 2HS, red) according to the 
schematics on top of each graph. Viability of B220+ splenocytes was 
measured by trypan blue exclusion. Viability of zebrafish embryos was 
measured by the absence of opaque tissues. Values in (A and B) represent 
the mean of triplicate experiments ± SEM and t-test was used to assess 
significance. 
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vertebrate cells to repeated stress conditions.  
 
2.3 BCL6 mediates vertebrate stress tolerance through a lateral groove 
on its BTB domain 
Human BCL6 is a potent transcriptional repressor, and to determine the 
biochemical mechanism through which BCL6 mediates vertebrate adaptation 
to stress, we turned to the conserved BTB domain as a prime candidate for 
conferring similar functions in other species as the RD2 domain is less 
conserved (Figure 4.5A). The repression functions of the BTB domain are 
mediated through the binding of a 17-residue BCL6 binding domain (BBD) 
motif in the NCOR, SMRT, and BCOR corepressors to the lateral groove 
surface of the BTB dimer and are highly conserved (Ahmad et al., 2003; Ghetu 
et al., 2008). Notably the residues lining the lateral groove are not conserved 
in other BTB-ZF proteins (Stogios et al., 2010). Point mutations of BCL6 BTB 
lateral groove residues that disrupt corerepressor binding but do not affect 
protein folding ablate repressor activity of the BCL6 BTB domain (Ahmad et al., 
2003). It is important to note that these BTB point mutations do not diminish 
the activity of the RD2 domain in the linker region and have no effect on BCL6 
binding to its target genes (Huang et al., 2013). When engineered into the 
endogenous BCL6 locus in mice, these BTB point mutations result in specific 
loss of the ability of BCL6 to maintain the survival and proliferation of GC B 
cells but do not affect BCL6 functions in T cells or macrophages (Huang et al., 
2013). 
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Collectively, these data led us to consider whether the BCL6 BTB lateral 
groove is responsible for the conserved stress adaptation function of BCL6. To 
address this question, we first mapped the sequence conservation of the 
BCL6 BTB domain from a wide selection of vertebrates on to the surface of 
the structure (Figure 4.5B). Strikingly, we observed that all residues from the 
lateral groove that contact the NCOR, SMRT, and BCOR corepressors were 
conserved, even in the lamprey sequence. In contrast other regions of the 
surface were highly variable (Figure 4.5B). Likewise the NCOR, SMRT, and 
Figure 4.5 The lateral groove of the BCL6 BTB domain is highly 
conserved in vertebrates. (A) Protein sequence alignment of the BCL6 
RD2 minimal domain with KKYK cluster highlighted in red. (B) Shannon 
entropy values were calculated by MUSCLE multiple sequence alignment 
(v3.8) and mapped onto the structure of the BCL6 BTB domain, protein data 
bank entry 1R2B. Provided by G. Privé. 
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RHESUS MACAQUE       L-VSPQSPQKSDCQPNSPTESCSSKNACILQ-----ASGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKPEGPEQAELGRLSPRVYTAPPACQPPMEPENLDLQ--------SPT-KLSASG
HUMAN         L-VSPQSPQKSDCQPNSPTESCSSKNACILQ-----ASGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKPEGPEQAELGRLSPRAYTAPPACQPPMEPENLDLQ--------SPT-KLSASG
GORILLA         L-VSPQSPQKSDCQPNSPTESCSSKNACILQ-----ASGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKPEGPEQAELGRLSPRAYTAPPACQPPMEPENLDLQ--------SPT-KLSASG
COW    L-VSPQSPQKSDCQPNSPTESCSSKNACILQ-----TSGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKPEGPEQAELGRLSPRAYAAPPACQPPMEPDSLDLQ---------SPT-KLSTSA
FLYING FOX   L-VSPQSPQKSDCQPNSPTESCSSKNACILQ-----TSGSPPAKSPTDPKACNWKKYKFIVLNSLNQKAKPEGPEQAELGRLSPRAYTAPPACQPPMEPENLDLQ---------SPT-KLSANG
HORSE         L-VSPQSPQKSDCQPNSPTESCSSKNACILQ-----TSGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKPEGPEQAELGRLSPRAYTAPPACQPPMEPENLDLQ---------SPT-KLSANG
ELEPHANT   L-VSPQSPQKSDCQPNSPTESCSSKNACILQ-----TSGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKPEGPEQGELGRLSPRAYTAPPACQPPMEPDSLDLQ--------SPT-KLSIGG
DOG    L-VSPQSPQKSDCQPNSPTESCSSKNACILQ-----TSGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKPEGPEQAELGRLSPRAYTAPPACQPPMEPESLDLQ---------SPT-KLSASG
MOUSE         L-VSPQSPQKSDCQPNSPTESCSSKNACILQ-----ASGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKPEGSEQAELGRLSPRAYPAPPACQPPMEPANLDLQ--------SPT-KLSASG
RAT          L-VSPQSPQKSDCQPNSPTESSSSKNACILQ-----ASGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKPEGSEQAELGRLSPRAYPAPPACQPPMEPANLDLQ--------SPT-KLSASG
MARMOSET        L-VSPQSPQKSDCQPNSPTESCSSKNACILQ-----ASGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKPEGPEQAELGRLSPRAYTAPPACQPPMEPENLDLQ--------SPT-KLSANG
PLATYPUS       L-VSPQSPQKSDCQPNSPTESSSSKNACIRQ-----ASGSPVAKSPSDPKACNWKKYKFIVLNSLNQTNKTDGAESGDLGRLSPRTYVPASSCQQSMEPENLDIQ-------SPT-KMSANG
TASMANIAN DEVIL       L-VSPQSPQKSDCQPNSPTESSSSKNACILQ-----GAGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKSDGAEQAELGRLSPRAYTKLSVSA---------------------------------------------------
ZEBRA FINCH        L-I SPQSPQKSDCQPNSPTESSSSKNARIGQ-----NSSSLFTKSPTDPKACNWKKYKFIVLNSLNQNTKQDSADQNEMGTLSPRTYVPMSTCQQSMEPEHLNVQ------SPT-KISVNG
CAROLINA ANOLE     L-I SPQSPQKSDCQPNSPTESSSSKNACIGQ-----GAGSLAAKSPTDPKACNWKKYKFIVLNSLNQSAKQDGPEQNEAGTLSPQSYTPSLTCQQPMEPENLDLQ------SPT-KMNVNG
FROG    GLVSPQSPQKSDCQPNSPTESSSSKNARISQ---GSSSPVSKNSTDPKACNWKKYMMLSSLKQRDKESCTKQSEIDNL-SPNSYTSLSSYQHPVKSADDQA-----------SP--KINEN
ZEBRAFISH        LMSSPQSPLKSDCQPNSPTESSSSKNAALAQA---LQPPTSQGTSDPKARNWKKYKFIVLN---QSSKEEETNPPDPGMHSPQRP-GLSAFLHHVDSEHPDSK---------VTT-KISEQG
LATIMERIA   LMVSPQSPLKSDCQPNSPTESSSSKNASQIQ---GVGSPPSKSPI NPKACNWKKYKFIVLNSLNQSTKEEGSNQSEAGSHSPHSS-SSSTCNQSSEPESTDVL-------SPT-KITMNV
LAMPREY          --------ARRESEPSSPPDSH------------REVAPPG--GGQ----V--------------KSCNWKKRRFLVQTTSSSSTSSSPPSSPSSSSSSPTSDSV--AVAPSTPPTRLSPAPEAKVMTTLSPVTPRGRDG
BCL6 RD2 minimal domain
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BCOR BBDs are also highly conserved in these species (Figure 4.6A-B). To 
determine whether the lateral groove of the BTB domain mediates the stress 
adaptation function of BCL6, we performed proteotoxic stress response 
experiments using B cells from wild-type mice and mice engineered to contain 
point mutations that disrupt corepressor binding to the BTB domain lateral 
groove. As an additional control, we performed the same experiments using B 
cells from mice where the Bcl6 locus was engineered to express a form of 
BCL6 with point mutations that disrupt the function of the less conserved RD2 
domain (Figure 4.5A) but leave the BTB domain intact. After the first heat 
shock, there was no difference in cell death in wild-type, Bcl6BTBMUT or 
Bcl6RD2MUT (Figure 4.7A). After the second heat shock there was again a five-
fold reduction in cell death in the wild-type and Bcl6RD2MUT mice (Figure 4.7A). 
However in marked contrast, cell death was equivalent at both time points in 
the Bcl6BTBMUT mice. Hence the highly conserved BCL6 BTB domain lateral 
groove mediates the stress adaptation function of BCL6.  
 
In order to extend this paradigm to other vertebrate species, we took 
advantage of a second orthogonal approach that we developed to disrupt 
corepressor binding to the BCL6 BTB lateral groove. This involves the use of a 
peptidomimetic compound that was shown to penetrate cells, localize to the 
nucleus, bind specifically to the BCL6 BTB lateral groove but not to other BTB 
proteins, and blocks BCL6 from binding and recruiting SMRT and NCOR to its 
target genes (Cerchietti et al., 2009b; Polo et al., 2004). This retro-inverso 
BCL6 peptide inhibitor (RI-BPI) was also shown to phenocopy the Bcl6BTBMUT 
mice (Cerchietti et al., 2009b; Polo et al., 2004). Because the BCL6 lateral 
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groove binding site is conserved throughout vertebrate evolution (Figure 4.5B), 
RI-BPI would be expected to be suitable for experiments in other species.  
  
NCOR2 (SMRT)
Percent identity
BCOR
BCL6 binding domain
RHESUS MACAQUE PGN----------------GCA IYRSEIISTAPSSWVVPGPSPNEEN--------------------------
HUMAN   PGN----------------GCA IYRSEIISTAPSSWVVPGPSPNEEN--------------------------
GORRILA   PGN----------------GCA IYRSEIISTAPSSWVVPGPSPNEEN--------------------------
COW    PGN----------------GCA IYRSEIISTAPSSWVVPGPSPNEEN--------------------------
FLYING FOX   PGN----------------GCA IYRSEIISTAPSSWVVPGPSPNEEN--------------------------
HORSE   PGN----------------GCALYRSEIISTAPSSWVVPGPSPNEEN--------------------------
ELEPHANT   PGN----------------GCA IYRSEIISTAPSSWVVPGPSPNEEN--------------------------
DOG    PGN----------------GCA IYRSEIISTAPSSWVVPGPSPNEEN--------------------------
MOUSE   PGN----------------GCS IYRSEIISTAPSSWVVPGPSPNEEN--------------------------
RAT    PGN----------------GCS IYRSEIISTAPSSWVVPGPSPNEEN--------------------------
MARMOSET   PGN----------------GCA IYRSEIISTAPSSWVVPGPSPNEEN--------------------------
PLATYPUS   SGN----------------GCALYRPDIISTAPSSWVVPGPGPNEDLG-----------------------
TASMANIAN DEVIL  SGN----------------SCT I YRPEIISTAPSSWVVPGPSPNEDN-------------------------
ZEBRA FINCH  PGN------------------SCPIYRPEIISTAPSSWIVPGPSPSEE----------------------------
CAROLINA ANOLE  PGN----------------CCPVYRPEIISTAPSSWVVPGPAPSEDN-------------------------
FROG    PTN----------------SSG I VRPEI ISTAASSWVVPGITHTEET---------------------------
ZEBRAFISH   SSS----------AVSTSKTPERPEIISTLPSSWVVPSPTQTISSE-----------------AS-----
LATIMERIA   LGN----------------GCSADRPEI ISTSHSTWIVPGPSPADTQ--------------------------
BCOR
NCOR2 (SMRT)
BCL6 binding domain
RHESUS MACAQUE PLKLK--PAHEGLVATVKEAGRS I HEIPREELRHTPELPL---APRPLKEGSITQGTPLKYDT
HUMAN   PLKLK--PAHEGLVATVKEAGRS I HEIPREELRHTPELPL---APRPLKEGSITQGTPLKYDT
GORILLA   PLKLK--PAHEGLVATVKEAGRS I HEIPREELRHTPELPL---APRPLKEGSITQGTPLKYDT
COW    PLKLK--PAHEGLVATVKEAGRS I HEIPREELRRTPELPL---APRPLKEGSITQGTPLKYDT
FLYING FOX   PLKLK--PAHEGLVATVKEAGRS I HEIPREELRRSPEPPL---APRALKEGSITQGTPLKYDT
HORSE   PLKLK--PAHEGLVATVKEAGRS I HEIPREELRRTPELPL---APRPLKEGSITQGTPLKYEP
ELEPHANT   PLKLK--AAHEGLVATVKEAGRS I HEIPREELRRTPELPL---APRPLKEGSITQGTPLKYDT
DOG    ----P-------AHEGLVATVKEAGRS I HEIPREELRRTPELPL---APRPLKEGSITQGTPLKYDT
MOUSE   PLKLK--PTHEGVVATVKEAGRS I HEIPREELRRTPELPL--APRPLKEGSITQGTPLKYDS
RAT    PLKLK--PTHEGVVATVKEAGRS I HEIPREELRRTPELPL--APRPLKEGSITQGTPLKYDS
MARMOSET   PLKLK--PAHEGLVATVKEAGRS I HEIPREELRHTPELPL---APRPLKEGSITQGTPLKYDT
PLATYPUS   PLKMK-AGHEGLVATVKEAGRSI HEIPREELRHTPDLSM----TRALKEGSITQGTPLKYDS
TASMANIAN DEVIL  PLKIK-----GHEGLVATVKEAGRSI HEIPREELRHTPDLPG--PPRPLKEGSITQGTPLKYDS
ZEBRA FINCH  PLKMK--SAHEDLVATVKEAGRSI HEIPREELRRTPDISL-----TRPLKEGSITQGTPLKYDS
CAROLINA ANOLE  PLKTK--PGHEGHIATVKEAGRSI HEIPREELRRTPDVSL--MTRPVKEGSITQGTPLKYDN
FROG    PLKMK---AHEAMVATVKEVGRSVHEIPREEMRHTPEMQV-TPRSHKEGSITQGTPLKYDS
ZEBRAFISH   ALKS---RSHESMVPTVKEGGRSIHLIPPEGVVI-------------------GKPKEGSITQGTPLKQEP
LATIMERIA   SLKVPTAAHEALVTTVKEAGRS I HEIPKEELRHTPEMHM--AARPIKDGSIAQGTPLKYDT
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Figure 4.6 BCOR and SMRT are conserved in vertebrates. (A) Heatmap 
representing percent identify of predicted full-length BCOR (top) and 
NCOR2 (SMRT) (bottom) protein orthologs. (B) Protein sequence alignment 
of the BCL6 binding domain of BCOR (top) and NCOR2 (SMRT) (bottom). 
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To determine whether RI-BPI could abrogate stress adaptation similar to the 
BTB mutations, we first performed single and sequential proteotoxicity 
experiments in murine B cells. Exactly like in Bcl6BTBMUT mice, exposure to RI-
BPI had no effect on cell death after a single stress exposure but completely 
abrogated the ability of B cells to become stress tolerate (p=0.02, Figure 
4.7B). The same experiments were performed in two additional branches of 
vertebrates (avian and reptile) and invertebrate cells (Drosophila melanogaster 
S2 cells) as insects do not have a BCL6 paralog or the vertebrate corepressor 
BBD motifs. Again, exposure to RI-BPI had no effect on cell viability after a 
single stress exposure but abrogated stress adaptation response in both avian 
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Figure 4.7 BCL6 mediates stress tolerance through a lateral groove on 
its BTB domain. (A) Murine B220+ splenocytes were isolated from Bcl6+/+, 
Bcl6RD2MUT, and Bcl6BTBMUT mice and heat shocked either once (Post 1HS, 
orange) or serially heat shocked (Post 2HS, red) according to the schematic 
on the left. (B) Bcl6+/+ cells were treated with vehicle (CON) or 1 µM RI-BPI. 
Cells were heat shocked as described in (A). Cell viability was measured by 
trypan blue or DAPI exclusion. Values in (A-B) are a mean of triplicates ± 
SEM. A t-test was used to assess significance. 
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(p<0.001) and reptile cells (p<0.01, Figure 4.8A). In Drosophila S2+ cells, RI-
BPI did increase cell death after a single stress exposure (Figure 4.8B). 
However S2 cells were able to acquire stress tolerance after serial proteotoxic 
stress in the presence of RI-BPI (Figure 4.8B). Taken all together, these data 
suggest that the BCL6 BTB domain lateral groove is the effector mechanism 
for BCL6-mediated stress adaption throughout vertebrate evolution. Because 
the lateral groove is the most highly conserved protein interaction motif on 
BCL6, it seems likely that a major reason for the development of BCL6 during 
evolution was to enable vertebrate cells to better withstand continuous or 
repeated stress conditions. 
Figure 4.8 RI-BPI inhibits the acquisition of stress tolerance in 
vertebrates. (A) Chicken DT40 B cells, iguana IgH-2 epithelial cells, and 
sea lamprey typhlosole cells were treated with vehicle (CON) or 1 µM RI-
BPI and heat shocked either once (Post 1HS, orange) or serially heat 
shocked (Post 2HS, red) according to the schematic above. (B) Drosophila 
S2+ cells were treated with vehicle (CON) or 1 µM RI-BPI. Cells were heat 
shocked as described in (A). Cell viability was measured by trypan blue or 
DAPI exclusion. Values in (A-B) are a mean of triplicates ± SEM. A t-test 
was used to assess significance. 
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 2.4 A stress and cell growth transcriptional program is controlled 
through the BTB domain  
We speculated that BCL6-mediated repression of target genes that are 
dependent on its BTB domain function must be essential for its role in stress 
adaptation. To identify this gene set in mammalian cells, we performed mRNA-
seq in Bcl6+/+ and Bcl6BTBMUT B220+ cells before and 12 h after proteotoxic 
shock and compared and contrasted the resulting gene expression profiles. 
Multidimensional scaling analysis showed that replicate gene expression 
profiles were highly reproducible. The first principle component clearly 
distinguished specimens based on exposure to stress, and the second 
distinctly divided BTB mutant from WT expression profiles (Figure 4.9A). 
Likewise unsupervised analysis of post-stress gene expression profiles 
showed clustering of BCL6 wild type vs. BTB mutant into distinct nodes. 
(Figure 4.9B).  
 
As would be expected, a majority of genes downregulated (FDR<0.05) after 
heat shock were repressed in both wild type and BTB mutant cells (~70%). 
However, we also identified a set of 510 genes that were downregulated in 
Bcl6+/+ but not in Bcl6BTBMUT cells (Figure 4.9C). This gene set was further 
investigated for possible links to the actions of BCL6 in stress tolerance. 
These genes were significantly enriched in functional categories involved in 
stress response and cell cycle (Figure 4.9D), including acute inflammatory 
response (GO: 0050000), activation of immune response (GO: 0002526), and 
cell proliferation (GO: 0008283, GO: 0008284). Notably, this set of genes that 
were not repressed after heat shock in Bcl6BTBMUT cells were significantly more 
upregulated after BCL6 knockdown in B cell lines than genes that did not 
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change after heat shock in Bcl6BTBMUT cells (Wilcoxon test, p=0.003, Figure 
4.10A). GSEA analysis also showed strong enrichment of this gene set 
(FDR=0.02) among genes derepressed after BCL6 siRNA (Figure 4.10B) 
Figure 4.9 Gene expression profiling of Bcl6BTBMUT cells after heat 
shock. (A) Multi-dimensional scaling plot of the leading biological coefficient 
of variation between samples using 500 genes with the most 
heterogeneous expression in Bcl6+/+ and Bcl6BTBMUT B220+ splenocytes 
before (T0) and 12 h after a single heat shock (1 h at 43 °C, T12). (B) 
Clustering of the union of differentially expressed genes in Bcl6+/+ and 
Bcl6BTBMUT B220+ cells after heat shock as described in (A) using complete 
linkage clustering with Euclidean distance measure. The exact test 
(Robinson et al., 2010) was used to identify differentially expressed genes 
at FDR < 0.05. (C) Venn diagram of genes significantly (FDR < 0.05) 
downregulated after heat shock that are common and unique to Bcl6+/+ and 
Bcl6BTBMUT B220+ cells. (D) Heatmap of overrepresented gene ontology 
categories among genes that were not repressed in Bcl6BTBMUT B220+ 
splenocytes after heat shock relative to a randomly generated set of genes. 
Enrichment and depletion was measured by hypergeometric p values. 
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(Hatzi et al., 2013). The genes in the leading edge of the GSEA represent the 
genes that are dependent on the BTB domain for their repression after heat 
shock and are highly derepressed after BCL6 siRNA. A subset of these were 
strongly derepressed after heat shock in Bcl6BTBMUT cells relative to Bcl6+/+ 
cells including lfitm2, Npas4, Nr4a2, Prickle1, Rab34, Rasbp1 and Tox 
(Figure 4.11A). To validate these genes in an independent experiment and an 
additional tissue type, we exposed B cells and brain tissue from wild-type and 
Bcl6BTBMUT mice to heat shock and performed qRT-PCR. We observed 
consistent derepression of several of these genes after heat shock including 
Tox, Nr4a2 and Npas4 (Figure 4.11B), all three of which are transcription 
factors.  
 
2.5 Repression of TOX is required for the BCL6-mediated stress adaptive 
phenotype 
It is likely that repression of many target genes is necessary for the biological 
effect of BCL6. Yet as proof-of-principle to determine if one of these candidate 
genes was important for the actions of BCL6, we selected TOX, a transcription 
factor that has been mostly studied in T cells. To determine if repression of 
Tox contributes to the stress tolerance effect mediated by the BCL6 BTB 
domain, we performed serial stress response experiments in purified B cells 
from the spleens of Tox-/- mice. If there were rescue of the BCL6 loss-of-
function phenotype, we would expect Tox deletion to compensate. We used 
RI-BPI to prevent BCL6 BTB domain-mediated repression in Tox-/- or wild type 
B cells.  Tox-/- B cells were indeed more stress tolerant relative to Tox+/+ B 
cells (Figure 4.12A).  Similarly, Tox-depletion by two independent shRNAs in 
the murine B cell line, BCL1, enabled the cells to retain their ability to tolerate 
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serial heat shock despite the presence of RI-BPI, whereas a non-targeting 
control could did not rescue BCL6 function (Figure 4.12B). In summary these 
data indicate that BCL6 mediates its stress tolerance function through BTB-
dependent transcriptional repression of a set of target genes, including Tox.  
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Figure 4.10 Genes that fail to be repressed after stress in Bcl6BTBMUT 
cells are BCL6-regulated genes. (A) Comparison of fold gene induction in 
DLBCL OCI-LY1 cells after siBCL6 (log2 siBCL6/siNT, 48hr) (Hatzi et al., 
2013) of genes that did not change after heat shock or failed to be 
repressed in Bcl6BTBMUT B220+ splenocytes relative to Bcl6+/+ splenocytes. 
Values represent the mean ± SEM. Mann-Whitney test was used to 
evaluate significance. (B) GSEA of genes that fail to be repressed in 
Bcl6BTBMUT B220+ splenocytes after heat shock relative to Bcl6+/+ 
splenocytes with genes ranked based on decreasing log2 RPKM at 48hr 
post-BCL6 knockdown as described in (A). FDR was used to measure 
significance of enrichment (5000 permutations, weighted statistic).  
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Figure 4.11 A subset of BCL6 regulated genes are strongly 
derepressed after heat shock in Bcl6BTBMUT cells. (A) Heatmap 
representing the expression changes after heat shock of the GSEA leading 
edge genes described in Figure 4.10B in Bcl6BTBMUT relative to Bcl6+/+ 
B220+ splenocytes. (B) Validation of gene expression changes after heat 
shock in B220+ splenocytes and brain tissue of Bcl6BTBMUT relative to 
Bcl6+/+. 
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2.6 Tumor cells upregulate BCL6 after exposure to stress 
The general function of BCL6 in protecting normal cells from stress led us to 
wonder whether tumor cells might also rely on this evolutionarily conserved 
mechanism to facilitate their survival when exposed to potentially lethal stress, 
such as cytotoxic chemotherapy. To address this question, we exposed a 
panel of tumor cell lines of different histological origin to proteotoxic or 
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Figure 4.12 TOX repression is required for BCL6 to mediate 
thermotolerance through its BTB domain. (A) Fold decrease in dead 
B220+ splenocytes from Tox+/+ and Tox-/- (left) or (B) Tox-deficient BCL1 
cells (left) treated with 1 µM BPI and serially heat shocked. (B) Tox 
knockdown efficiency is shown on the right. Viability was measured by 
DAPI exclusion. Values represent mean of triplicates ± SEM. A t-test was 
used to evaluate significance. 
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cytotoxic stress through exposure to heat shock or low dose (100 nM) 
doxorubicin, respectively. We observed an increase in BCL6 mRNA both after 
heat shock and low dose doxorubicin (Figure 4.13A). There was also a strong 
positive correlation (Spearman r 0.8321, p<0.001) between BCL6 and 
HSPA1B induction after low dose doxorubicin (Figure 4.13B), consistent with 
the notion that BCL6 was induced as part of the stress response 
transcriptional program. Along these lines and to determine whether HSF1 
mediates doxorubicin-induced BCL6 expression, we used two independent 
siRNAs to deplete HSF1 expression in the breast and lung cancer cell lines, 
MDA-MB-468 and H460, respectively. Measurement of BCL6 nascent 
transcript induction revealed significant impairment after HSF1 knockdown 
(Figure 4.13C). Induction of BCL6 protein was also blunted upon HSF1 
knockdown in both cell lines (Figure 4.13D).  
 
2.7 BCL6 mediates stress tolerance in tumor cells  
To test whether BCL6 enables tumors to tolerate exposure to cytotoxic drugs, 
we investigated whether increasing concentrations of RI-BPI and doxorubicin 
resulted in enhanced cell killing in solid tumor and DLBCL cells. In almost 
every cell line tested, the concentration of RI-BPI required to yield 50% growth 
inhibition was reduced with concurrent treatment with doxorubicin (Figure 
4.14A). From the clinical perspective, BCL6 inhibitors are likely to be tested 
first in the context of DLBCL, a tumor type derived from GC B cells that are 
clearly dependent on BCL6 BTB stress signaling functions (Cerchietti et al., 
2008; Cerchietti et al., 2009b; Parekh et al., 2007; Ranuncolo et al., 2008a; 
Ranuncolo et al., 2008b). Therefore we more extensively combined RI-BPI 
with classes of drugs commonly used in DLBCL cytotoxic therapy including  
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Figure 4.13 HSF1 induces BCL6 in response to chemotherapy. (A) 
qRT-PCR of BCL6 mRNA after heat shock (HS, 2 h at 43 °C followed by 2 h 
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vincristine, dexamethasone, mechloretamine, and their combination 
(mechlorethamine, doxorubicin, vincristine, and dexamethasone), which is 
similar to the CHOP chemotherapy regimen. These combinations yielded 
Figure 4.14 Therapeutically target BCL6-stress dependence in tumor 
cells with BTB inhibitors. (A) Dose reduction index for RI-BPI at the 
concentration that inhibited growth by 50% (GI50) after concurrent exposure 
of cells to increasing concentrations of DOXO for 48 h. (B) Heatmap 
representing the combination index of doxorubicin, vincristine, 
dexamethasone, mechlorethamine, and CHOP (the combination of 
cyclophosphomide, doxorubicin, vincristine, and prednisone) with RI-BPI at 
the GI50 in DLBCL cell lines treated for 48 h. A combination index below 0.9 
is synergistic; between 0.9 and 1.1 is additive; and above 1.1 is infra-
additive. Provided by L. Cerchietti and S. Yang. (C) Combination index of 
concurrent administration of DOXO and RI-BPI at the GI50 in MDA-MB-231 
and MDA-MB-468 cells transduced with a scrambled or two TOX-targeting 
shRNAs treated for 48 h. 
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mostly synergistic anti-tumor effects (Figure 4.14B).  
 
We previously demonstrated that TOX repression by BCL6 was required for 
cells to acquire thermotolerance, and if we depleted RI-BPI-treated cells of 
TOX, they could reacquire thermotolerance (Figure 4.12A-B). Because of its 
role in mediating cell death after BCL6 BTB inhibition, we hypothesized that 
TOX derepression plays a crucial role in the anti-tumor activity of RI-BPI and 
other chemotherapies. We knocked down TOX in triple-negative MDA-MB-231 
and MDA-MB-468 breast cancer cell lines and found that the combination 
index of RI-BPI and doxorubicin increased with TOX knockdown, 
demonstrating that the combination was less effective at cell killing (Figure 
4.14C). These results suggest that the derepression of TOX that occurs after 
CL6 BTB inhibition is required to hinder thermotolerance and chemotolerance. 
 
To determine whether targeting BCL6 might also yield more potent antitumor 
effects when combined with cytotoxic drugs in vivo, we engrafted human OCI-
LY7 DLBCL cells in mice and evaluated whether RI-BPI enhanced the anti-
tumor effect of chemotherapy. Once tumors reached 100 mm3 in size mice 
were assigned to a schedule of RI-BPI (25 mg/kg), doxorubicin (0.6 mg/kg), 
the combination or vehicle only. Doxorubicin or RI-BPI alone each had 
significant antitumor activity as compared to vehicle (p=0.02 and p=0.0001, 
respectively). However the combination of doxorubicin with RI-BPI was the 
most potent and yielded significantly greater antitumor effect (p<0.001) 
(Figure 4.15A).  
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Cell lines maintained for years in culture may not fully reflect the biological 
dependencies of primary tumor cells from patients. Therefore we purified 
lymphoma cells from DLBCL biopsy specimens by enriching for CD19+ cells 
obtained from lymph node biopsies of 21 BCL6+ DLBCL patients. The 
specimens were plated using a dual-chamber co-culture system with a feeder 
layer of HK dendritic cells. CD19+ cells were then exposed to increasing 
concentrations of RI-BPI or the combination of mechlorethamine, doxorubicin, 
vincristine and dexamethasone that mimic the CHOP regimen. The Webb 
fractional product of the drug combination was determined for each patient 
sample. 62% (13/21) of patient specimens manifested synergistic antitumor 
effects after exposure to the combination, and an additional four patients 
showed additive effect for a total response rate of 80% (Figure 4.15B). Taken 
Figure 4.15 BCL6 BTB inhibitors have anti-lymphoma activity in 
preclinical and clinical models. (A) Area under the curve (AUC) of tumor 
growth curves for 14 days in OCI-LY7 xenografted mice treated with vehicle 
(DMSO, 10% in saline, n=15), DOXO (0.6 mg/kg, n=19), RI-BPI (25mg/kg, 
n=13), or the combination of RI-BPI and DOXO (n=14). (B) The webb 
fractional product of 10 µM BPI and CHOP at GI50 in primary DLBCL patient 
samples. Values in (A) represent the mean of two independent experiments 
± SEM. A t-test was used to measure significance. Provided by L. Cerchietti 
and S. Yang. 
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together, the evolutionarily conserved role of BCL6 and its BTB domain in 
mediating tolerance to stress in vertebrates provides the basis for the rational 
translation of therapies that target the BCL6 BTB domain to induce 
chemosensitization of solid tumors that have limited therapeutic options. The 
combinatorial effect of BCL6 BTB inhibition and other chemotherapies would 
more effectively eradicate DLBCLs, a tumor type derived from a stress-
dependent cell of origin. 
 
3. Discussion 
BCL6 is multi-faceted protein due to its multiple and distinct repressor domains. 
Here we demonstrate a more primitive role for BCL6 as a stress response 
gene. Like HSP90 and other stress response proteins, BCL6 mRNA and 
protein is induced after heat stress by HSF1, the master regulator of the heat 
shock response, in mammalian, avian, and reptilian cells in addition to a model 
of jawless vertebrates, the sea lamprey. We find that BCL6 mediates its stress 
tolerant phenotype through its BTB domain while its second repressor domain, 
RD2, is dispensable for this function. The BCL6 BTB domain is highly 
conserved in all vertebrates whereas the BCL6 RD2 domain, particularly the 
KKYK residues that facilitate interactions with HDAC2 and MTA3-NuRD are 
not conserved in jawless vertebrates, which are basal to jawed vertebrates. 
Because we have demonstrated that RD2 repressor activity is lost when KKYK 
residues are mutated, it is possible that the BCL6 RD2 domain has no function 
in these organisms, and BCL6 mediates its entire biological output through 
only the BTB domain. Thus the original function of BCL6 may have been to 
confer stress resistance after exposure to environmental stress stimuli. While 
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HSPs are induced to repair damaged and misfolded proteins, BCL6 may be 
induced because of its complementary role in tolerating DNA damage. 
 
Both jawed and jawless vertebrates share the feature of recombinatorial 
rearrangement of their antigen-binding modules to generate a diverse 
repertoire of antigen receptors albeit employing structurally distinct types of 
receptors (Ig vs leucine-rich repeat, LRR, modules). In lampreys, flanking LRR 
coding units are randomly inserted into the germline VLR genes through short 
homology sequences at the ends of the modular LRR units as they lack 
recombinatorial signal sequences and RAG proteins (Boehm et al., 2012). 
BCL6 expression has been found in VLR-B+ cells, which are similar to B-
lymphocytes in jawed vertebrates (Hirano et al., 2013). The presence of BCL6 
likely allows the VLR-B+ cells to tolerate the genomic damage associated with 
the rearrangement of LRR coding units, as it does in GC B cells. If this were 
true, BCL6 inhibition by either peptidomimetic or small molecule inhibitors 
would disrupt the LRR immune response and decrease LRR receptor 
diversification. It is interesting to note that a more divergent BCL6 ortholog can 
be identified in C. intestionalis a member of urochordates (G. Privé 
unpublished results). Given its role in mediating stress tolerance, it is tempting 
to speculate that the emergence of BCL6 in vertebrates might have been an 
influential event that allowed cells to tolerate genomic recombination events, 
which is the basis for generating antigen receptor diversity and thus the 
adaptive immune response.  
 
The repression of TOX by BCL6 is critical for cells to adapt and survive 
repeated rounds of stress. TOX is markedly increased after heat shock in 
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Bcl6BTB mutant cells, and TOX depletion can restore stress tolerance in BPI-
treated cells. TOX is a member of the HMG-box family of DNA binding proteins 
that are structure-dependent but not sequence-dependent (O'Flaherty and 
Kaye, 2003). TOX homologs are found in lampreys and in arthropods. 
Although TOX has been previously described to be required for the 
development of the CD4 T cell lineage, it is not yet clear how TOX mediates its 
effects (Aliahmad and Kaye, 2008). HMG-box proteins bind to chromatin and 
modify the architecture of DNA (O'Flaherty and Kaye, 2003). TOX may act in a 
similar manner to modulate gene expression changes during thymocyte 
selection and stress response. BCL6 regulates TOX in DLBCL cells as 
demonstrated by TOX derepression after BCL6 knockdown in DLBCL cell lines. 
TOX is deleted in a subset of DLBCL, childhood acute lymphatic leukemia 
(4%) and prostate cancer (48%). Given its role in reducing stress tolerance 
and as a chromatin architecture protein, we postulate that TOX may act as a 
tumor suppressor by functioning as a rheostat of genomic damage. 
 
The stress tolerance axis of HSF1 and BCL6 is conserved between heat 
stress and chemotherapy. Like what occurs after heat shock, HSF1 induces 
BCL6 in tumor cells treated with chemotherapy agents. We have previously 
demonstrated that BCL6 is required for the survival of imatinib-resistant ALL 
cells (Duy et al., 2011). The results of the current study suggest that the 
mechanisms that mediate thermotolerance are the same at play in 
chemotolerance. We find that we can harness this therapeutically by 
combining conventional chemotherapy with BCL6 BTB inhibitors. Moreover 
when we test the relevance of the BCL6 target, TOX, we find that its 
repression is also required for an effective anti-tumor combination of 
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chemotherapy and RI-BPI. While BCL6 is the most frequently deregulated 
oncogene in DLBCL, it is also amplified in 30% of lung cancer, 24% of ovarian 
cancer, 22% of cervical cancer, and 19% of head and neck cancers. While 
DLBCL has a relatively high response rate to therapy, patients with solid 
tumors have a worse prognosis and are sometimes more refractory to 
treatment, particularly patients with triple-negative breast cancer and bladder 
cancer. Although BCL6 inhibitors have been described to have potent anti-
lymphoma activity, our study provides a basis for the rational translation of 
BCL6 inhibitors to induce chemosensitization of solid tumors that have 
otherwise limited therapeutic options. 
 
4. Materials and Methods 
Animals 
Hsf1+/+ and Hsf1+/- were obtained from Jackson Laboratories. Bcl6-/- mice were 
kindly provided by Dr. Hilda Ye (Albert Einstein Medical College). Bcl6BTBMUT 
and Bcl6RD2MUT mice were generated by Dr. Chuaxin Huang from the Melnick 
lab (Huang et al., 2014; Huang et al., 2013). Tox+/+ and Tox-/- mice were 
maintained at Cedars-Sinai Medical Center by the laboratory of Dr. Jonathan 
Kaye (Cedars-Sinai Medical Center). SCID mice were obtained from the 
National Cancer Institute. The maintenance and procedures of all animals 
were in accordance with and approved by the Research Animal Resource 
Center of the Weill Cornell Medical College. 
 
Mammalian Cell Lines 
Normal human adult dermal fibroblasts (ATCC) were grown in fibroblast blast 
medium supplemented with the serum-free fibroblast growth kit (ATCC). 
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Murine BCL1 cells (ATCC) were grown in RPMI 1640 supplemented with 10% 
FBS, penicillin G/streptomycin, and 0.05 mM 2-ME. Dog Cf2Th cells (ATCC) 
were grown in DMEM with 20% FBS, penicillin G/streptomycin, and non-
essential amino acids. The DLBCL cell lines OCI-LY1, OCI-LY7, and OCI-
LY10 were grown in Isocove’s medium supplemented with 10% or 20% (OCI-
LY10) FBS and penicillin G/streptomycin; OCI-LY3, Farage, SU-DHL4, and 
SU-DHL6 were grown in RPMI 1640 supplemented with 10% FBS, penicillin 
G/streptomycin, L-glutamine, and HEPES. The bladder cancer cell line RT4 
was grown in McCoy’s 5a medium supplemented with 10% FBS and penicillin 
G/streptomycin; 97-1 was grown in Ham’s F-12 medium supplemented with 
10% FBS and penicillin G/streptomycin. The breast cancer cell lines MCF7, 
T47D, HCC1806, MDA-MB-231, and MDA-MB-468 were grown in DMEM 
supplemented with 10% FBS and penicillin G/streptomycin. The colon cancer 
cell line HCT116 was grown in DMEM supplemented with 10% FBS and 
penicillin G/streptomycin. The lung cancer cell lines A549, NCI-H727, NCI-
H460, and NCI-H1299 were grown in DMEM supplemented with 10% FBS, 
penicillin G/streptomycin, and L-glutamine. The ovarian cancer cell lines 
A2780 and OVCAR-5 were grown in RPMI 1640 supplemented with 10% FBS, 
penicillin G/streptomycin, and L-glutamine. Cell lines were obtained from 
ATCC, DMSZ or the Ontario Cancer Institute and grown in 37 ºC with 5% CO2. 
 
Non-mammalian cell lines 
Iguana IgH-2 cells were grown in EMEM with 10% FBS, penicillin 
G/streptomycin, L-glutamine, and non-essential amino acids. Chicken DT40 
cells were grown in DMEM with 10% FBS, 5% chicken serum, 10% tryptose 
phosphate broth, penicillin G/streptomycin, and 0.05 mM 2-ME. IgH-2 and 
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DT40 cell lines were obtained from ATCC and grown at 37 ºC with 5% CO2. 
Drosophila S2+ cells were kindly provided by Dr. Eric Lai (Memorial Sloan 
Kettering Cancer Center) and grown in Schneider’s Drosophila medium, 10% 
FBS, and penicillin G/streptomycin at 25-26 ºC with ambient CO2.  
 
Real-time RT-qPCR 
Tissues from Hsf1+/+ and Hsf1+/- mice, zebrafish embryos, lamprey typhlosole, 
or cells were heat shocked (43 ºC for 2 h followed by recovery at 37 ºC for 2 h, 
with the exception of zebrafish embryos that were heat shocked at 37 ºC 
followed by recovery at 28 ºC) or treated with 100 nM doxorubicin (Sigma) for 
4 h. Cells were resuspended in Trizol reagent (Invitrogen) and stored at -80 ºC 
until RNA extraction. After thawing, 1/5 volume of chloroform was added, and 
the samples were shaken vigorously for 15 sec. After 2 min incubation at room 
temperature, the samples were spun at 12,000xg for 15 min at 4 ºC. The 
aqueous phase was aspirated into a new tube, and 1 volume of isopropanol 
was added. Samples were mixed and incubated for 10 min at room 
temperature or overnight at -80 ºC. Tubes were spun again at 12,000xg for 10 
min, and then washed with 75% ethanol. Tubes were spun at 7,500xg for 5 
min, aspirated, and allowed to dry at room temperature for 5-10 min. RNA was 
resuspended in RNase-free H2O and quantified with the Nanodrop (Thermo 
Scientific). cDNA was prepared using the Verso cDNA synthesis kit (Thermo 
Scientific) and detected by fast SYBR Green (Quanta Biosciences) on the 
7900HT Fast Real-Time PCR System (Applied Biosystems). Gene expression 
was normalized to a housekeeping gene, RPL13A (human), Hprt1 (mouse, 
dog), Actb (chicken, iguana, zebrafish), or GAPDH (lamprey), and expressed 
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as values relative to control using the ddCt method. Results were represented 
as fold change in expression with the standard error for 3 series of triplicates. 
 
siRNA transfection 
Normal adult dermal fibroblasts and MDA-MB-468 cells were transfected using 
Lipofectamine 2000 (Invitrogen) with 50 nM siRNAs targeting HSF1 
(Hs_HSF1_6/9, Qiagen) and a non-targeting control (Stealth RNAi medium 
GC duplex, Invitrogen). 
siRNA sequences: 
siHSF1-1 (Hs_HSF1_6): 5’-GCUUCGUGCGGCAGCUCAATT-3’ 
siHSF1-1 (Hs_HSF1_9): 5’-GGUUGUUCAUAGUCAGAAUTT-3’ 
 
Nascent RNA capture 
Human cells transfected with HSF1-targeting siRNA for 48 h were heat 
shocked at 43 ºC for 2 h followed by recovery at 37 ºC for 2 h or treated with 
100 nM doxorubicin for 4 h while simultaneously pulsed with 0.2 mM ethnyl 
uridine (EU). EU-labeled RNA was captured with the Click-It Nascent RNA 
capture kit (Molecular Probes). Briefly, RNA was extracted using Trizol reagent 
(Invitrogen), resuspended with RNase-free H2O, and quantified with the 
Nanodrop (Thermo Scientific). 1 µg total RNA was biotinylated by a click 
reaction with 0.5 µM biotin azide and re-precipitated with Glyco-blue (Ambion), 
ammonium acetate, and ice cold 100% ethanol. RNA was spun at 13,000xg 
for 15 min at 4 ºC, washed with 75% ethanol, dried for 5 min at room 
temperature, and resuspended in RNase-free H2O. RNA concentration was re-
measured by the Nanodrop (Thermo Scientific) and equal amounts of RNA 
(0.75-1 µg) was allowed to bind to 25 µL Dynabeads MyOne Streptavidin T1 
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beads (Invitrogen) in the presence of RNaseOUT recombinant ribonuclease 
inhibitor (Invitrogen) for 30 min at room temperature with gentle agitation. The 
bound RNA was washed with the provided Click-it wash buffers and 
resuspended in 12 µL RNase-free H2O. The RNA bound to the beads was 
taken directly into a cDNA synthesis reaction using the SuperScript III first-
strand synthesis system (Invitrogen). A fraction of the undiluted cDNA was 
used in real-time quantitative PCR and detected by fast SYBR Green (Quanta 
Biosciences) on the 7900HT Fast Real-Time PCR System (Applied 
Biosystems). 	  
Immunoblot 
Cell suspensions or sonicated tissue samples (in the case of lamprey 
typhlosole) were used to prepare whole cell lysate with lysis buffer (20mM Tris 
pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100) supplemented with 
protease inhibitors. Protein was cleared, quantified by Bradford reagent 
(Pierce) and resolved by SDS-PAGE, transferred to PVDF membranes, 
probed with primary antibodies (anti-HSF1 E-4, Santa Cruz; anti-β-ACTIN AC-
15, Sigma, anti-BCL6 N3/D8, Santa Cruz; anti-GAPDH FL-335, Santa Cruz; 
anti-αTUBULIN DM1A, Sigma) followed by HRP-conjugated secondary 
antibodies (Santa Cruz) and detected with enhanced chemiluminescence 
(Pierce). 
 
Protein sequence variability analysis 
BCL6, BCOR, and NCOR2 (SMRT) orthologs were found with the orthologous 
matrix browser and aligned with the multiple sequence comparison by log-
expectation (MUSCLE) (Edgar, 2004). The protein variability server (Garcia-
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Boronat et al., 2008) was used for a sequence variability analysis (Shannon 
Diversity Index) of the multiple sequence alignment. Sequence entropy values 
were mapped onto the structure of Protein database entry 1R2B. 
 
Primary isolation of murine B220+ cells 
Single-cell suspensions of mononuclear cells were generated from murine 
spleens using red blood cell lysis (Qiagen) or Fico/Lite-LM density gradient 
media (Atlanta Biologicals). Splenocytes were purified using B220 positive 
selection or CD43 depletion using the autoMACS cell separation system 
(Miltenyi Biotec). 
 
Thermotolerance 
(i) Thermotolerance of cells grown at 37 ºC:  Primary murine splenic B220+ 
cells, BCL1 cells, DT40 cells, and IgH-2 cells were left untreated or treated 
with control or 1 µM RI-BPI peptide. Cells were heat shocked at 43 ºC for 1 h, 
allowed to recover at 37 ºC for 12 h, heat shocked again at 43 ºC for 1 h, and 
allowed to recover at 37 ºC for 1 h. Cell viability was monitored with Trypan 
blue exclusion or flow cytometry using DAPI exclusion.  
(ii) Thermotolerance of zebrafish embryos grown at 28 ºC: 2 ng control 
morpholino (mo) (GeneTools) or bcl6 mo (Open Biosystems) were injected 
into the yolk of 1-2 cell stage embryos. At 24 h post-fertilization (hpf), embryos 
were separated into petri dishes and heat shocked in a water bath at 37 ºC for 
1 h, allowed to recover at 28 ºC for 12 h, heat shocked again at 37 ºC for 1 h, 
and allowed to recover at 28 ºC for 12 h. Zebrafish embryos were counted 
non-viable if there was an absence of opaque tissues. 
Morpholino sequences: 
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Control mo: 5’- CCTCCTACCTCAGTTACAATTTATA -3’ 
Bcl6 mo: 5’- TCTACAAATGAAAATATACCTGGAC -3’ 
(iii) Thermotolerance of lamprey typhlosole cells grown at 16 ºC: Cells from 
lamprey typhlosole were isolated and treated with 1 µM control or RI-BPI 
peptide. Cells were heat shocked at 29 ºC for 1 h, allowed to recover at 16 ºC 
for 12 h, heat shocked again at 29 ºC for 1 h, and allowed to recover at 16 ºC 
for 12 h. Cell viability was monitored flow cytometry using DAPI exclusion.  
(iv) Thermotolerance of Drosophila cells grown at 25-26 ºC: Drosophila S2+ 
cells treated with control or 1 µM RI-BPI peptide were heat shocked at 37 ºC 
for 1 h, allowed to recover at 25 ºC for 12 h, heat shocked again at 37 ºC for 1 
h, and allowed to recover at 25 ºC for 1 h. Cell viability was monitored with 
Trypan blue exclusion.  
 
mRNA-seq 
B220+ splenocytes from Bcl6+/+ (n=2) and Bcl6BTBMUT(Huang et al., 2013) (n=2) 
mice were heat shocked at 43 ºC for 1 h and allowed to recover at 37 ºC for 12 
h. RNA was purified using Trizol extraction (Invitrogen) and treated with Dnase 
(Qiagen). RNA quality was verified using the Agilent 2100 Bioanalyzer (Agilent 
Technologies) and the RNA integrity number values were greater than 8 for all 
samples. Sequencing libraries were generated with polyA+ RNA using the 
TruSeq RNA sample prep kit (Illumina). Libraries were cluster amplified and 
sequenced for 50 cycles using the Illumina HiSeq2000. Reads were aligned to 
mm10 using Tophat (Trapnell et al., 2009), and gene expression values were 
calculated by counting how many reads map uniquely to the union of all gene 
exons using HTseq-count. Samples were normalized for sequencing depth, 
and differentially expressed genes were identified with the edgeR package 
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(Robinson et al., 2010). Genes with counts per million > -3 and an FDR value 
< 0.05 were considered differentially expressed. mRNA-seq data was 
validated using splenic B220+ cells and brain tissue from Bcl6BTBMUT and 
Bcl6RD2MUT mice, using the same experimental plan discussed earlier in this 
section.  
 
Lentiviral transduction 
Lentivirus was produced in 293T by calcium phosphate transfection of 
pLKO.1-puro vectors (The RNAi Consortium) and envelope and packaging 
vectors. Lentivirus was collected 48 h after transfection and concentrated with 
PEG-it (Systems Biosciences). Cells were transduced and selected with 1 
µg/mL puromycin 48 h after infection. Murine BCL1 cells were transduced with 
shSCR, shTox-1, and shTox-2. Human MDA-MB-231 and MDA-MB-468 cells 
were transduced with a non-targeting control shRNA, shTOX-1, and shTOX-2. 
Puromycin-resistant cells were selected for at least 4 days prior to 
thermotolerance or cell viability experiments. 
Control shRNA sequences: 
shSCR: 5’- CCTAAGGTTAAGTCGCCCTCG -3’ 
Murine shRNA sequences: 
shTox-1: 5’- CCATTCTGATTTCTGTTGGTT -3’ 
shTox-1: 5’- CTGTACCTAAGTTCTCACTAT -3’ 
Human shRNA sequences: 
shTOX-1: 5’- CCCTACTATTGCAACAAGTTT -3’ 
shTOX-2: 5’- CGATGATACCTCTAAGATCAA -3’ 
 
Drugs 
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Doxorubicin, dexamethasone, vincristine, mechlorethamine, 
cyclophosphamide, and prednisone were purchased from Sigma. Drugs were 
dissolved in DMSO (Sigma) or distilled pure water. RI-BPI (retro-inverted 
BCL6 peptidomimetic inhibitor) and control peptides were produced by 
Biosynthesis Inc from published sequences (Cerchietti et al., 2010b).  
 
Growth inhibition  
DLBCL and solid tumor cell lines were grown at concentrations sufficient to 
keep untreated cells in exponential growth over the complete drug exposure 
time. Cell lines were exposed concurrently to 6 concentrations of RI-BPI and 
drug for 48 h and analyzed for cell viability using a fluorometric reduction 
method (CellTiter-Blue, Promega) or ATP quantitation (CellTiter-Glo, 
Promega). Fluorescence (560Ex/590Em) or luminescence was determined with 
the Synergy4 microplate reader (Biotek). The number of viable cells was 
calculated using the linear least-squares regression of the standard curve. The 
fluorescence/luminescence was determined for three replicates per treatment 
condition and normalized to their respective controls (vehicle-treated). 
CompuSyn software (Biosoft) was used to plot dose-effect curves, determine 
the drug concentrations that inhibit the growth of the cell lines by 50% and 
75% compared to control (Fa50 and Fa75, respectively), and calculate the dose 
reduction index (DRI) at the Fa50 and Fa75. The DRI is a measure of how many 
fold the dose of each drug in a combination may be reduced at a given effect 
level compared to the dose of each drug alone. DRI is based on the following 
equation: DRI = (Dx)1 / (D)1, where (Dx)1 represents the dose of drug 1 for a 
given effect x and were (D)1 represents the dose of drug 1 given in 
combination to reach the same effect x.  
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Mice xenotransplant 
Six- to eight-week old male SCID mice housed in a barrier environment were 
subcutaneously injected in the left flank with 107 human DLBCL cells (OCI-
LY7). Tumor volume was monitored every other day using electronic digital 
calipers in 2 dimensions. Tumor volume was calculated using the following 
formula: tumor volume (mm3) = (smallest diameter2 × largest diameter)/2. 
When tumors reached a palpable size (approximately 75 to 100 mm3 after 21 
days after injection), the mice were randomized to 4 different treatment arms. 
One group was injected intraperitoneally with vehicle (10% DMSO) and the 
other group received 0.6 mg/kg doxorubicin for 1 day. On day 2 of treatment, 
the mice were randomized to 2 arms, generating 4 different treatment arms. 
One group received intraperitoneal injections of sterile PBS or 25 mg/kg RI-
BPI daily for 3 days. The schedule of 1 dose of doxorubicin followed by 3 days 
of RI-BPI was repeated 2 times. RI-BPI was stored lyophilized at -20 °C until 
reconstituted with sterile pure water immediately before use. Mice were 
weighed twice a week. All mice were euthanized by cervical dislocation under 
anesthesia when at least 2 out of 10 tumors reached 20 mm in any dimension 
(equivalent to 1 gram), which was generally on day 14 of the treatment 
schedule. 
 
Primary isolation and growth inhibition of human lymphoma samples 
Human CD19+ B cells were affinity-purified from de-identified lymph node 
biopsies of confirmed DLBCL specimens in accordance with and approval 
from the Institutional Review Board (IRB) of Weill Cornell Medical College. 
Single-cell suspensions were obtained from lymph node biopsies by physical 
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disruption of tissues followed by cell density gradient separation with Fico-Lite 
LmphoH (Atlanta Biologicals). CD19 cells were affinity-purified from 
mononuclear cells using anti-CD19 microbeads and the autoMACS cell 
separator (Miltenyi Biotec). Primary DLBCL cells were co-cultured with HK 
dendritic cells in 96-well chambers with two compartments separated by 0.4 
µm porous polyester membrane (Corning Inc) as previously described 
(Cerchietti et al., 2010b). Cells were grown in advanced RPMI medium with 
10% human serum supplemented with antibiotics, l-glutamine, and HEPES for 
48 hours. Primary cells were seeded in HK-conditioned medium for 2 hours 
followed by 2 hours of drug exposure and transferred to the coculture system 
for the remainder of the experiment. Cells were treated with 10 μM of BPI, a 
combination of the drugs, or vehicle in 4 replicates. After 48 hours of exposure, 
viability was determined by using an ATP-based luminescent method 
(CellTiter-Glo; Promega) and by Trypan blue exclusion. To determine 
synergism in primary cells, we used the Webb fractional product method 
(Prichard and Shipman, 1990). This method is based on the equation Z = X + 
Y (1 − X), where Z is the expected effect of the combination and X and Y 
represent the effect of each drug alone. If Z is equal to the actual effect of the 
combination, then the relation is additive; if Z is higher then it is less than 
additive, and if Z is lower then it is more than additive (synergistic). 
 
Statistical analyses 
Student’s t-test was used for statistical analysis unless otherwise stated. All 
statistical analyses were done using GraphPad Prism 5.  
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